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ABSTRACT 
 
This study constitutes the first report on type-specific human papillomavirus (HPV) 
concordance and transmission in heterosexually active couples that are human 
immunodeficiency (HIV)-seronegative, HIV-seropositive or HIV-discordant and in which 71% 
of female participants have normal cervical cytology. 
 
Aims: The aims of the study were to investigate the aspects of human papillomavirus (HPV) 
infection in a cohort of South African heterosexual couples including HIV-negative, HIV-
concordant and HIV-discordant couples: 
i. The prevalence of HPV types according to age, HIV status and CD4 count  
ii. The impact of HIV co-infection on HPV viral load, the natural history of HPV infection 
and the type-specific HPV concordance in couples. 
iii. The impact of cervical disease on HPV viral load, the natural history of HPV infection 
and the type-specific HPV concordance in the couples. 
iv. The distribution HPV antibodies to 9 HPV types and predictors of HPV sero-
conversion over a 12 month period.  
v. Factors associated with HPV acquisition, clearance and transmission. 
 
Methodology: A total of 486 black heterosexually active couples were recruited from the 
Manyanani clinic, Empilisweni centre, Gugulethu, Cape Town and followed for 24-months. 
Cervical and penile HPV types were determined by Roche Reverse Linear Array HPV 
genotyping assay. HPV viral loads of 12 high-risk (HR) HPV types in cervical and penile cells 
were determined by hpVIR real-time polymerase chain reaction (Gustavsson et al., 2009). HPV 
antibodies (combined IgG, IgA and IgM) to the major capsid protein L1 of 9 HPV types were 
determined by Luminex-based multiplex serology (Waterboer et al., 2005 and 2006). HPV 
prevalence, acquisition, clearance and transmission in couples were analysed using STATA 
11.0 (StataCorp, College Station, TX, USA).  
 
Results: HPV infection in women and men was significantly influenced by HIV status, age and 
CD4 count.  HIV-positive women had significantly more HPV compared to HIV-negative 
women (74% 205/277 and 37% 76/207 respectively, P<0.0001). HIV-positive men also had 
significantly more HPV compared to HIV-negative men (81% 121/149 and 49% 159/322 
respectively, P<0.0001). Women were found to have more HPV antibodies to single and 
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multiple HPV types than men. In men, type-specific HPV concordance was associated with 
their own HIV-positive status (P=0.05) and their female partner’s HIV status (P=0.005). In 
women type-specific HPV concordance was associated with their HIV-positive status and low 
CD4 count (P<0.0001) but not their male partner’s HIV-positive status (P=0.08). Women or 
men with high HR-HPV viral load were more likely to have HPV concordance compared to 
women or men with low viral load. Among couples with a female partner with abnormal 
cervical cytology the type-specific HPV concordance was significantly higher compared to 
couples where the female partner had normal cervical cytology (64% 84/131 compared to 34% 
108/314, P<0.0001).  
 
Natural history studies showed the rate of clearing of any HPV was higher in men (95.12, 95% 
confident interval (CI): 83.3-108.1 per 1000 person-months) compared to women (66.95, 95% 
CI: 57.0-78.5 per 1000 person-months, P=0.001). Women with abnormal cervical cytology had 
lower clearance HPV rates compared to women with normal cervical cytology. The HPV 
antibody responses were not associated with HPV clearance in either women or men. The risk 
of acquiring any HPV type in men was higher compared to women (3.07, 95% CI: 2.65-3.54 
compared to 1.82, 95% CI: 1.53-2.14 per 1000 person-months).  
 
In both women and men, HIV-infection, having an HIV-positive partner and having a sexual 
partner infected with an HPV type similar to the one acquired were significantly associated 
with increased risk of acquiring new HPV types during follow-up. In women,  a HIV viral load 
≥10 000 copies per mL (relative risk (RR): 1.46, 95% CI: 0.99-2.16), living with the study 
partner (RR: 1.45, 95% CI: 1.02-2.07),  more lifetime sex partners (P=0.015), more sexual acts 
with study partner in the last month prior to the study visit (P<0.001) and the presence of 
genital warts in the last 6-months before the study (RR: 3.07, 95% CI: 1.06-2.93), were also 
associated with an increased risk of acquiring new HPV types during follow-up but not in men.  
 
Female to male HPV transmission was more common compared to male to female HPV 
transmission (28.0 compared to 11.7 rates per 1000 person-months). HIV-positive women were 
found to be at high risk of HPV transmission from their male partners compared to HIV-
negative women (RR: 2.31 95% CI: 1.08-4.92, P=0.03). HIV-positive men with <350mL CD4 
counts had high risk of HPV transmission from female partners compared to HIV-positive men 
≥350/mL CD4 counts (RR: 3.17, 95% CI: 1.05-9.55, P=0.04). In male to female transmission 
events, LR-HPV transmission was more common while in female to male transmission events, 
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HR-HPV transmission rate was similar to LR-HPV transmission rate. HPV transmission to 
women or men was not associated with increased number of sexual act with study partner a 
month prior the visit. These findings suggest that the observed transmissions were not just HPV 
deposited by the partner from previous sexual act but true infection. 
 
Conclusion: Data from this study indicate that HIV co-infection increases HPV prevalence, 
multiple infections and viral load in both women and men. HIV co-infection in couples or a 
female partner increased type-specific HPV concordance and transmission. In men, type-
specific HPV concordance with their female partner is influenced by their own HIV status and 
that of their female partner while in women type-specific HPV concordance is influenced by 
their own HIV status but not that of their male partner. Couples with type-specific HPV 
concordance were found to have higher HPV viral load compared to couples with no type-
specific HPV concordance, suggesting that high HPV viral load may play a role in HPV 
transmission between partners. Female to male HPV transmission was more common compared 
to male to female HPV transmission. HPV transmission was not influenced by increased 
number of sexual act a month before study visit, indicating the observed HPV transmissions are 
true infections not just HPV deposited by the partner during previous sexual act. Men 
demonstrated a higher HPV acquisition and clearance during follow-up compared to women. 
The data from this study adds to very limited data on the natural history of HPV in men and 
sexually active couples and assist to inform the government on HPV vaccine policy. 
 
This study resulted to the following published articles 
 
1. Zizipho Z. A Mbulawa, Dianne J. Marais, Leigh F Johnson, David Coetzee, Anna-
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Infectious Disease in Press. 
 
2. Zizipho Z. A Mbulawa, Dianne J. Marais, Leigh F Johnson, Andrew Boulle, David 
Coetzee, Anna-Lise Williamson. Influence of human immunodeficiency virus and CD4 count 
on the prevalence of human papillomavirus prevalence in heterosexual couples. Journal of 
General Virology 91(Pt12): 3023-31. 2010 
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1. INTRODUCTION 
1.1 The burden of cervical cancer and HPV-related cancers world-wide 
 
Cervical cancer is the second most common cancer in women worldwide (Lowy and Schiller, 
1998) and the most common cancer in South African women (Mqoqi et al., 2004). A total of 
530,000 cases of cervical cancer and 275,000 deaths caused by cervical cancer were reported in 
2008 (Ferlay et al., 2010). It has been reported that 85% of these cases and subsequent deaths 
occur in developing countries (Ferlay et al., 2010). Eastern, Western and Southern Africa are 
the high risk regions. South Africa have a 26.6 per 100,000 age standardised incidence rate and 
14.5 per 100, 000 age standardised mortality rate for cervical cancer (Ferlay et al., 2010). The 
incidence of cervical cancer is higher than mortality due to cervical cancer. Survival rates 
differ between countries and are higher in developed countries than in developing countries 
where cervical cancer cases are often presented at health care services in an advanced stage 
(Parkin & Bray, 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Worldwide age standardized incidence and mortality rates of cervical cancer 
(Ferlay et al., 2010) 
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3 
Figure 1.2 demontrate the cervical incidence and mortality rate in countries in Africa. Guinea 
has the highest incidence and mortality rate of cervical cancer while Egypt has the lowest rate. 
South African has 27 per 100,000 women-years incidence rate and 14 per 100,000 women-
years mortality rate of cervical cancer in 2008. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Age standardized incidence and mortality rates of cervical cancer (per 100,000 
women-years) in African countries (Arbyn et al., 2011). 
 
Human papillomavirus (HPV) persistent infection is essential for the development of 
precancerous lesions and cervical cancer (Walboomers et al., 1999; Parkin et al., 1999; Munoz 
et al., 2006; Castellsague et al., 2006; Parkin & Bray, 2006). HPV DNA is found in almost all 
cervical cancers at 99.7% (Walboomers et al., 1999; Bohmer et al., 2003). HPV is also 
responsible for 40-50% cases of penile cancer worldwide (WHO, 2006; Parkin and Bray, 
2006). A total of 26,000 penile cancer cases are reported annually (Parkin & Bray, 2006). 
Whereas the peak prevalence of penile cancer occurs in the elderly around the age of 60 years, 
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4 
it also occurs occasionally in young men (Bleeker et al., 2008). High-risk (HR) HPV DNA is 
detected in 30%-100% of penile carcinoma cases (Bleeker et al., 2008). A history of genital 
warts is reported to be strongly associated with penile cancer, indicating that genital warts are a 
risk marker for penile cancer (Daling et al., 2005). Low-risk (LR) HPV, HPV-6 and -11 are 
associated with 95% of genital warts (Bleeker et al., 2008). Table 1.1 demonstrates cancer 
cases attributable to HPV in both developed and developing countries. According to Parkin & 
Bray (2006), HPV is associated with 100% cancer cases of the cervix, 40% of the penis, 40% 
of vulva and vagina, 90% of anus, 3% of mouth and 12% of oro-pharynx.   
 
Table 1.1. HPV infection-attributable cancer in developing and developed countries (Parkin & 
Bray, 2006) 
 
 
 
 
 
 
                                                                                                                                                     
 
Men with penile high grade lesions are reported to have a higher prevalence of penile HR-HPV 
infection and also a higher HPV viral load compared to men with no penile lesions (Bleeker et 
al., 2002; Bleeker et al., 2005b). This shows the positive association between HR-HPV and 
penile lesions in men. Men with female sexual partners with cervical or vulval HPV associated 
cancers are at increased risk of becoming HPV infected and later to develop penile lesions 
(Bleeker et al., 2002; Bleeker et al., 2005b). According to Bleeker et al., (2005b) the rate of 
flat penile lesion regression is low in males with female sexual partners that are HPV positive 
with the same HPV type compared to those men whose partners are HPV negative, suggesting 
that the HPV re-infection between partners plays an important role in this scenario.  
 
1.2 HPV structure and genome organisation 
HPVs are small non-enveloped DNA viruses of approximately 55nm in diameter classified 
within the Papillomaviridae family (Bernard et al., 2010). Structurally, their genetic material is 
enclosed within a capsid comprising 72 capsomeres each containing 5 L1 proteins. Figure 1.3 
shows a three-dimensional model of HPV. 
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Figure 1.3. A 3-D (dimensional) model of human papillomavirus L1. 
 
Genomically, HPVs have a double stranded circular DNA genome. Their genome is 
approximately 8 kilobase pairs in size with eight open reading frames (ORFs, Doorbar, 2007). 
These ORFs are further divided into three regions; the early, late and noncoding or upstream 
regulatory region (URR). The URR is also known as long control region (LCR); it encodes no 
proteins but contains the origin of replication and promoter (Settheetham-Ishida et al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Human papillomavirus (HPV) genome, presenting late region, early region genes 
and upstream regulatory region (URR; Munoz et al., 2006). 
 
The URR is reported to play a role in determining the host range and tissue tropism of each 
HPV type. It is also important in regulating viral gene expression after HPV infection (Doorbar 
et al., 2007; Nishimura et al., 2007). The early region encodes six ORFs that express non-
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structural proteins namely, E1, E2, E4, E5, E6 and E7. The early proteins control the DNA 
replication and the assembly of virus particles. The late region encodes two ORFs expressing 
structural proteins, namely, L1 a self assembling major protein, and the minor protein L2. 
(Figure 1.4). The E1 protein is highly conserved when compared with other proteins and is 
responsible for HPV replication. E2 proteins also play a role in HPV replication and in HPV 
transcription as well as in segregation of the HPV genome after cell division.  It is interesting 
to note that although E4 is encoded in the early region it is not expressed during the early phase 
of the HPV life cycle, however the exact function of E4 is not yet clear but it is reported to play 
a role in the collapse of the cellular cytokine rating network and this process can facilitate viral 
release (Doorbar, 2007; Hamid et al., 2009). 
 
The E5 protein play a role in transformation and sometimes it can be referred to as an 
oncogene because it is reported to have the ability to transform mouse fibroblasts and 
keratinocytes (Hamid et al., 2009). Both E6 and E7 are oncogenic; they play a role in viral 
replication and in tumourigenesis and they both have transforming and immortalization 
properties (Hamid et al., 2009). E6 and E7 act by inactivating the functions of two tumor 
suppressor proteins. The oncogenic function of E6 and E7 from high-risk (HR) and low-risk 
(LR) HPV differ (Hamid et al., 2009).  
 
E7 protein binds and degrades retinoblastoma (Rb) tumor suppressor protein while E6 protein 
binds and degrades p53 tumor suppressor protein (Seavey et al., 2006). Nakagawa et al., 
(1999) reported that HPV positive women showed p53 gene mutations which may disrupt 
important functions of p53 including regulation of cell division and DNA repair. Late proteins 
(L1 and L2 proteins) are structural proteins they are responsible for the formation of the viral 
capsid (Hamid et al., 2009; Table 1.2). Host cell proliferation is directly affected by E6 and E7 
oncogenes and then E2 regulates E6 and E7 transcription. The disruption of the E2 gene results 
in loss of expression of E2 protein. The loss of E2 expression leads to the termination of proper 
HPV virus life cycle and deregulation of E6 and E7 protein. The loss of E2 expression is very 
important in tumourigenesis (Hamid et al., 2009). 
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Table 1.2. The HPV proteins and functions (Hamid et al., 2009) 
 
 
 
 
 
 
 
 
 
 
  
 
 
1.3 HPV classification 
The papillomaviruses are a diverse family of viruses and have been detected in more than 20 
different mammalian species, birds and reptiles (Doorbar, 2007; Bravo et al., 2010). The 
papillomaviruses belong to the Papillomaviridae family with 29 different papillomavirus (PV) 
genera identified; these include Alpha, Beta, Gamma, Nu, Mu etc. (Figure 1.5). Within the 
genera there are HPV species; an HPV species refers to the HPV types that belong to the same 
evolutionary branch. For example the Alpha genus contains HPV species, namely α1, α2 up to 
α14 HPV species (Schiffman et al., 2009a; Bernard et al., 2010). More than 200 genomically 
different HPV types have been iden ified (Jung et al., 2004). HPV types are defined as having 
more than a 10% L1 gene sequence difference, HPV subtypes have 2% to 10% homology from 
that of the original HPV type and then a HPV variant must have less than 2% homology (de 
Villiers et al., 2004).  
 
HPV types are divided into two groups, cutaneous and mucosal HPV types (Gross & Pfister, 
2004; Jung et al., 2004). Cutaneous HPV are those that infect squamous epithelium and cause 
skin warts; while, mucosal HPV infect mucous membranes of the genital tract, oral cavities, 
conjuctiva and respiratory tract (Gross & Pfister, 2004). There are forty genital-mucosal HPVs 
that have been identified and grouped as HR, probably HR or LR-HPV types according to their 
link with cervical cancer. HR-HPV types are associated with the development of precancerous 
lesions and cervical cancer; while LR-HPV types are associated with the development of 
genital warts and/ or low grade cervical neoplasia (Munoz et al., 2003; Munoz et al., 2006). 
Probable HR-HPV types are possibly carcinogenic however they are rarely detected in cervical 
cancers (Schiffman et al., 2009a). HPV types that belong to α7 and α9 HPV species are known  
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                                            Figure 1.5. The phylogenetic tree of papillom
avirus types based on L1 O
R
F sequence 
(B
ernard et al., 2010). 
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to be the most common HR-HPV types (de Villiers et al., 2004; Schiffman et al., 2009a; 
Bernard et al., 2010, Figure 1.5). Fifteen HPV types have been classified as HR-HPV types, 3 
have been classified as probable HR-HPV types, 12 have been classified as LR-HPV types and 
3 have undetermined risk (Munoz et al., 2006; Table 1.3). 
 
Table 1.3. Classification of Human papillomavirus (HPV) types by cervical oncogenicity 
(Adapted from Baseman & Koutsky, 2005) 
 
Risk of classification HPV types 
High-risk 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82 
Probable high-risk 26, 53, 66 
Low-risk 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, 83, 89 
                                                                                
1.4 HPV life cycle 
HPVs infect cutaneous and mucosal skin and their life cycle is linked to the stages of 
differentiation of the host epithelial cell. HPV enters the cells through microabrasions of 
epithelium. During HPV infection, HPV virions adsorb to cells via heparin sulphate on the 
heparin sulphate proteoglycan basement membrane receptors (Shafti-Karamat et al., 2003; 
Johnson et al., 2009; Sun et al., 2010). Successful HPV infection depends on the virus gaining 
access to the mitotically active cells (Culp et al., 2006). It is reported that HPV infection occurs 
in basal keratinocytes and these cells are reported not to be easily accessed by immune cells. 
During the early phase of the HPV life cycle HPV keeps a low profile. In this way the virus 
avoids the activation of the innate immune system (Stanley, 2006). As the cells differentiate, 
the expression of early proteins such as E6, E7, E1, E2, and E5 is initiated at a very low level 
and as the cell further differentiates the expression of viral genes is also up-regulated (Zheng & 
Baker, 2006, Figure 1.6).  
 
It is estimated that approximately 3 weeks are required to release matured HPV virus after the 
time of infection (Grimes, 2006). There is no need for HPV to destroy the cells it infects 
because the keratinocytes have a short life span of around 3 weeks so at the time HPV matures; 
the keratinocytes are destined to die naturally as they are sloughed off into the lumen of the 
genital tract. This mechanism assists the virus to evade immune system. No inflammation is 
induced during cell death and the innate immune system is neither alerted nor adaptive 
immunity triggered to fight HPV infection. Due to the various degrees of oncogenicity of the 
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different HPV types, the time from HPV infection to the development of cytological lesion is 
found to vary from weeks to months in different studies (Oriel, 1971; Winer et al., 2005; 
Doorbar, 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. The human papillomavirus life cycle. (Doorbar, 2006). 
 
1.5 Risk of HPV infection 
Numerous studies have revealed that HPV is sexually transmitted and is the most common 
sexually transmitted virus (Kjaer et al., 2001; Schiffman & Castle, 2005; Rodriguez et al., 
2007; Winer et al., 2008; Winer et al., 2010). HPV can also be transmitted by nonsexual 
routes, such as environmental fomite and vertical transmission but the sexual route is the most 
common type of transmission (Schiffman & Castle, 2005; Winer et al., 2008; Winer et al., 
2010). Microscopic tears that commonly occur during sexual intercourse allow HPV access to 
the basal cells of the epithelium and to be transmitted successfully. Fifty percent of sexually 
active women and men will become HPV infected in their lifetime and the highest HPV 
incidence is in young individuals (Gross & Pfister, 2004; Cuschieri et al., 2004; Dunne et al., 
2006; Chin-Hong et al., 2009). HPV infection is very rare in virginal women and genital HPV 
DNA appears as they initiate sexual intercourse and increases with an increasing number of 
sexual partners (Kjaer et al., 2001; Rodriguez et al., 2007; Winer et al., 2008).  
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Winer et al., (2008) conducted a study in which the participants were virgins at the time of 
enrolment or they had had their first intercourse with one male partner within the last 3 month 
period. The incidence of HPV infection in these women within a 1 year period was 28.5% after 
intercourse with one male partner, their first sexual partner, and HPV incident increased to 
39.2% after 2 years and to 49.1% after 3 years. It was noted that in women with male partners 
who were sexually experienced with ≥2 female partners, the risk of HPV incidence was 
increased compared to those women with male partners that were not sexually experienced 
(Winer et al., 2008). According to Trottier et al., (2010) individuals’ sexual behaviour is 
associated with HPV infection and re-infection. Reeves et al., (1994) reported that HPV 
prevalence is high in individuals who first participated in sexual activity recently compared to 
those who are sexually experienced for years. Those who have been sexually active may have 
encountered the virus in the past and therefore immune memory plays a role in the clearance of 
the virus (Reeves et al., 1994). However, the role played by natural immunity in HPV natural 
history is not clear. Recently Trottier et al., (2010) reported that HPV re-infection is not 
controlled by natural immunity. 
 
Infection with HR-HPV types is associated with a higher number of sexual partners and 
abnormal cervical cytology (Levi et al., 2002).  A high HPV viral load may enhance HPV 
transmission between partners. Females with male sexual partners with HPV infection are 
more likely to acquire HPV infection and develop cervical disease (Heard et al., 2000).   Men 
with four or more female sexual partners are more likely to have HPV infection, confirming 
that multiple sexual partners increase the risk of acquiring HPV infection (Kjaer et al., 2001; 
Svare et al., 2002; Rodriguez et al., 2007). 
 
The number of lifetime and the number recent sexual partners are risk factors for HPV 
infection in women (Burk et al., 1996; Tarkowski et al., 2004) and in men (Hippelainen et al., 
1993; Franceschi et al., 2002). Strong association between lifetime sexual partners and genital 
HPV acquisition has been reported in several studies (Winer et al., 2008). Sexual activity prior 
to the age of 16, sexual behaviour, sexual history of a partner as well as number of partners 
increases the risk of developing cervical cancer (Lehtinen et al., 1996; Silins et al., 2002; 
Richardson et al., 2005; Winer et al., 2008). Kyo et al., (1994) reported that women with 
genital HPV DNA infected male partners are more likely to have cervical HPV DNA, 
indicating that the HPV status of a male partner influences HPV prevalence in women. 
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According to Richardson et al., (2005) the use of condoms during sexual intercourse increased 
the probability of clearing LR-HPV infection.  
 
1.6 Natural history of HPV infection 
After HPV infection the immune system and other mechanisms may clear the infection. If the 
immune response fails the infection will persist which increases the possibility of a cervical 
lesion progression to cancer (Koshiol et al., 2008). Different HPV types have different abilities 
to persist in genital epithelium (Tindle, 2002; Molano et al., 2003). Most women will still clear 
their precancerous lesion but if the lesions are not cleared or are left untreated they progress to 
cervical cancer after years or decades (Figure 1.7 and 1.8). There are other co-factors that 
enhance or speed up the steps to the development of cervical cancer such as smoking; parity; 
the presence of sexually transmitted infections (STIs) such as human immunodeficiency virus 
(HIV), herpes simplex virus (HSV) and Chlamydia; immunosupression and infection with 
other micro-organisms (Schiffman et al., 2007; Schiffman & Castle, 2005). These cofactors 
will be further explored in next section.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7. Development of cervical precancerous lesions and cancer after HPV infection 
(Woodman et al., 2007).  
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Peak prevalence of HPV is observed in young individuals soon after sexual debut and declines 
with increasing age even in highly exposed women such as sex workers. In some populations a 
second peak of HPV prevalence after menopause is been observed in all continents except in 
Asia (Castle et al., 2005; de Sanjosé et al., 2007). The observed second peak could be due to 
decreased immune and response hormonal changes at menopause resulting to reactivation of 
latent HPV infections (Molano et al., 2002; de Sanjosé et al., 2007). The change of sexual 
behaviour in women after menopause and that of their male partner could be the result of 
observed second peak (Molano et al., 2002; Sanjosé et al., 2007). The stages leading to 
development of cervical neoplasia and cancer are shown in Figure 1.7 and 1.8.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8. Stages leading to development of cervical cancer after HPV infection and cofactors 
enhancing its development. The peaks of the curves are not drawn to scale, HLA: human 
leukocyte antigen (Schiffman & Castle, 2005).  
 
 
A large number of women are infected with HPV each year but only a few of them will 
develop precancerous lesions (Figure 1.9). Bosch, (2009) estimated that annually 300 million 
women are infected with genital HPV, with 30 million developing genital warts and 30 million 
developing low-grade cervical lesion over a number of years. It should be noted that women 
who develop low-grade cervical lesion, genital wart can also be detected as well. Of these, 10 
million will develop high-grade cervical lesions over years to decades and then 0.5 million will 
develop cervical/genital cancer (Bosch, 2009). Ostor, (1993) reviewed all the scientific reports 
from 1950 to early 90s. Out of all women reported in these studies, 60% of low grade 
squamous intraepithelial lesion (LSIL) cases regressed, 30% were persistent, 10% were found 
Co-factors 
(STIs, smoking, immuno-suppression, contraceptive use, 
nutrition, polymorphism in HLA and other genes, etc.)  
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to progress to high-grade squamous intraepithelial lesion (HSIL) and 1% progressed to 
invasive cervical cancer (Ostor, 1993).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9. Worldwide estimates of the burden of human papillomavirus (HPV) and related 
genital disease (Bosch, 2008). 
 
Although HPV infection has been studied extensively in women, data on male HPV infections 
and on transmission between couples are limited. The dearth of information on male HPV 
infection was related to the difficulty in sampling for genital HPV in men. However, recently 
more comprehensive sampling methods have enabled the more accurate determination of the 
presence of genital HPV in men (Weaver et al., 2004; Nicolau et al., 2005). A review by 
Dunne et al., (2006) which included 40 publications, reported a genital HPV DNA prevalence 
in men from 1.3 to 72.9%. The sampling method, site sampled and processing method affected 
the prevalence of HPV infection in the men (Gross & Pfister, 2004; Dunne et al., 2006). Men 
are HPV carriers and vectors. Although anogenital HPV infection in men is largely 
asymptomatic, men are believed to be responsible for the sustained transmission of HPV to 
their female partners and thus the perpetuation of HPV in the population (Castellsague et al., 
2003).  
 
1.7 HPV distribution in cervical cancer 
Figure 1.8 demonstrates 15 high-risk (HR) HPV types that are associated with 94.5% cases of 
cervical cancer worldwide.  There are eight most common HPV types, namely HPV-16, -18, -
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31, -33, -35, -45, -52 and -58, frequently detected in cervical cancer in Africa, and HPV 16 and 
-18 are detected in approximately 70% of the cases (Clifford et al., 2006).  In South Africa 
HPV-16 is detected in more than 50% cases of cervical cancers (Kay et al., 2003). HPV-16 is 
the most dominant HR-HPV type, its prevalence in cervical cancer cases varies between 52% 
and 58% in different countries. HPV-16 prevalence in HSIL ranges from 34% to 52%, in LSIL 
ranges between 16% and 29% (Clifford et al., 2006). HR-HPV DNA is detected in 99.7% of 
cervical cancers, in 50% of women with ASCUS and in 80% of women with LSIL 
(Walboomers et al., 1999; Solomon et al., 2001; Depuydt et al., 2003; Figure 1.10).  
 
 
 
                             
 
 
 
 
 
 
 
 
 
 
Figure 1.10. HPV types associated with cervical cancer from the IARC pooled-analysis of 
3,085 cases Munoz  et al. 2004. Adapted from Clifford et al., 2006. 
 
Miralles-Guri et al., (2009) conducted a literature review on penile cancer reports that were 
published between 1986 and 2008 evaluating HPV prevalence. Global HPV prevalence for 
penile cancer was found to be 46.9%. HPV-16 was the most dominant HPV types in penile 
carcinoma (28.3%) followed by HPV-18 (6.3%) and HPV-6/11 (3.8%, Figure 1.11). 
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Figure 1.11. The distribution of HPV types in penile carcinomas (Miralles-Guri et al., 2009) 
 
1.8 Risk factors associated with development of cervical and penile disease  
Although cervical or penile HPV infection and persistence leads to the development of cervical 
or penile lesions, there are other cofactors that may enhance the development of these lesions 
(Castellsague et al., 2006). Figure 1.12 demonstrates overview of factors that are associated 
with cervical cancer. Different factors play role at different stages in the natural history of HPV 
and development of cervical cancer even though for some of the factors it is not clear where 
exactly they play role in the carcinogenesis process (Moscicki et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12. Factors associated with HPV natural history (Moscicki et al., 2006). 
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1.8.1 Smoking 
Smoking is one of the risk factors in the development of cervical cancer. Recent smoking and 
past smoking are associated with high risk of HPV infection compared to non smokers (Rohan 
et al., 1991; Xi et al., 2009). Smoking is a risk factor for the development of SIL and invasive 
cancer in women and penile cancer in men (Maden et al., 1993; Daling et al., 2005). Women 
infected with HR-HPV types who smoke or who previously smoked are more likely to be 
diagnosed with HSIL or invasive cancer than women with a non-smoking history (Intyre-
Seltman et al., 2005). Strong association between smoking and penile cancer and its precursor 
lesions has also been reported (Maden et al., 1993; Daling et al., 2005). In women that are 
smoking, benzo[a]pyrene, one of major carcinogens in tobacco smoke is detected in mucus of 
the cervix, indicating that cervical cells of smoking women are exposed to the benzo[a]pyrene 
carcinogen (Melikian et al., 1999). Using raft cultures Alam et al., (2008) demonstrated that in 
the presence of benzo[a]pyrene a 10-fold increase of HPV-31 was observed. As a result Alam 
et al., (2008) suggested that benzo[a]pyrene in smoking women may increase HPV replication, 
leading to high HPV viral load and increased likelihood of developing cervical cancer. 
However, according to Xi et al., (2009) HPV viral load is not positively associated with 
smoking intensity and duration. 
 
It has been reported that smoking affects the circulation of carotenoids, vitamin C and folate 
(Alberg et al., 2000; Alberg, 2002). Decreased levels of folate, carotenoids and vitamin C have 
been reported to lead to increased blood homocysteine which has been associated with 
increased risk of neoplasia (Ziegler et al., 2002). Free radicals and oxidants are found at a high 
concentration in tobacco smoke.  Free radicals and oxidants are reported to damage DNA, 
proteins and lipids (Eiserich et al., 1995). That is probably why smoking is associated with 
increased risk of developing cervical cancer (Oh et al., 2008).  
 
1.8.2. HPV type, persistent infection and viral load 
Persistent infection with HR-HPV types (for example HPV 16, -18, -35 and -45) increase the 
likelihood of HSIL development or indeed cancer (Khan et al., 2005; Castellsague et al., 
2006). Trimble et al., (2005) observed a 36.4% regression of LSIL in patients infected with any 
HPV types (except HPV 16), a 29.2% regression in patients infected with HPV-16 and other 
HPV types and 20.5% regression in patients infected with HPV-16 alone (Trimble et al., 
2005). Cumulative incidence of CIN2/3 after 3 years of HPV-16 or -18 incident infection 
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among women was significantly higher (27%) compared to women with any HPV incident 
infection other than HPV-16 or -18 (Winer et al., 2005; Figure 1.13).  
 
 
 
 
 
 
 
 
 
 
Figure 1.13. The cumulative incidence of CIN2/3 months after incident infection of HPV-16 
or -18 or any HPV type other than HPV-16 or -18 (Moscicki et al., 2006 from Winer et al., 
2005). 
 
According to Nobbenhuis et al., (1999) the progression to and maintenance of SIL requires 
persistent HR-HPV infection. The same research team demonstrated that in the absence of HR-
HPV, HPV infection was cleared after 6 months and no progression to SIL was observed. This 
indicates that infection with HR-HPV types play an important role in progression to cervical 
cancer. Furthermore, patients infected with HR-HPV types are less likely to have spontaneous 
regression than women infected with LR-HPV types (Trimble et al., 2005). Infection with any 
other HPV types concurrently is associated with longer duration of persistent HPV infection 
and also increased risk of disease progression (Woodman et al., 2001; van der Graaf et al., 
2002). 
 
The detection of the HPV viral load in cervical and penile cells may provide information on 
whether the HPV infected men or women are at risk of developing penile or cervical cancer 
(Moberg et al., 2005). High HPV viral load in cervical and penile specimens indicates a high 
copy number of HPV and is one of the risk factors for the development of pre-cancerous 
lesions and cancer in both women and men (Moberg et al., 2005; Daling et al., 2005; Bleeker 
et al., 2008). High viral load cannot be detected in women with latent HPV infection (Trottier 
et al., 2010). The presence of high HPV viral load in cervical cells of women with normal 
cervical cytology together with persistent HPV infection may indicate that the women are at 
increased risk of developing SIL and cervical cancer (Dalstein et al., 2003; Ho et al., 1998). It 
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is hypothesised that women or men with high viral load might be at increased risk of HPV viral 
integration into the human genome (Moberg et al., 2005).  HPV integration into the human 
genome leads to the deregulation of the expression of viral oncogenes and disruption of 
important host cell genes such as Rb tumour suppressor gene (Doorbar, 2007; Mark et al., 
1996). Disruption of tumour suppressor genes may lead to accumulation of DNA mutations in 
the host genome and this accumulation may play a significant role in the development of 
cervical cancer (Doorbar, 2007). 
 
There are other factors which influence HPV viral load including low CD4 count. It has been 
reported that HPV-16 viral load increases with the decreasing CD4 count, which correlates 
with more severe SIL grade (Ylitalo et al., 2000; Lefevre et al., 2004). Women with 
cytological abnormalities (suggestive of HSIL) compared with women with normal cytology 
showed an 81-fold increase of HPV-16 viral load, and a significantly higher viral load was 
observed in women with HSIL compared to women with LSIL (Lefevre et al., 2004). Swan et 
al., (1999) investigated the difference in HPV DNA load between specific HPV genotypes.  
HPV-16 showed the highest viral load compared to all other HPV types and it was the most 
highly significant HPV type associated with cervical disease, while the viral load for HPV-18, 
-31, and -45 did not increase significantly with increasing cervical disease severity. The HPV-
16 viral load median value was 60-fold higher in women with HSIL compared to women with 
normal cytology and 30-fold higher when compared to women with LSIL, regardless of single 
or multiple HPV infection (Swan et al., 1999).   
 
1.8.3 Sexual transmited infections (STIs)  
High prevalence of STIs is observed in young women and men between the ages of 15-25 
years even though this group constitute only 25% of sexually active population (Weinstock et 
al., 2004). Infection with other micro-organisms such as human immunodeficiency virus 
(HIV), Chlamydia trachomatis and herpes simplex virus-2 (HSV-2) may possibly increase the 
development of cervical or penile disease (Lehtinen et al., 1996; Sun et al., 1997; Smith et al., 
2002). HSV-2 enhances the development of cervical disease by increasing HPV replication and 
the integration of HPV DNA sequences into host cell chromosomes (Brink et al., 2002). An 
individual with STI is more likely to acquire or transmist STI, including HIV, compared to STI 
unifected individual (Weinstock et al., 2004). 
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HIV co-infection also affects the development of HPV-associated genital disease. Studies 
investigating the global distribution of HIV reported that three quarters of the HIV infected 
people world-wide live in Africa and most of them are located in sub-Saharan Africa 
(UNAIDS, 2010). Approximately 26 million people in Africa are living with HIV, and 
thousands of deaths are caused by HIV infection/ acquired immunodeficiency syndrome 
(AIDS) annually (UNAIDS, 2010). Infection with both HIV and HPV may lead to a serious 
crisis in Africa (Nosarka et al., 2007). HPV acquisition is found to significantly increase in 
women who HIV seroconverted and the risk of LSIL is also found to be increased in these 
women (Wang et al., 2011). In Zimbambean women, a 5-fold increase of multiple HPV 
acquisition 12-months after HIV acquisition is been observed (Nowak et al., 2011). 
 
Women infected with both HIV and HPV are at increase risk of developing cervical 
precancerous lesions and cervical cancer compared to women infected with HPV only (La et 
al., 1998). HPV-associated cancers in HIV-positive individuals occurred more frequently than 
in HIV-negative individuals. In women, the occurrence of HPV-associated cervical, vulval or 
vaginal cancer and anal cancer and in men, penile and anal cancers were significantly increased 
in HIV-positive individuals compared to HIV-negative individuals (Frisch et al., 2000). Viscidi 
et al., (2005) demonstrated that HIV-positive women are four times more susceptible to 
infection by HR-HPV types. HIV infection and its associated immune suppression increase the 
probability of progression to HSIL and conversely decrease the probability of regression or 
clearance of HPV infection (Viscidi et al., 2005; Sun et al., 1997). HIV-positive women 
progress to cervical cancer about 10 years earlier than HIV-negative women (Lomalisa et al., 
2000). HIV-positive men are reported to have a higher prevalence of genital HPV DNA and a 
higher HPV viral load in urine than HIV-negative men (Smits et al., 2005). In a longitudinal 
study conducted by Eckert et al., (1999) HIV-positive women displayed an increased 
progression, persistence of HPV and reoccurrence of abnormal cervical cytology. In contrast, 
in HIV-negative women the reoccurrence of abnormal cytology was decreased.  
 
HR-HPV positive women and men are also at increase risk of HIV acquisition and the risk if 
found to increase with increasing multiple HR-HPV infections (Smith-McCune et al., 2010; 
Auvert et al., 2011). HPV clearance of either LR-HPV or HR-HPV was significantly 
associated with increased risk of HIV acquisition during follow-up. While persistent HPV 
infection was not significantly associated with HIV acquisition (Smith-McCune et al., 2010). 
Most HPV infections are cleared by innate and adaptive immune mechanism, making it 
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biologically possible that the local immune response elicited by HPV infection are exposed to 
HIV, and that women in the process of clearing an HPV infection might be at increased risk of 
acquiring HIV (Smith-McCune et al., 2010). 
 
 
It has been suggested that the high incidence of HPV infection and HPV-associated disease in 
HIV infected individuals could be a result of immunosuppresion caused by HIV (Palefsky et 
al., 1999; Strickler et al., 2005). HPV prevalence is greater in HIV infected women with 
≤200/mL CD4 count and high plasma HIV RNA levels and that HIV-infected women have a 
deregulated anti-HPV IgA response (Palefsky et al., 1999; Strickler et al., 2005). Fewer HIV-
positive women display anti-HPV IgA responses than HIV-negative women which could 
impact on their ability to manage HPV infection (Marais et al., 2000). Apart from 
immunosuppression there are other ways in which HIV may increase the persistence of HPV 
infection and development of cancer. It is reported that HIV infection increases the 
transcription of HPV proteins. Dolei et al., (1999) demonstrated that after HIV infection and in 
the presence of cytokines such as interleukin-6 (IL-6), the transcription of the E1 and L1 HPV 
proteins increases and the action is HPV dependent. Dolei et al., (1999) concluded that there is 
a direct action of HIV on HPV-18 through Tat transactivation and indirectly through IL-6 
activity (Dolei et al., 1999). It is also reported that HIV increases the transcription of the HPV 
E7 protein (Arany & Tyring, 1998). Increased levels of E7 protein could possibly result in a 
high rate of Rb tumor suppressor protein inactivation and degradation (Seavey et al., 2006).  
 
1.8.4 Contraceptives  
The use of oral contraceptives by women is strongly associated with risk of cervical 
abnormalities due to increased risk of HPV acquisition among these women (Hildesheim et al., 
2001; Moreno et al., 2002; Marks et al., 2011a, Marks et al., 2011b). The increasing years of 
oral contraceptive exposure is associated with increased risk of SIL and cancer (Hildesheim et 
al., 2001; Moreno et al., 2002). However, Vaccarella et al., (2006) reported that short or long 
term use of oral contraceptives is not associated with increased risk of HPV acquisition and 
persistence (Vaccarella et al., 2006). According to Syrjanen et al., (2006) the use of oral 
contraceptives is not an independent risk factor for HR-HPV infection, persistence or clearance 
and cytological abnormalities. However, the different sexual behaviours observed among 
women who use oral contraceptives, nonusers of oral contraceptives and those who use any 
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kind of contraceptive account for increased HR-HPV infection and development of cytological 
abnormalities. Women who use contraceptives are more likely to be those with high risk sexual 
behaviours (Syrjanen et al., 2006). Mark et al., (2010) conducted a study in which they treated 
cells with 17β-estradiol and progesterone (sex steroid hormones) and they found that these 
hormones suppress the inflammatory response and enhance the regulatory response to HPV-16 
VLPs. These findings suggest that women on contraceptives are at increased risk of persistent 
HPV infection because their immune response is suppressed by these hormones. However, 
Shapiro et al., (2003) did not observe any association between injectable contraceptive; 
progestogen the commonly used injectable contraceptives in South Africa; with cervical cancer 
in South African women.  
 
1.8.5 Parity 
High parity has been reported to be associated with cervical cancer (Castellsague & Munoz, 
2003). An increasing number of pregnancies are associated with an increased risk of cervical 
cancer (La et al., 1998; Hildesheim et al., 2001; Munoz et al., 2002; Moreno et al., 2002). It is 
important to note that parity is an indication of unprotected sex. Hormonal changes that occur 
during the pregnancy may decrease HPV clearance and increase HPV persistence thus 
enhancing the development of cervical abnormalities (Sethi et al., 1998). Therefore, parity, 
short and long term use of oral contraceptives might play role in progression of HPV infection 
to development of cervical neoplasia (Castellsague & Munoz, 2003; Vaccarella et al., 2006). 
 
1.8.6 Other factors 
Sastre-Garau et al., (2004) demonstrated that SIL regression may be influenced by age. Their 
study concluded that women of 30 years or younger have a 62% likelihood of SIL regression 
which is significantly reduced to 37% in women older than 30. The decreased proportion of 
SIL regression in older women can be explained by decreased immune competence in older 
women compared to younger women.  
 
Ultraviolet B rays from sunlight can be carcinogenic and promote viral activation including 
HPV (Hrushesky et al., 2005). The longer the duration of sunlight exposure the greater is the 
likelihood of progression to cancer. This is presumably because components of sunlight repress 
the cellular immune response allowing HPV the opportunity to persist and result to high HPV 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 1 
                                           
 
 
23 
viral load that will enhance the development of precancerous lesion (Hrushesky et al., 2005). 
Avoiding exposure to sunlight may assist in minimising chances of SIL progression.  
 
Socioeconomic status is considered as a secondary risk factor for HPV infection. It is measured 
based on education level and amount of income (Kahn et al., 2005). In a study by Kahn et al., 
(2005), the likelihood of HPV positive women progressing to HSIL or cancer was significantly 
greater in those with less than a high school education when compared with those with tertiary 
education. Regions with poorer socioeconomics status have increased risk of cervical cancer 
incidence and mortality (Müller et al., 2011). 
 
Consumption of vegetables such as carrots, broccoli, cabbage or green beans by women 
increases their probability of clearing HPV infection more rapidly (Richardson et al., 2005). 
Consumption of fruits, vegetables, vitamins C and E, beta-carotene, alpha-carotene, lycopene, 
luterin and cryptoxanthin can possible protect against HPV persistent infection. Vegetables, 
folate, retinol, vitamins C, E and B12, beta-carotene, alpha-caroten, lycopene, luterin and 
cryptoxanthin also demonstrate the protective effect of cervical neoplasia (Kanetsky et al., 
1998; Weinstein et al., 2001; Schiff et al., 2001). Tissues with folate deficiency have a high 
risk of DNA damage. Folate is important during DNA synthesis and DNA repair. Therefore 
tissues with low levels of folate are at increased risk of damage to DNA and with decreased 
abilities to repair DNA (Giuliano et al., 1998; Follen et al., 2001). Low levels of folate also 
increase blood homocysteine which has been reported to possibly increase the risk of cervical 
neoplasia (Alberg et al., 2000; Ziegler et al., 2002).  
 
1.9 HPV vaccines 
The development of HPV vaccines commenced in the early 90s after the discription of HPV 
virus-like particles (VLPs) (Kirnbauer et al., 1992; Kirnbauer et al., 1994; Trus et al., 1996; 
Stanley et al., 2006). It was then demonstrated that immunization with cottontail rabbit 
papillomavirus (CRPV), bovine papillomavirus (BPV) and canine oral papillomavirus (COPV) 
L1 VLP resulted in high antibody levels and protection against viral challenge in animals 
(Breitburd et al., 1995; Suzich et al., 1995; Kirnbauer et al., 1996; Ghim et al., 2000). The 
results from animal studies showed that vaccination with HPV L1 could reduce the prevalence 
of genital warts, cervical precancerous lesions and cancer worldwide.   
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The first clinical trials were carried out using HPV-11 L1 VLPs and the study was very 
successful and encouraged the researchers and companies to proceed and develop vaccine 
based on multiple HPV types (Smith et al., 1995). Even though procedures involved in the 
development of HPV vaccine are complex, expensive research continued. Currently there are 
two prophylactic HPV vaccines, Gardasil® produced by Merck and Cervarix® produced by 
GlaxoSmithKline. Both vaccines are prepared from L1 major capsid proteins which self 
assemble to form an empty shell (called VLP) that resembles the HPV virion in morphology 
and immunogenicity for each specific type (Stanley et al., 2006; Arbyn & Dillner, 2007). 
Gardasil® protects against HPV-6, -11, -16, and -18 while Cervarix® protects against HPV-16 
and -18. HPV-16 and -18 are responsible for 70% cases of cervical cancer worldwide (Clifford 
et al., 2006) and HPV-6 and -11 are associated with ~90% cases of genital warts (Giuliano, 
2007). In Gardasil®, L1 VLP production is based on recombinant yeast technology and uses 
aluminium hydroxyphosphate sulphate as adjuvant while Cervarix® is based on recombinant 
baculovirus technology and uses aluminium hydroxide combined with 3-deacylated 
monophosphoryl lipid A. Gardasil®, is administered at month 0, 2 and 6 while Cervarix® is 
administered at month 0, 1 and 6. Both vaccines are injected intra-muscularly at 0.5mL. Both 
Gardasil® and Cervarix® HPV vaccines are approved in many countries including South 
Africa. In most countries it has been licensed to be used in girls and boys. 
 
During natural HPV infection antibodies are generated by some of infected individuals 
however the antibody levels are low. HPV life cycle does not have a viraemic phase. As 
mentioned previously, HPV infection does not involve the activation of apoptosis during HPV 
release which assists HPV in evading the immune system. No inflammation is induced during 
cell death the innate immune system is neither alerted nor adaptive immunity triggered to fight 
HPV infection (Doorbar, 2006). The high antibody levels in individuals who received HPV 
vaccine compared to those with natural HPV infection are because the HPV VLPs in vaccine is 
delivered intra-muscularly, resulting in VLPs in blood and the production of high titres of 
neutralising serum antibodies. The success of the HPV vaccines in protecting against HPV  
infection has been attributed to the their immunogenicity and efficiency  in eliciting  high titres 
of long lasting serum neutralising antibodies (Harper et al., 2006; Stanley et al., 2006). After 
HPV vaccination 100% of women develop antibodies to all HPV types vaccinated against and 
the antibody levels are reported to remain high for more than six years after the initial dose 
(Stanley et al., 2006; Arby & Dillner, 2007; Harper et al., 2008). The duration of HPV vaccine 
protection is not yet known (Sankaranarayanan, 2009). HPV vaccines have indicated 
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considerable HPV type specificity apart from some cross protection shown for very 
phylogenetically closely related types (HPV-31 and -45; Harper et al., 2006; Smith et al., 
2008).  
 
Assuming a 100% type specificity and vaccine efficacy of a polyvalent HPV vaccine 
containing L1 VLP of the eight most common HPV types could potentially prevent ~90% 
cases of cervical cancer (Smith et al., 2007). The current HPV vaccine will not only reduce 
genital warts and cervical cancer but will also help to reduce cancers of the anus, vulva, vagina, 
penis, oropharynx and mouth (Parkin & Bray 2006). HPV vaccines are very promising in 
reducing the cervical cancer cases and other HPV related cancers, however, there are still 
challenges in implementation of HPV vaccine especially in low-resource countries as HPV 
vaccines are expensive, delivered by intra-muscular injection of three doses over a period of 6-
months and require cold chain storage. Development of a thermo-stable vaccine and a needle-
free vaccine would reduce the challenges and provide more advantages (Jacob et al., 2005; 
Stanley et al., 2008).  
 
The prevalence of HPV infection varies worldwide. Müller et al., (2010) recently reported 78% 
HPV prevalence in South African heterosexually active men and that HPV-6, -11, -16 and -18 
were the most dominant types in men with genital warts. It is important that we determine the 
extent of genital HPV infection and the types of HPV in men, in addition to that of women in 
South Africa. The prevention of HPV infection in men is considered therefore another way of 
eliminating cervical, penile, anal, vaginal, oropharynx cancers and genital warts in both men 
and women. It is important to have studies that will be relevant in determining those HPV 
types associated with genital cancers in South African populations and the immune response to 
those types and to evaluate the possible efficacy of HPV vaccines in eliminating HPV 
infection.  
 
1.10 The aims of the study 
Although much is known about HPV and cervical cancer in women, data on male genital HPV 
infections and on heterosexually active couples is limited especially in South Africa. The 
overall objectives of the study were to investigate HPV natural history in South African HIV-
positive, HIV-negative and HIV discordant heterosexually active couples. According to our 
knowledge this is the first report on HPV sharing and transmission in heterosexually active 
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couples that are HIV-negative, HIV-positive and HPV discordant and in which 71% of female 
participants have normal cervical cytology. 
 
The aims of the study were: 
i) to investigate the HPV prevalence, acquisition and clearance in South African HIV-positive 
and HIV-negative women and men; 
 
ii) to investigate factors that are associated with HPV prevalence, acquisition and clearance in 
HIV-positive and HIV-negative women and men;  
 
iii) to investigate factors that predict abnormal cervical cytology in women;  
 
iv) to investigate prevalence of HPV sharing and transmission in young and older 
heterosexually active couples that were HIV-positive, HIV-negative, HIV-discordant where the 
female or the male partner was HIV-positive;  
 
v) to investigate factors associated with HPV sharing and transmission in heterosexually active 
couples;  
 
vi) to investigate hpVIR HPV viral load in HIV-positive and HIV-negative women and men 
and its influence on hpVIR HR-HPV sharing among sexually active couples 
 
vii) to investigate the HPV seroprevalence of nine different types among HIV-positive and 
HIV-negative women and men and risk factors for HPV seropositivity; and 
 
viii) to investigate the impact of HIV seropositivity on the prevalence, sharing, transmission 
and viral load of genital HPV infection in heterosexually active couples. 
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2.1 INTRODUCTION 
In 2009 approximately 5.6 million people in South Africa were living with HIV (UNAIDS, 
2010). HIV prevalence is reported to be higher in women compared to men and in women the 
peak is observed between 25-29 years of age while in men is observed between 30-34 years of 
age (UNAIDS, 2010). HPV-associated cancers in HIV-positive individuals occur more 
frequently than in HIV-negative individuals (Frisch et al., 2000). HIV-positive women 
progress to cervical cancer about 10 years earlier than HIV negative women (Lomalisa et al., 
2000). The high prevalence of cervical cancer and HIV infection are both major public health 
problems in South Africa. HIV-positive men and women are reported to have a higher 
prevalence of genital HPV DNA, multiple HPV infection and higher HPV viral load compared 
to HIV-negative men and women (Palefsky et al., 1999; Eckert et al., 1999; Levi et al., 2002; 
Riva et al., 2007). In HIV-positive individuals HPV infection is more persistent compared to 
HIV-negatives (Heard et al., 2000; Smits et al., 2005). High HPV prevalence and viral load in 
HIV-positive individuals may indicate the reactivation of latent HPV infection and prolonged 
persistence of HPV due to HIV induced immune suppression as well as high risk behaviour 
(Critchlow et al., 1998; Abba et al., 2003; Silverberg et al., 2006). High HPV viral load is 
associated with increased risk of cervical abnormalities and enhanced viral transmission 
(Ylitalo et al., 2000).  
 
HPV infection has been studied extensively in women but data on men HPV infections is 
limited.  Men are believed to be responsible for the sustained transmission of HPV to their 
female partners (Castellsague et al., 2003). Müller et al., (2010) reported a 100% HPV 
prevelance in South African heterosexually active men and HIV seropositivity was found to 
significantly influence HPV prevelance and multiple HPV infections. The risk of HPV 
infection is increased in women and men with multiple sexual partners (Heard et al., 2000; 
Kjaer et al., 2001; Winer et al., 2008). Women with a male partner in a polygamous 
relationship have a higher risk of HPV infection compared to women in a monogamous 
relationship (Hippelainen et al., 1994; Bosch et al., 1996). Increased lifetime number of sexual 
partners of both women and their male partners are associated with increased risk of cervical 
abnormalities (Ferreccio et al., 2004). The risk factors of HPV DNA detection in men and in 
women are reported to be similar, these include, age, age at first sexual intercourse, number of 
lifetime sexual partners, number of recent sexual partners, the number of lifetime sexual 
partners of the partner, history of STDs and non-use of condoms (Svare et al., 2002; Vaccarella 
et al., 2006; Giuliano et al., 2008). 
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Prevalence of HPV multiple infections in HIV-negative women is reported to range from 20% 
to 50% and in HIV-positive women it ranges from 50% to 80% (Franco et al., 1999; Palefsky 
et al., 1999; Levi et al., 2002). When Chaturvedi et al., (2005) investigated HPV species that 
are commonly found in multiple HPV infections; they found that α9 HPV species (these 
include HPV-16, -31, -33, -35, -52 and -58) are less likely to be involved in multiple infections 
compared to other HPV species. The reason for these findings are not yet clear however they 
might be influenced by different risk factor profile and transmission pattern observed in 
different HPV species. The combination of HPV types in multiple infections among HPV types 
is reported to be formed randomly with little consideration of phytologenetically related or 
unrelated types (Chaturvedi et al., 2005). It has been reported that women who were HPV 
positive at baseline visit were found to be at higher risk of acquiring new HPV infection of 
both phylogenetically related and unrelated genotypes during follow-up visit compared to 
women who were HPV negative at baseline visit (Rousseau et al., 2001). This indicates that 
once women are infected with one HPV type sooner or later they will have multiple HPV 
infection especially those that are immunocompromised. 
 
Male circumcision is reported to decrease the rate of HPV acquisition, HPV transmission to the 
sexual partner and also decrease the risk of cervical cancer in their female partners 
(Castellsague et al., 2002; Castellsague et al., 2003). Genital HPV prevalence in men is 
reported to be highest on the penile shaft with the highest proportion of multiple HPV 
infections followed by glans, scrotum, urethra and perianal areas; suggesting that penile shaft 
and glans are most important for HPV transmission during sexual intercourse (Nielson et al., 
2007). HPV prevalence is reported to decrease with increasing age in women and then increase 
after menopause in some populations (Kjaer et al., 2000; Castle et al., 2005). Jacobs et al., 
(2000) also reported a decline of HPV prevalence with age in women; however LR-HPV types 
were not found to decline as was reported for HR-HPV types. Along with decreasing HPV 
prevalence, there is a decreased prevalence of cytologic abnormalities in older women (>54 
years; Kovacic et al., 2006). HPV prevalence is reported to increase with increasing cervical 
abnormalities, predominantly the HR-HPV types in which amongst them HPV-16 and -18 are 
associated with 70% cases of cervical cancer worldwide (Clifford et al., 2006). In men, HPV 
prevalence is reported to be higher in young men (18-20 years) and then declines, however 
there is no clear decreasing or increasing trend as age increase in men (Giuliano et al., 2008a). 
HPV prevalence of specific HPV type is not positively associated with age (Giuliano et al., 
2008a; Giuliano et al., 2008b).  
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The objectives of this study were  
(i) to investigate the prevalence of genital HPV infection in HIV-positive and HIV-negative 
men and women; 
(ii) to investigate factors affecting HPV prevalence including age; 
(iii) to investigate the prevalence of HPV in women with abnormal and normal cervical 
cytology; and 
(iv) to investigate the effect of HIV status and CD4 count on abnormal cervical cytology. 
 
 
2.2 MATERIALS AND METHODS 
 
2.2.1 Study population and specimen collection 
A total of 601 women and 601 men were recruited between 2006 and 2009 from the 
Manyanani clinic, Empilisweni centre, Gugulethu, Cape Town. There were no special 
eligibility criteria during recruitment except that participants had to be sexually active couples. 
Women and men were recruited even if their CD4 count level was low and on ARVs. When we 
were enrolling for the study we selected all women and men from HIV concordant and 
discordant partnership and then some from HIV-negative partnership. A total of 209 HIV-
negative women, 277 HIV-positive women, 333 HIV-negative men and 153 HIV-positive men 
were enrolled for this study. The remaining 115 women and 115 men were HIV-negative. 
Participants were recruited by recruitment team from Gugulethu Township and the specimens 
were then collected at Manyanani clinic. Dr David Coetzee and Dr Mercy Kampura were 
responsible for the management of the clinic. The mean age of women and men participants 
was 35 years (range: 18-66 years) and 38 years (range: 19-67 years) respectively. Of the men 
in this study, 96.6% (451/467) were traditionally circumcised and 11 declined to answer the 
question on circumcision and the circumcision status was not noted by the clinicians during the 
collection of penile swabs and most of the men were Xhosa speaking where men are 
traditionally circumcised. 
 
The study was approved by the Research Ethics Committee of the University of Cape Town. 
Cervical cells were collected using a Digene cervical sampler (Qiagen, Hilden, Germany). 
Samples were not collected from women if they were menstruating on the day of enrolment 
and if blood was visible in the cervical area. Penile cells were collected with a dry Digene swab 
(Qiagen, Hilden, Germany) by thorough brushing of the penile shaft and glans as well as the 
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foreskin in uncircumcised men. Both cervical and penile cells were stored in Digene transport 
medium at -80ºC until DNA was extracted. 
 
2.2.2 HPV genotyping 
The investigator (Zizipho Mbulawa) perfomed DNA extraction and HPV genotyping for 2010 
WHO HPV LabNet Proficiency study to make sure that the investigator was proficient for 
detecting all HPV genotypes even if the viral load was low as 5IU per 5µl. The investigator 
was found proficient for detection of HPV using Roche Linear Array HPV genotyping test (see 
Appendix 1). DNA was extracted from both cervical and penile cells using the MagNA Pure 
Compact Nucleic Acid Isolation Kit (Roche diagnostics, Mannheim, Germany) and the 
automated MagNA Pure Compact machine (Roche diagnostics, Mannheim, Germany). 
Extracted DNA was stored at -20ºC until further use. HPV typing was performed on DNA 
extracted from cervical and penile cells using the Roche Linear Array HPV genotyping test 
(Roche diagnostics, Mannheim, Germany) according to the manufacturers’ instructions. There 
are four major procedures involved in Linear Array HPV genotyping test, namely, specimen 
preparation (includes sample collection and DNA extraction), polymerase chain reaction (PCR) 
amplification of target DNA using HPV primers; hybridization  of the amplified product to 
oligonucleotide probes and detection of the probe-bound amplified products by colometric 
detection (Roche Linear Array HPV genotyping test booklet, 2008). 
 
HPV genotyping was performed according to manufacturer’s instructions. Briefly, a total 
volume of 580μl master mix containing PGMY09/11 primers to amplify HPV DNA of 37 
different HPV genotypes (450bp) and GH20/PC04 primers to amplify β-globin gene (268bp) 
was mixed with 125μl Magnesium chloride solution to give a working master mix. A total of 
50μl DNA sample were added to 50μl working master mix and amplified. Positive and 
negative controls provided by Roche were included in each amplification procedure. The 
positive control consists of HPV-16 DNA and β-globin gene, and the negative control had no 
HPV DNA and no β-globin gene. PCR was performed under the following conditions: 50°C 
for 2 min to activate AmpErase, 95°C for 9 minutes, followed by 40 cycles consisting of 95°C 
for 30 sec, 55°C for 1 minute, 72°C for 1 minute and a final hold at 72°C for 5 minutes on an 
AB9700 machine (Applied Biosystems, Inc, Foster City, CA, USA). The reaction was kept at 
72°C until the addition of an alkaline denaturation solution (Roche diagnostics, Mannheim, 
Germany) to denature the amplicons and AmpErase.  
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The post-amplification detection of 37 different HPV genotypes and the β-globin gene to 
evaluate sampling adequacy, DNA extraction and amplification efficiency was carried out 
using Linear Array Detection Kit (Roche diagnostics, Mannheim, Germany). Each run 
included a positive and a negative control to make sure that there was no contamination and the 
assay was working properly. HR-HPV types included HPV-16, -18, -31, -33, -35, -39, -45, -51, 
-52, -56, -58, -59, -68, 73 and -82; LR-HPV types included HPV-6, -11, -40, 42, -54, -55, -61, -
62, -64, -67, -69, -70, -71, -72, -81, -83, -84, -89 (HPV-CP6108) and IS39 and probable HR-
HPV types included HPV-26, -53 and -66. The probable HR-HPV types were grouped with 
HR-HPV types. The grouping of probable HR-HPV types with HR-HPV types was suggested 
by the reviewers of our first paper on this study (Mbulawa et al., 2009). The Linear Array HPV 
genotyping strips consist of cross-reactive oligonucleotide probe that hybridizes with HPV-33, 
-35, -52 and -58. The Roche Linear Array HPV genotyping test does not detect HPV-52 
individually. The specimens that tested negative for HPV-33, -35 and -58 individually but 
tested positive for the HPV-52/33/35/58 group are considered to be HPV-52 positive. The 
specimens that tested positive for HPV-33, -35 and -58 individually and tested positive for the 
HPV-52/33/35/58 group are not considered to be HPV-52 positive however the co-infection of 
HPV-52 cannot be ruled out.  
 
Each strip was placed into the appropriate well of the 24-well tray leaving an empty well in 
between strips to avoid cross contamination. A total of 75μl denatured amplicon was 
transferred to appropriate wells containing pre-warmed hybridization buffer. Each amplicon 
was hybridized to the strip at 53°C. Following hybridization, the strips were stringently washed 
with washing buffer containing sodium lauryl sulfate (SDS) and sodium salts to remove all 
unbound material. Streptavidin-horseradish peroxidase conjugate (SHPC) was added to the 
strip to bind to the biotin-labeled amplicon hybridised to the probe on strip. The strip was then 
washed to remove any unbound SHPC and a substrate solution of hydrogen peroxide and 
3,3’,5,5’-tetramethylbenzide (TMB) was added. The TMB substrate in the presence of 
hydrogen peroxide was oxidised to a blue colour by catalysis action of SHPC in the presence 
of hydrogen peroxide. The blue colour precipitated at probe positions where hybridization 
occurred. The strips were then washed with distilled water and read visually by comparing the 
pattern of blue lines to the Linear Array Genotyping test reference guide. 
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2.2.3 Statistical analysis 
All comparisons of HPV prevalence levels were conducted using chi-squared tests. Factors 
affecting the risk of any HPV infection were assessed using multivariate logistic regression. 
All analyses were conducted for HR-HPV types and LR-HPV types separately, as well as for 
HR-HPV and LR-HPV types combined. Dr Leigh Johnson (Centre for Infectious Disease, 
Epidemiology and Research, University of Cape Town) conducted all statistical analyses using 
STATA 11.0 (StataCorp, College Station, TX, USA). X2 test (EpiInfo Version 5 Statcalc) was also 
used in comparing prevalence. In all analyses P-values ≤0.05 were considered significant.  
 
2.3 RESULTS 
 
2.3.1 Genital HPV prevalence according to gender and HIV status 
To ensure sample adequacy, the presence of the β-globin gene was evaluated and found to be 
negative in 0.4% (2/486) cervical samples and in 3.1% (15/486) penile samples. Four of these 
penile samples were HPV DNA positive and nine were HPV negative indicating that even if 
the sampling was deemed inadequate by the less sensitive β-globin gene assay. HPV DNA was 
still detected from the penile sample; while in cervical samples with negative β globin gene no 
HPV DNA was detected. These findings probably mean that some of these viruses were free 
virus they were not in cells or it means that few cells were collected and they were not enough 
to reach the required level required by the Roche Linear array HPV genotyping assay.  A total 
of 277 HIV-positive women, 207 HIV-negative women, 149 HIV-positive men and 322 HIV-
negative men had a positive β-globin band. All β-globin negative samples were excluded from 
the analysis. Figure 2.1 illustrates a strip with sample that was β-globin high and β-globin low 
positive, HPV-6, -11, 16, -18, -55, 73, and -83 positive.  
 
Genital HPV prevalence was significantly higher in both HIV-positive women (74% 205/277) 
and men (81% 121/149) compared to HIV-negative women (37% 76/207) and men (49% 
159/322, P<0.0001 for both men and women). HIV-negative men showed a significantly 
higher prevalence (49%) of genital HPV than HIV-negative women (37%, P= 0.004), while the 
HPV prevalence was not significantly different between HIV-positive men (81%) and women 
(74%; P=0.5). HIV-positive women were found to have 3.4 fold higher risk of multiple HPV  
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Figure 2.1. Roche linear array HPV genotyping strip demonstrating a HPV-6, -11, 16, -18, -55, 
73, -83, β -globin low and high positive sample. 
 
infection compared to HIV-negative women (50% 139/277 compared to 15% 31/207, 
P<0.0001). HIV-positive men were found to have 2.2 fold higher risk of multiple HPV 
infection (66% 99/149 compared to 30% 96/322, P<0.0001). HIV-negative men were found to 
have 2 fold higher risk of multiple HPV infection compared to HIV-negative women (30% 
96/322 compared to 15% 31/207, P<0.0001). These results indicate that HIV-positive 
individuals have a significantly higher risk of having ≥2 HPV types than HIV-negative 
individuals regardless of gender (Figure 2.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Genital HPV (HR and LR) prevalence in HIV-negative and HIV-positive women 
and men. Red lines indicate prevalence of multiple HPV infection. Neg: negative, Pos: positive 
HIV-pos women, N=277 HIV-neg women, N=207 HIV-pos men, N=149 HIV-neg men, N=322
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HIV-positive women were found to have significantly higher prevalence of HR-HPV and LR-
HPV prevalence compared to HIV-negative women (HR-HPV: 52% 144/277 compared to 29% 
59/207, P<0.0001; LR-HPV: 65% 181/277 compared to 28% 58/207, P<0.0001). HIV-positive 
men were found to have significantly higher prevalence of HR-HPV prevalence compared to 
HIV-negative men (67% 100/149 compared to 32% 102/322, P<0.0001) and LR-HPV (67% 
101/149 compared to 39% 124/322, P<0.0001). When we group HPV prevalence according to 
species level HIV-positive women and men were found to have significantly higher prevalence 
of all HPV species (Table 2.1). HR-HPV types were found to dominate in HIV-negative 
women (63% 64/101); however in HIV-positive women, HIV-negative and HIV-positive men 
the distribution of HR-HPV and LR-HPV types were not found to differ (Table 2.1). The 
number of isolated HPV types varied between men and women and according to the HIV 
status. 
 
Table 2.1. The prevalence of HPV species in women and men according to HIV status 
 
  WOMEN     MEN 
Variable HIV+, n=277 HIV-, n=207 P-value   HIV+, n=149 HIV-, n=322 P-value 
HPV positive 205 (74%) 76 (37%) <0.0001  121 (81%) 159 (49%) <0.0001 
HR-HPV 144 (52%) 59 (29%) <0.0001  100 (67%) 102 (32%) <0.0001 
LR-HPV 181 (65%) 58 (28%) <0.0001  101 (68%) 124 (39%) <0.0001 
α3 HPV species 217 (78%) 9 (4%) <0.0001  144 (97%) 120 (37%) <0.0001 
α5 HPV species 46 (17%) 11 (5%) 0.0001  29 (20%) 30 (9%) 0.002 
α6 HPV species 62 (22%) 26 (13%) <0.0001  40 (27%) 45 (14%) 0.0007 
α7 HPV species 84 (30%) 14 (7%) <0.0001  101 (68%) 66 (21%) <0.0001 
α9 HPV species 127 (46%) 26 (13%) <0.0001  72 (48%) 54 (17%) <0.0001 
α10 HPV species 25 (9%) 4 (2%) 0.001  43 (29%) 20 (6%) <0.0001 
α1/α8/α11/α13/α15 HPV 
species 58 (21%) 4 (2%) <0.0001   51 (34%) 29 (9%) <0.0001 
Due to HPV multiple infection some of women are counted more than once.  Bold p-values are statistically significant.   
HIV+: HIV-positive. HIV-: HIV-negative. α1 HPV species includes HPV-42.  α3 HPV species includes HPV-61, -62, -72, -81, 
-83, -84 and -89. α5 HPV species includes HPV-26, -51, 69, -82 and –IS39. α6 HPV species includes HPV-53, -56 and -66. α7 
HPV species includes HPV-18, -39, -45, -59, -68 and -70. α8 HPV species includes HPV-40 . α9 HPV species includes HPV-
16, -31, -33, -35, -52, -58 and -67. α10 HPV species includes HPV-6, -11 and -55. α11 HPV species include HPV-73.  α13 
HPV species includes HPV-54. α15 HPV species includes HPV-71. 
 
Among HIV-positive men the most frequently detected types were HPV-62 (20.8%), HPV-61 
(18.8%), HPV-70 (16.8%), HPV-53 (16.1%), HPV-89 and -45 (14.8%), HPV-55, -81, -83 and 
-16 (13.4%). Among HIV-negative men HPV-62 (8.1%), HPV-61 (6.8%), HPV-66 (6.5%), 
HPV-53 (6.2%), HPV-83 (5.9%), HPV-81 (5.3%), HPV-89, -16 and -51 (5.0%) were most 
frequently detected. Among HIV-positive women the most frequently detected HPV types 
were HPV-62 (12.6%), HPV-52 (11.2%), HPV-58 (10.1%), HPV-53 (9.7%), HPV-61 and 
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Figure 2.3. Prevalence of genital HPV types in human immunodeficiency (HIV)-positive and 
HIV-negative women (A) and men (B) 
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HPV-16 (9%), HPV-45 (8.7%), HPV-70, -72, -83 and -18 (8.3%). Among HIV-negative 
women HPV-11 (5.3%), HPV-6 (4.3%), HPV-52, HPV-40, -61, -16, -35 and -58 (2.4%) were 
frequently detected (Figure 2.3).  
 
2.3.2 HPV prevalence in women and men and the impact of HIV and other variables 
HIV-positive men with a CD4 count of <350/mL had a similar HPV prevalence when 
compared to HIV-positive men with CD4 counts of ≥350/mL (78% compared to 75%; odds 
ratio (OR), 1.19 [95% CI: 0.57-2.52]). In contrast, HIV-positive women with CD4 counts of 
<350/mL were found to have a higher HPV prevalence compared to HIV-positive women with 
CD4 counts of ≥350/mL (81% compared to 67%; OR, 2.13 [95% confidence interval (CI): 
1.23-3.7]). HPV prevalence was found to decrease significantly with increasing age in both 
men (P=0.007) and women (P<0.001). In the unadjusted analysis, for both women and men 
HPV prevalence was not influenced by whether they lived with their sexual partners or not, nor 
the duration of the relationship nor their number of lifetime sexual partners. Similarly, in men 
and women young age at first sexual intercourse did not significantly influence HPV 
prevalence (Table 2.2). 
 
Table 2.2. Genital HPV prevalence in men and women, and the influence of HIV infection and 
other variables (univariate analysis). 
Variable    Men      Women   
    n HPV% OR 95% CI P-value  n HPV% OR 95% CI P-value 
Total  471 58%     484 58%    
Age group             
<30 years  95 68% ref  0.007  165 69% ref  <0.001 
30-39 years  185 62% 0.74 0.44-1.25   174 57% 0.59 0.38-0.92  
40-67 years  191 50% 0.47 0.28-0.78   145 46% 0.38 0.24-0.61  
HIV status             
Negative  313 49% ref  <0.001  207 36% ref  <0.001 
Positive  158 77% 3.38 2.20-5.19   277 74% 5.01 3.39-7.40  
CD4 count (if HIV-positive)          
≥350/ml  77 75% ref  0.64  135 67% ref  0.007 
<350/ml  79 78% 1.19 0.57-2.52   142 81% 2.13 1.23-3.70  
Age at first sex             
<16 years  125 60% ref  0.927  77 56% ref  0.079 
16-18 years  247 58% 0.92 0.59-1.42   293 62% 1.28 0.77-2.12  
>18 years  94 59% 0.94 0.55-1.62   111 50% 0.78 0.43-1.39  
Lifetime number of sexual partners        
1-2  87 53% ref  0.465  179 56% ref  0.456 
3-5  130 63% 1.52 0.88-2.64   220 57% 1.04 0.70-1.55  
6-10  128 59% 1.3 0.75-2.26   71 66% 1.55 0.87-2.75  
>10  121 56% 1.14 0.66-1.99   11 64% 1.38 0.39-4.89  
ref: Reference 
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2.3.3 The impact of age on HPV prevalence 
In women, prevalence of any HPV, HR-HPV and LR-HPV were found to decrease with 
increasing age (R2=0.79, R2=0.93 and R2=0.83 respectively, Figure 2.4A). When women were 
grouped according to HIV status HPV prevalence profile differed among HIV-positive women 
and HIV-negative women. HIV-positive women had a significantly higher prevalence of any 
HPV compared to HIV-negative women at the age of 18-25 years (86%  38/44 compared to 
61% 25/41, P=0.008); 26-35 years (68% 88/129 compared to 39% 23/59, P=0.0002), at the age 
of 36-45 years (73% 52/71 compared to 24% 15/63, P<0.0001) and at the age of 46-66 years 
(82% 27/33 compared to 30% 13/44, P<0.0001). In HIV-positive women, prevalence of any 
HPV, HR-HPV and LR-HPV were not found to significantly decrease with increasing age and 
peak up in old age women (R2=0.01, R2=0.29 and R2= 0.22 respectively, Figure 2.4B). Among 
HIV-positive women any HPV prevalence was 86% at age 18-25 years and was found to 
decrease at age 26-35 years to 68% and increase at age 36-45 years to 73% and at age 46-66 
years to 82%.  In HIV-negative women prevalence of any HPV and HR-HPV HPV were found 
to decrease with increasing age (R2=0.7, R2=0.96 respectively); while prevalence of LR-HPV 
was not found to significantly decrease with increasing age (R2=0.4), Figure 2.4C). Among 
HIV-positive women CD4 counts were only found to be statistically different in women 
between the age of 46-66 years (median: 432/mL CD4 counts, range: 181-1592/mL CD4 
counts) and 26-35 years (median: 335/mL CD4 counts, range: 14-1343/mL CD4 counts) and 
26-35 years (median: 346/mL CD4 counts, range: 10-1762/mL CD4 counts).  
 
In men, prevalence of any HPV, HR-HPV and LR-HPV was also found to decrease with 
increasing age (R2=0.9, R2=0.95 and R2=0.87 respectively, Figure 2.5A). In HIV-positive men, 
prevalence of any HPV, HR-HPV and LR-HPV were found to decrease with increasing age 
(R2=0.9, R2=0.9 and R2= 0.8 respectively, Figure 2.5B). In HIV-negative men prevalence of 
any HPV and HR-HPV HPV were also found to decrease with increasing age (R2=0.8, R2=0.8 
respectively); while prevalence of LR-HPV was not found to significantly decrease with 
increasing age (R2=0.3), Figure 2.5C). HPV prevalence was higher in HIV-positive men of all 
ages compared to HIV-negative men, however the difference was not significantly higher at the 
age of 18-25 years (88% 7/8 compared to 77% 27/35 respectively, P=0.46) and then 
significantly higher at the age of 26-35 years (77% 49/63 compared to 49% 46/93, P=0.0004), 
at the age of 36-45 years (76% 50/66  compared to 50% 51/101, P=0.001) and at the age of 46-
66 years (71% 15/21 compared to 42% 35/84, P=0.01). Among HIV-positive men the level of 
CD4 counts was not found to significantly differ in different age groups.  
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 2 
                                           
 
 
39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. The prevalence of any HPV, HR-HPV, LR-HPV according to age in all women 
(A), HIV-positive women (B) and HIV-negative women (C).  
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Figure 2.5. The prevalence of any HPV, HR-HPV, LR-HPV according to age in all men (A), 
HIV-positive men (B) and HIV-negative men (C).  
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2.3.4 HPV prevalence in women according to the cervical disease status. 
Papanicolaou (Pap) smear results were monitored by Prof Margaret Hoffman and Dr Jennifer 
Moodley. Women were stratified based on Papanicolaou (Pap) smear results; 483 women had 
Pap smear results. A total of 67% (322/483) had normal cytology, 9% (42/483) had atypical 
squamous cell of undetermined significance (ASCUS), 17% (80/483) had low grade squamous 
intraepithelial lesion (LSIL), 2% (12/483) had high grade squamous intraepithelial lesion 
(HSIL) and 6% (27/483) had an inadequate sample. HPV prevalence was found to increase 
significantly with increasing cervical abnormalities (48% 153/322 for normal cytology; 69% 
29/42 for ASCUS; 94% 75/80 for LSIL and 100% 12/12 for HSIL, R2=0.95). HR-HPV 
prevalence was found to increase significantly with increasing cervical abnormalities (34% 
108/322 for normal cervical cytology; 60% 25/42 for ASCUS; 85% 68/80 for LSIL and 100% 
12/12 for HSIL, R2=0.99). LR-HPV prevalence was also found to increase significantly with 
increasing cervical abnormalities (33% 107/322 for normal cervical cytology; 33% 14/42 for 
ASCUS; 59% 47/80 for LSIL and 58% 7/12 for HSIL, R2=0.78, Figure 2.6).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6. The prevalence of HPV infection in women with normal cytology, atypical 
squamous cell of undetermined significance (ASCUS), low grade squamous intraepithelial 
lesion (LSIL) or high grade squamous intraepithelial lesion (HSIL). 
 
 
HIV-positive women with normal cervical cytology were found to have significantly higher 
CD4 counts compared to HIV-positive women with abnormal (includes ASCUS, LSIL and 
HSIL) cervical cytology (median: 401/mL, range: 14-1762/mL compared to median: 307/mL, 
range: 10-1279/mL, P=0.0005, Figure 2.7). 
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Figure 2.7. The levels of CD4 counts in HIV-positive women with normal and abnormal 
cytology. 
 
HIV-positive women with normal cytology had a significantly higher prevalence of any HPV 
compared to HIV-negative women (66% 109/166; 28% 44/156 respectively, P<0.0001) and 
women with ASCUS (87% 20/23; 47% 9/19 respectively, P<0.0001). Both HIV-positive and 
negative women with LSIL or HSIL showed a similar prevalence of HPV. HIV-positive 
women with normal cytology had a significantly higher prevalence of HR-HPV prevalence 
compared to HIV-negative women (46% 76/166; 21% 32/156 respectively, P<0.0001) and 
women with ASCUS (78% 18/23; 37% 7/19 respectively, P=0.006). Both HIV-positive and 
negative women with LSIL or HSIL had a similar HR-HPV prevalence. HIV-positive women 
with normal cytology were also found to have a significantly higher prevalence of LR-HPV 
prevalence compared to HIV-negative women (50% 83/166; 15% 24/156 respectively, 
P<0.0001), women with ASCUS (48% 11/23; 16% 3/19 respectively, P=0.03) and women with 
LSIL (67% 42/63; 29% 5/17 respectively, P=0.006). HIV-positive and negative women with 
HSIL had a similar LR-HPV prevalence but the sample size was small (Table 2.3).  
 
Women with abnormal cervical cytology were found to have a significantly higher prevalence 
of α3, α5, α6, α7, α9, α10 and α1/α8/α11/α13/α15 HPV species compared to women with 
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normal cervical cytology (Table 2.4). In women with abnormal cervical cytology the frequently 
detected HPV species were in descending order of prevalence, α3 (61.9% 83/135) α9 (61.2% 
82/135) α7 (49.3% 66/135), α6 (29.1% 39/135) α5 (21.6% 29/135) α1/α8/α11/α13/α15 (14.9% 
20/135) and then α10 (13.4% 18/135). HPV-16 and -18 were detected in 58% (7/12) of women 
with HSIL even though only 12 study participants had HSIL 
 
Table 2.3.  The prevalence of HPV infection in HIV-positive and HIV-negative women 
according to cervical cytology (normal, ASCUS, LSIL and HSIL). 
 
    Any HPV P-value HR-HPV P-value LR-HPV P-value 
    %           n/t  %            n/t  %            n/t  
Normal 
 
HIV-pos 66       109/166 <0.0001 
 
46        76/166 <0.0001 
 
50         83/166 <0.0001 
 HIV-neg 28       4/156 21        32/156 15         24/156 
ASCUS 
 
HIV-pos 87       20/23 0.006 
 
78         18/23 0.006 
 
48         11/23 0.03 
 HIV-neg 47       9/19 37         7/19 16         3/19 
LSIL 
 
HIV-pos 94       59/63 0.71 
 
87         55/63 0.23 
 
67         42/63 0.006 
 HIV-neg 94      16/17 76         13/17 29         5/17 
HSIL 
  
HIV-pos 100    10/10 na 
 
100      10/10 na 
 
60         6/10 0.68 
 HIV-neg 100    2/2 100      2/2 50         1/2 
n/t: HPV positive samples/ total number of samples. na: not analysed 
 
In women with normal cervical cytology the frequently detected HPV species, in descending 
order were α3 (25.5% 82/322) α9 (18% 58/322) α7 (18% 58/322) α1/α8/α11/α13/α15 (9.6% 
31/322) α6 (8.4% 27/322) α5 (6.8% 22/322) and then α10 (3.4% 11/322). HIV-positive women 
with abnormal or normal cervical cytology were found to have high prevalence of all species 
compared to HIV-negative women with abnormal or normal cervical cytology respectively. 
When looking at α9 HPV species the most prevalent species in women with abnormal cervical 
cytology, HIV-positive women with abnormal cervical cytology were found to have 
significantly higher prevalence of HPV species compare to HIV-negative women with 
abnormal cervical cytology (72.9% 70/96 compared to 28.9% 11/35, P<0.0001). When looking 
at α7 HPV species the second most prevalent species in cervical cancer, HIV-positive women 
with abnormal cervical cytology were found to have significantly higher prevalence of HPV 
species compare to HIV-negative women with abnormal cervical cytology (58.3% 56/96 
compared to 15.8% 6/38, P<0.0001). The high prevalence of α3 HPV species in women with 
abnormal cervical cytology was associated with multiple HPV infection and none of women 
with abnormal cervical cytology were found to have α3 HPV species as a single infection 
(Table 2.4). When we look at individual HPV types, women with abnormal cervical cytology 
were found to have a higher prevalence of HPV-58 (14.2%), HPV-16, -52 and 62 (13.4%) and 
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HPV-45 (10.4%) while women with normal cervical cytology were found to have a higher 
prevalence of HPV-62 and -82 (5.3%), HPV-61 (4.7%), HPV-58 (4.3%) and HPV-54 (4.0%).  
 
Table 2.4 HPV prevalence in women according to cervical cytology (abnormal and normal) 
and HIV status 
  Women with abnormal cytology 
P-value* 
  Women with normal cytology 
P-value# P-value$ 
HPV type 
All 
n=134 
HIV+ 
 n=96 
HIV- 
n=38  
All 
 N=322 
HIV+ 
 n=166 
HIV- 
 n=156 
  n % n % n %   N % n % n % 
Any HPV 116 86.6 89 92.7 27 71.1 0.0009  153 47.5 109 65.7 44 28.2 <0.0001 <0.0001 
HR-HPV 105 78.4 83 86.5 22 57.9 0.0003  108 33.5 76 45.8 32 20.5 <0.0001 <0.0001 
LR-HPV 68 50.7 59 61.5 9 23.7 <0.0001  107 33.2 83 50.0 24 15.4 <0.0001 0.0006 
α3 83 61.9 77 80.2 6 15.8 <0.0001  82 25.5 73 44.0 8 5.1 <0.0001 <0.0001 
HPV61 15 11.2 13 13.5 2 5.3 0.14  15 4.7 12 7.2 2 1.3 0.009 0.01 
HPV62 18 13.4 17 17.7 1 2.6 0.02  17 5.3 16 9.6 1 0.6 0.0003 0.003 
HPV72 12 9.0 11 11.5 1 2.6 0.09  12 3.7 11 6.6 1 0.6 0.005 0.02 
HPV81 13 9.7 12 12.5 1 2.6 0.07  4 1.2 4 2.4 0 0.0 0.05 <0.0001 
HPV83 9 6.7 9 9.4 0 0.0 0.04  17 5.3 14 8.4 3 1.9 0.009 0.56 
HPV84 12 9.0 12 12.5 0 0.0 0.01  9 2.8 9 5.4 0 0.0 0.002 0.006 
HPV89 4 3.0 3 3.1 1 2.6 0.68  8 2.5 7 4.2 1 0.6 0.04 0.49 
α5 29 21.6 34 35.4 1 2.6 <0.0001  22 6.8 12 7.2 4 2.6 0.05 <0.0001 
HPV26 5 3.7 5 5.2 0 0.0 0.18  1 0.3 1 0.6 0 0.0 0.52 0.009 
HPV51 13 9.7 13 13.5 0 0.0 0.01  8 2.5 6 3.6 2 1.3 0.163 0.0009 
HPV69 1 0.7 7 7.3 0 0.0 0.09  8 2.5 1 0.6 1 0.6 0.74 0.2 
HPV82 5 3.7 5 5.2 0 0.0 0.18  3 0.9 3 1.8 0 0.0 0.14 0.05 
   IS39 5 3.7 4 4.2 1 2.6 0.56  2 0.6 1 0.6 1 0.6 0.74 0.03 
α6 39 29.1 37 38.5 2 5.3 <0.0001  27 8.4 23 13.9 4 2.6 0.0003 <0.0001 
HPV53 17 12.7 15 15.6 2 5.3 0.09  14 4.3 11 6.6 3 1.9 0.04 0.001 
HPV56 10 7.5 10 10.4 0 0.0 0.03  3 0.9 3 1.8 0 0.0 0.14 0.0001 
HPV66 12 9.0 12 12.5 0 0.0 0.01  10 3.1 9 5.4 1 0.6 0.01 0.008 
α7 66 49.3 56 58.3 6 15.8 <0.0001  58 18.0 48 28.9 8 5.1 <0.0001 <0.0001 
HPV18 13 9.7 12 12.5 1 2.6 0.07  10 3.1 9 5.4 1 0.6 0.01 0.004 
HPV39 11 8.2 6 6.3 1 2.6 0.36  8 2.5 4 2.4 2 1.3 0.37 0.006 
HPV45 14 10.4 13 13.5 1 2.6 0.05  11 3.4 11 6.6 0 0.0 0.001 0.003 
HPV59 6 4.5 6 6.3 0 0.0 0.13  6 1.9 4 2.4 2 1.3 0.37 0.11 
HPV68 12 9.0 11 11.5 1 2.6 0.09  7 2.2 6 3.6 1 0.6 0.07 0.001 
HPV70 10 7.5 8 8.3 2 5.3 0.42  16 5.0 14 8.4 2 1.3 0.003 0.3 
α9 82 61.2 70 72.9 11 28.9 <0.0001  58 18.0 46 27.7 9 5.8 <0.0001 <0.0001 
HPV16 18 13.4 16 16.7 2 5.3 0.08  11 3.4 9 5.4 2 1.3 0.04 <0.0001 
HPV31 8 6.0 7 7.3 1 2.6 0.28  4 1.2 2 1.2 2 1.3 0.66 0.008 
HPV33 8 6.0 8 8.3 0 0.0 0.06  7 2.2 4 2.4 2 1.3 0.37 0.04 
HPV35 11 8.2 10 10.4 1 2.6 0.13  10 3.1 8 4.8 1 0.6 0.02 0.02 
HPV52 18 13.4 15 15.6 2 5.3 0.09  11 3.4 9 5.4 1 0.6 0.01 <0.0001 
HPV58 19 14.2 14 14.6 5 13.2 0.83  14 4.3 13 7.8 1 0.6 0.002 0.0002 
HPV67 0 0.0 0 0.0 0 0.0 ..  1 0.3 1 0.6 0 0.0 0.52 0.7 
α10 18 13.4 16 16.7 2 5.3 0.08  11 3.4 9 5.4 2 1.3 0.04 0.0001 
HPV6 8 6.0 7 7.3 1 2.6 0.28  2 0.6 2 1.2 0 0.0 0.26 0.001 
HPV11 4 3.0 3 3.1 1 2.6 0.68  1 0.3 1 0.6 0 0.0 0.52 0.03 
HPV55 6 4.5 6 6.3 0 0.0 0.13  8 2.5 6 3.6 2 1.3 0.18 0.2 
α1/α8/α11/ 
α13/α15 20 14.9 20 20.8 0 0.0 0.002  31 9.6 27 16.3 4 2.6 <0.0001 0.108 
HPV40 2 1.5 2 2.1 0 0.0 0.511  3 0.9 3 1.8 0 0.0 0.09 0.46 
HPV42 4 3.0 4 4.2 0 0.0 0.26  3 0.9 2 1.2 1 0.6 0.6 0.12 
HPV54 9 6.7 9 9.4 0 0.0 0.29  13 4.0 11 6.6 2 1.3 0.015 0.23 
HPV64 0 0.0 0 0.0 0 0.0 ..  0 0.0 0 0.0 0 0.0 .. .. 
HPV71 5 3.7 5 5.2 0 0.0 0.18   12 3.7 11 6.6 1 0.6 0.005 0.99 
Abnormal cytology includes ASCUS, LSIL and HSIL. * comparing HIV-positive and HIV-negative women with abnormal cytology.  # 
comparing HIV-positive and HIV-negative women with normal cytology. $ comparing all women with abnormal cytology and those with 
normal cytology. Due to HPV multiple infection some of women are counted more than once. α1 HPV species includes HPV-42.  α3 HPV 
species includes HPV-61, -62, -72, -81, -83, -84 and -89. α5 HPV species includes HPV-26, -51, 69, -82 and –IS39. α6 HPV species includes 
HPV-53, -56 and -66. α7 HPV species includes HPV-18, -39, -45, -59, -68 and -70. α8 HPV species includes HPV-40 . α9 HPV species 
includes HPV-16, -31, -33, -35, -52, -58 and -67. α10 HPV species includes HPV-6, -11 and -55. α11 HPV species include HPV-73.  α13 HPV 
species includes HPV-54. α15 HPV species includes HPV-71. Bold p-values are statistically significant. 
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2.4 DISCUSSION  
This study examined the HPV prevalence in HIV-positive and HIV-negative women and men. 
To our knowledge this is the first report on genital HPV in HIV-positive and HIV-negative 
men that were not recruited from a STI clinic but from the general population in South Africa. 
The impact of HIV co-infection on genital HPV prevalence was evident in the present study 
where we observed a higher prevalence of cervical HPV infection (74%) in HIV-positive 
compared to HIV-negative women (37%). A similar HPV prevalence of 70% among HIV-
positive South African women has been reported else where (Dols et al., 2011). Tobian et al., 
(2011) also reported a significant higher HPV prevalence between HIV-positive and HIV-
negative Ugandan women (74% compared to 48%, P<0.001). However, Baay et al., (2004) 
reported a lower HPV prevalence in HIV-positive women (54%) and HIV-negative women 
(27%) compared to what was observed in our study.  
 
The prevalence of HPV infection in our study was also higher in HIV-positive men (81%) 
compared to HIV-negative men (49%). Müller et al., (2010) also reported a significant higher 
HPV prevalence in HIV-positive South African men compared to HIV-negative South African 
men (90.4% compared to 65.1%, P<0.001). Müller et al., (2010) observed a higher HPV 
prevalence (65.1%) among HIV-negative men compared to our study (49%). The high 
prevalence of genital HPV in HIV-positive women and men was previously reported by 
Palefsky et al., (1999) and by Gomousa-Michael et al., (2000). A higher prevalence of cervical 
and penile HPV infection in HIV-positive women and men compared to HIV-negative women 
and men is a result of HIV induced immune suppression. HIV co-infection was found to 
increase genital HPV infection in both men and women (Levi et al., 2002; Riva et al., 2007) 
 
In our study, an increase in HPV multiple infections were also observed in both HIV-positive 
women and men compared to HIV-negative women and men. Similar findings were reported 
by Levi et al., (2004); Riva et al., (2007) and Müller et al., (2010). HIV-positive and HIV-
negative men displayed a higher prevalence of multiple infections and LR-HPV types 
compared to HIV-positive and HIV-negative women and similar findings have been reported 
by Bleeker et al., (2005b). Women and men co-infected with HIV have a higher prevalence of 
multiple HPV infection and a higher HPV viral load because they are more susceptible to new 
HPV infections and reactivation of latent HPV infection compared to HIV-negative women 
and men due to their HIV-induced immune suppression (Palefsky et al., 1999; Strickler et al., 
2005). Immune suppression may also provide favourable conditions for the virus resulting in a 
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high HPV viral load in HIV-positive women and men (Levi et al., 2004). Interaction between 
HIV proteins and HIV-induced cytokines with HPV proteins is also reported to increase the 
rate of HPV replication resulting in high HPV viral load in HIV co-infected individuals (Dolei 
et al., 1999; Arany and Tyring et al., 1998). HIV-positive women had LR-HPV types that were 
not detected in HIV-negative women, but it remains to be determined if these LR-HPV types 
favour the cervix of HIV-positive women. Riva et al., (2007) reported a higher prevalence of 
HPV-62 (LR-HPV type) in HIV-positive women compared to HIV-negative women and 
suggested that this was probably because HPV-62 favours an immune compromised host. 
HPV-62 prevalence was also higher in our study in both HIV-positive and HIV-negative 
women.  
 
The distribution of HPV types in women seems to be influenced by HIV co-infection and 
lesion type. In our study HPV-62, -52 and -58 were the three commonly detected types among 
HIV-positive women. However in a study reported by Marais et al., (2008) HPV-16, -45 and -
66 were the three most common HPV types detected in Cape Town HIV-positive women. In a 
study reported by Firnhaber et al., (2009) in Johannesburg HIV-positive women HPV-16, -35, 
-51 were the three most common types observed. In our study among women with abnormal 
cytology the three most common HPV types were HPV-58, -16 and -52. In Cape Town, 
women with LSIL the three most common HPV types were HPV-52, -53 and -16 in women 
with HSIL HPV-16, 35 and -18 were the most prevalent type (Allan et al., 2008). While in 
women with HSIL from Pretoria, HPV-35, -58 and -66 were the most prevalent types (Said et 
al., 2009). The different HPV distribution in women observed in our study compared to other 
South African studies could be influenced by the high percentage of women with normal 
cytology (71%) in our study participants. According to Clifford et al., (2006) the prevalence of 
HPV-16 and -18 increases as the cervical cytology disease severity increases while all other 
HPV types decrease with increasing lesion severity.   
 
The high prevalence of HPV-6 and -11 in HIV-negative women compared to HIV-positive 
women can be explained by the fact that only the cervix was sample. HPV-6 and -11 are more 
prevalent in genital warts than in cervical cancer probable if the vagina was also sampled the 
prevalence would differ. In HIV-positive men, HPV-6 and -11 was more prevalent compared 
to HIV-negative men. Müller et al., (2010) also reported a high prevalence of HPV-6 and 11 
among HIV-positive men compared to HIV-negative men. South African men with penile 
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warts demonstrated a 68.5% of HPV-6/11 prevalence (Firnhaber et al., 2010) however in our 
study penile warts data was not available. 
 
In HIV-positive men, HIV-negative men and in HIV-negative women the prevalence of HPV 
was found to decrease with increasing age while in HIV-positive women there was no 
significant change with increasing age. HPV prevalence is reported to be high in young women 
and men and this could be because just started participating in sexual activities and they 
participate frequently in sexual activities at this age (Canadas et al., 2004; Schiffman & Castle 
2005). The risk of HPV infection was found to decrease with the increasing age in HIV-
negative women and men; and this has been reported previously (Kjaer et al., 2000; Cuschieri 
et al., 2004), although in this study the risk of having LR-HPV types did not significantly 
decrease with age in men. In few studies from African countries HPV prevalence was to found 
to decrease with increasing age in women (Thomas et al., 2004; De et al., 2010; Hammouda et 
al., 2011). It is important to notice that HPV prevalence was very low in some of these reports, 
for example in Algerian women (6.3%) compared to South African women in our study 
(Hammouda et al., 2011). In previous study on South African men in Johannesburg HPV 
prevalence was not found to decrease with increasing age (Müller et al., 2010).  
 
De Sanjosé et al., (2007) reviewed distribution of HPV according to age group worldwide and 
found that HPV prevalence decrease with increasing age and pick up in women aged 45 years 
in all continents except in Asia. Banura et al., (2008) reported a similar HPV prevalence 
(74.6%) among Ugandan women of 12-24 years age group as the one observed in our study 
(76%). It was interesting to note that HPV-prevalence decreased from age 18-25 years to 26-35 
years and then increased among older HIV-positive women. The difference in effect of age on 
HPV between HIV-positive and HIV-negative women could be the result of the high rate of 
HPV reactivation due to a more suppressed immune system in older aged women as a result of 
hormonal changes during menopause (Palefsky et al., 1999; Levi et al., 2004; Strickler et al., 
2005; de Sanjosé et al., 2007). Numerous studies report that HPV prevalence in women 
declines with increasing age (Kjaer et al., 2000). According to Kjaer et al., (2000) HPV 
prevalence declines with age even in highly sexually active women such as sex workers. It is 
suggested that the HPV positive women of older age fail to clear the infection they acquired at 
a young age or later, due to immune senescence (Giuliano et al., 2002’Andersson et al., 2005). 
Immune senescence in men has not been reported. The persistence of genital HPV infection 
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could then increase the likelihood of cervical disease progression in these women (Wallboomer 
et al., 1999).  
 
Generally, LR-HPV types were more prevalent among HIV-negative men compared to HIV-
negative women in this study. This was probably because the samples from women were only 
collected at the cervix and not vulva while a single swab from men sampled penile shaft, glans 
and foreskin (in uncircumcised men). It has been reported that more LR-types are likely to be 
detected in specimens from the vagina than in samples from the cervix (Jones et al., 2007). The 
difference in genital HPV types in women and men whether HIV-positive or not can be due to 
the different type of epithelial cells at sampled sites in women (i.e. mucosal epithelium) and 
men (i.e. keratinized epithelium). It is reported that mucosal epithelium is more susceptible to 
HPV infection and replication compared to keratinized epithelium (Thompson et al., 2004). 
Circumcised penises are protected by keratinized stratified squamous epithelium compared to 
the mucosal epithelium of the cervix in women (Castellsague et al., 2002). In our study the 
majority of men were traditionally circumcised and their circumcision was not medical 
confirmed. A high percentages of men circumcised traditionally have an incomplete 
circumcision with some foreskin still remaining on the glans (Morris, 2007; Bailey et al., 
2008).  
 
Not surprisingly the prevalence of HPV infection was found to increase with increasing 
cervical abnormalities confirming the role played by HPV infection in cervical abnormality and 
validity of the test used. All women with HSIL were found to have HPV infection, particularly 
HR-HPV types as reported by others (Walboomers et al., 1999; Lie et al., 2005). Among 
women with abnormal cytology the majority were HIV-positive. HIV-positive women with 
abnormal cytology were also found to have a lower CD4 count compared to those with normal 
cytology. Firnhaber et al., (2010) also reported that HIV-positive women with <200/mL CD4 
count are at increased risk of cervical lesions compared to those with >500/mL CD4 counts. 
 
Women with abnormal cytology were found to have significantly higher prevalence of α3, α5, 
α6, α7, α9 and α10 HPV species compared to women with normal cytology but not 
α1/α8/α11/α13/α15 HPV species. HIV-positive women were also found to have higher 
prevalence of all HPV species regardless of cytology results. The α3 HPV species were found 
to be the most frequently detected species followed by α9 and α7 HPV species in both women 
with abnormal and normal cytology.  Kovacic et al., (2006) also reported high prevalence of α9 
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and α7 HPV species in women with abnormal cytology compared to women with normal 
cytology and that the proportion of cytologic abnormality varies by HPV type. The high 
prevalence of α3 HPV species types (LR-HPV) in women with abnormal cervical cytology was 
because of high prevalence of multiple infections in women with abnormal cervical cytology 
and these types were always found co-infected with HR-HPV types. Majority of women with 
abnormal cervical cytology were HIV-positive and the co-infection of α3 HPV species was 
more prevalent among HIV-positive-women. South African HIV-positive women have been 
reported to have higher prevalence of co-infection with LR-HPV types and this is found to 
increase with decreasing CD4 counts (Richter et al., 2008).  
 
 
HPV-16 and -18 were not the dominant HPV types in this cohort, the reason of these findings 
is that majory of study participants had normal cervical cytology while only 2.5% (12/483) 
women had HSIL. Even though only 12 HSIL cases were observed in our study participants, 
HPV-16 and -18 were detected in 58% of women with HSIL. Firnhaber et al., (2010) also 
reported that HPV-16 and -52 were the most dorminant types in South African women with 
HSIL. In Ugandan women 80% of cervical carcinoma cases are associated with HPV-16 and -
18 single infections (Odida et al., 2008). In Nigerian women 67.6% and 10.3% of invasive 
cervical cancer cases are associated with HPV-16 and HPV-18 respectively (Okolo et al., 
2010). HIV-postive women from Botswana also demonstrated a 51% HPV-16 and -18 
prevalence (Ramogola-Masire et al., 2011). These fidings indicate that proper itroduction of 
HPV vaccines in African coutries will be of great benefit in women. 
 
In conclusion, data from this study showed a significant difference in HPV prevalence 
including multiple infections between HIV-positive women and HIV-negative women as well 
as HIV-positive men and HIV-negative men. We also demonstrated that among HIV-negative 
women HPV prevalence decreases with increasing age and peaks at age 46-66 years however 
in HIV-positive women the peak of HPV prevalence is observed earlier at age 36-45 years, 
suggesting that HIV-positive women require different cervical cytology screening strategy than 
the one of HIV-negative. Among men, HPV prevalence was found to decrease with increasing 
age regardless of HIV-status, however among HIV-negative men the LR-HPV prevalence was 
not found to significantly decrease with increasing age.  We also demonstrate that women with 
abnormal cytology have high prevalence of HPV infection and the most dominant species were 
α9 and α7 HPV species. The α3 HPV species were more prevalent among women with 
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abnormal cytology that were HIV-negative not as single infection. The data from this study 
provides information on distribution of HPV types according to HIV status and cervical disease 
severity in women. The high prevalence of HPV-16, -18 and HPV related types in HIV-
positive women and women with HSIL indicate that proper introduction of HPV vaccine in 
South Africa will be of great benefit as well as regular cervical screening in HIV-positive 
women. 
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3.1. INTRODUCTION 
 
HPV is the most common sexually transmitted virus and 75% of sexually active women and 
men will acquire genital HPV infection at some time in their life. HPV infection can be 
acquired even if a sexual act is not penetrative sex (Kjaer et al., 2001; Schiffman & Castle, 
2005; Palefsky et al., 2007). The highest prevalence of HPV infection and multiple HPV 
infections are observed in young women and men, soon after sexual debut (Kjaer et al., 2001; 
Schiffman & Castle, 2005). Women and men with a high number of current and life sexual 
partners and those who started sexual debut at a younger age are reported to be at increased 
risk of HPV infection and HPV associated disease (Kahn et al., 2002; Winer et al., 2006; 
Burchell et al., 2006, Table 3.1). The high risk sexual behavior of an individual’s sexual 
partner is also reported to increase the risk of HPV infection and HPV associated disease 
(Munoz et al., 1996; Bosch et al., 1996; Winer et al., 2008; Trottier et al., 2010). A sexual 
partner’s HPV-positive status increases the risk of HPV in women and men (Burchell et al., 
2010a). Forming partnerships with older partners or a more sexually experience partner may 
increase the risk of HPV acquisition especially in young women where the cervix is still 
immature with an inadequate production of protective cervical mucus and increased cervical 
ectopy (Collins et al., 2005; Winer et al., 2008). Simultaneous infection with other STIs and 
immune suppression due to infection with HIV or transplantation are also associated with 
increased likelihood of HPV acquisition and transmission (Table 3.1, Burchell et al., 2006; 
Palefsky et al., 2007) 
 
Table 3.1. Factors that increase or decrease the risk of HPV acquisition and transmission 
(Burchell et al., 2006). 
 
 
 
 
 
 
 
 
 
 
Arrows indicate the direction of the association, that is, whether they increase risk via the proposed mechanism  
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 3 
                                           
 
 
53 
Women with male sexual partners with HPV infection and/ or flat penile lesions are more 
likely to acquire HPV infection and later develop cervical disease (Heard et al., 2000). Men 
with female sexual partners with cervical or vulval HPV associated cancer are also at increased 
risk of becoming HPV infected and developing penile lesions (Bleeker et al., 2002; Bleeker et 
al., 2005b). According to Bleeker et al., (2002) the rate of flat penile lesion regression is lower 
in men with female sexual partners who are HPV positive with the same HPV type compared 
to those men with sexual partners who are negative, suggesting that HPV re-infection between 
partners may play an important role in this scenario.  
 
The type-specific concordance in these reports varied between 2 to 64%, presumably because 
of the different sampling methods used. However, recent reports demonstrate a high prevalence 
of HPV type-specific concordance suggesting that recent, improved sampling methods afford 
more accurate genital HPV detection in men (Flores et al., 2008). There are factors that may 
affect HPV concordance among sexually active couples such as sexual behavior of the couple 
investigated, sampling method used, the sensitivity of the test used to detect DNA and the 
differences between acquisition rate in men and women thus resulting in different findings in 
different studies (Parada et al., 2010). 
 
A summary of some studies on HPV concordance and type-specific concordance among 
sexually active couples is presented in Table 3.2. Studies on HPV infection in sexually active 
couples have reported different findings with regards HPV concordance or type-specific 
concordance (Hippelainen et al., 1994; Baken et al., 1995; Strand et al., 1995; Castellsague et 
al., 1997; Rosenblatt et al., 2004; Bleeker et al., 2005a; Giovannelli et al., 2007). Bleeker et 
al., (2005) reported that out of all couples screened, 37% (67/181) shared  at least one HPV 
type; however when both partners were HPV positive the HPV type-specific concordance 
increased to 57.8% (Bleeker et al., 2005a). Giovannelli et al., (2007) reported that all HPV 
positive couples evaluated in their study 64.4% (29/45) shared at least one identical HPV. 
Recently Parada et al., (2010) reported on 504 couples a 79% HPV concordance and 61.8% 
HPV type-specific concordance. 
 
The aims of the study were:  
 (i) to investigate the HPV concordance and type-specific concordance in penile and cervical 
samples from heterosexually active couples that were HIV-positive, HIV-negative, HIV- 
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Table 3.2. Review of some studies describing HPV concordance and type-specific concordance among sexually active couples (Modified from 
Burchell et al., 2006) 
 
Reference Population Sample Age Relationship 
duration 
Findings 
Hippelainen et al., 1994 Women with abnormal 
Pap smear and their 
male partners (Finland 
270 couples Women: mean 
27, range 15-62. 
Men: mean 32, 
range: 17-74 
Median: 18 
months; mean: 
41 months; 
range: 1-300.  
6% (15/270) of couples were HPV-positive concordant 
for the same type. 
Kyo et al.,1994 Women evaluated for 
infertility or who had 
CIN or cervical cancer 
and their male partner 
(Japan) 
53 couples Not reported All married for 
2+ years 
17% (9/53) of couples were HPV-16 positive concordant. 
In couples where at least one partner had HPV (n=26), 
35% were concordant. Discordance was more likely seen 
in female positive and male negative than female negative 
and male positive. 
Baken et al., 1995 Heterosexual partners 
attending STD clinic 
(Seattle, USA) 
50 couples, 45 with 
HPV results 
Women: mean 
26. Men: mean 
29 
Unspecified 29% (13/45) of couples were concordant for the same 
HPV type. In couple where at least one partner had HPV 
(n=41), 32% were concordant. Concordance decreased 
with time since last intercourse. 
Castellsague et al., 1997 Women enrolled in 
case-control studies for 
CIN and their husbands 
(Spain and Columbia) 
816 couples, 431 with 
HPV results 
Men: mean 45 Excluded 
relationships <6 
months duration 
66% (286/431) of couples were HPV-positive. Of these, 
2% (7/286) were HPV- type-concordant. 
Franceschi et al., 2002 Women enrolled in 
case-control studies for 
ICC and CIS and their 
husbands (Spain, 
Columbia, Brazil, 
Tailand and the 
Philippines) 
964 Men: median 45, 
50, and 38 for 
husbands of 
controls women, 
women with ICC 
and women with 
CIS respectively 
Excluded 
relationships <6 
months duration 
HPV-16 positive concordance observed in 0.02% (1/465), 
4% (17/383) and 3% (4/116) of couples where the wife 
was control, an ICC case or a CIS case respectively 
Bleeker et al., 2005a Women with CIN 
lesion and their male 
partners (The 
Netherlands). 
238 couples, 181 with 
HPV results 
Women: mean 
34.7, range: 19-
55. Men: mean 
37.6, range: 22-
58 
Mean: 10.6 
years; Range: 
0.6-35 years 
37% (67/181) of couple have type-specific HPV 
concordance. In couples where HPV was present in at 
least one partner, 38% (67/176) were type concordant. An 
increasing association was seen between viral load in one 
partner and HPV positivity in the other. 
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Reference Population Sample Age Relationship 
duration 
Findings 
Giovannelli et al., 2007 Women with CIN and 
their male partners 
(Italy). 
73 couples, 45 with 
HPV results 
Women: mean 
31, range: 21-51. 
Men: mean 36.7, 
range: 23-58 
>6 months as 
monogamous 
couple. 
64.4% (29/45) of couples had HPV type-specific 
concordance. 
Benevolo et al., 2007 women with vulvar 
condylomatosis and 
male partner had flat 
aceto-whitening lesion 
1 couple 33 years old 
women and 35 
years old men 
Not specified, 
however the 
relationship was 
a stable and 
monogamous  
HPV type specific concordance was observed for 5 
different HPV types 
Hernandez et al., 2008 Women with their male 
partners (Hawaii) 
38 couples, 25 with 
HPV results 
Women: mean 
26, range: 18-57 
years. Men: 
mean 28, range: 
18-59 years 
Not specified 56% (14/25) of couple have HPV concordance. In couples 
where HPV was present in at least one partner, 79% 
11/14) were type-specific concordant.  
Burchell et al., 2009* Women with intact 
uterus and no history of 
cervical lesions/cancer 
and male partners 
263 couples Women and 
men: age range: 
18-24 years 
<6 months 48% (125/263) both HPV positive. Among couples for 
whom at least one partner was HPV infected 64% were 
type-specific concordant for 1 or more types. Current 
partner’s status was important risk factor for prevalent 
HPV infection. 
Parada et al., 2010 Clinically healthy 
women and their male 
partners (Mexico) 
504 couples Women and 
men: age range: 
18-75 years 
>6 months 79% of HPV concordance. 61.8% showed type-specific 
concordance. 
Modified from Burchell et al., 2006. Note * Burchell et al., (2010b) was reported in Burchell et al., (2009), however in Burchell et al., (2010b) more factors were investigated.        
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discordant couples where the female partner was HIV-positive and HIV-discordant couples 
where the male partner was HIV-positive; 
 (ii) to investigate the influence of sexual partner’s HPV positive status on an individual’s 
genital HPV and the impact of HIV configuration of the partnership; 
(iii) to investigate the influence of HIV co-infection and other factors on HPV prevalence in 
women and men; and 
(iv) to investigate the effect of women abnormal cervical cytology on the HPV prevalence of a 
male partner and HPV sharing between couples. 
 
3.2 MATERIALS AND METHODS 
3.2.1 Study population, specimen collection and HPV genotyping 
A total of 601 black heterosexually active couples were recruited between 2006 and 2009 from 
the Manyanani clinic, Empilisweni centre, Gugulethu, Cape Town. For this study a total of 486 
black heterosexually active couples were randomly enrolled, of these 162 were both HIV-
negative, 115 were both HIV-infected, 163 were HIV-discordant in which only the female 
partner was HIV-positive and 46 were HIV discordant in which only the male partner was 
HIV-positive. The reason the remaining 115 couples were not enrolled in this study is because 
they were HIV-negative couples. Since there were sufficient (162 HIV-negative couples) to 
make statistically relevant conclusions they were not included. The mean age of women and 
men participants was 35 years (range: 18-66 years) and 38 years (range: 19-67 years) 
respectively. Samples were collected as described in chapter 2 section 2.2.1. HPV genotyping 
was performed as described in chapter 2 section 2.2.2. 
                                                                        
3.2.2 Statistical analysis 
Factors affecting the risk of any HPV infection were assessed using multivariate logistic 
regression. All analyses were conducted for HR-HPV types and LR-HPV types separately, as 
well as for HR-HPV and LR-HPV types combined. All statistical analyses were conducted 
using STATA 11.0 (StataCorp, College Station, TX, USA) by Dr Leigh Johnson (Centre for 
Infectious Disease, Epidemiology and Research, University of Cape Town) and X2 test (EpiInfo 
Version 5 Statcalc). In all analyses P-values ≤0.05 were considered significant.  
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3.3 RESULTS 
3.3.1 HPV concordance and HPV type-specific concordance in couples according to HIV 
status 
 
To ensure sample adequacy, the presence of the β-globin gene was evaluated and found to be 
negative in 0.4% (2/486) cervical samples and in 3.1% (15/486) penile samples. All β-globin 
gene negative samples were excluded from the analysis resulting in analysis on samples from 
469 couples. HPV concordance was defined as both partners being HPV positive with any 
HPV types. Type-specific HPV concordance among couples was defined as the presence of the 
same HPV genotypes in cervical and penile cells of a couple. Type-specific HPV concordance 
was also referred to as HPV sharing. In HIV-negative couples, 10% (16/155) showed type-
specific HPV concordance; among these couples 15 shared 1 HPV type while 1 couple shared 
2 HPV types. In HIV-positive couples 48% (54/112) showed type-specific HPV concordance; 
28 couple’s shared 1 HPV type and 26 shared 2-10 HPV types. In HIV-discordant couples 
where the female partner was HIV-positive, 30% (47/158) showed HPV type-specific 
concordance; 22 couple’s shared 1 HPV type and 25 couples shared 2-11 HPV types. In HIV-
discordant couples where the male partner was HIV-positive, 11% (5/44) showed type-specific 
HPV concordance; 3 couple’s shared 1 HPV type and 2 couples shared only 2 HPV types 
(Table 3.3).  
 
Table 3.3. Type-specific HPV concordance in HIV-negative couples, HIV-positive couples, 
HIV-discordant couples where the female partner was HIV-positive and HIV discordant 
couples where the male partner was HIV-positive. 
 
  Both HIV+ 
 
N=112 
HIV-discordant 
female HIV+ 
N=158 
HIV-discordant 
male HIV+ 
N=44 
Both HIV- 
 
N=155   
Only female is HPV+ 7        6% 38       24% 6       14% 25       16% 
Only male is HPV+ 17      15% 18       11% 11      25% 33       21% 
HPV concordance* 77      69% 81       51% 16      36% 27       17% 
Type-specific HPV 
concordance# 
    
54      48% 47       30% 5        11% 16        10% 
      1 HPV type 28/54     52% 22/47       47%      3/5          60% 15/16         94% 
      2-11 HPV types 26/54      48% 25/47       53%      2/5          40% 1/16            6% 
* HPV concordance is defined as both partners being HPV positive with any HPV types (different or similar).  
# Type-specific HPV concordance is the number of couples who had the same HPV type(s). HPV+: HPV-positive. 
HIV-: HIV-negative 
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In the adjusted assessment, for men, HIV infection and female partner HIV-positive status 
were both associated with a higher risk of type-specific HPV concordance as their sexual 
partner, though the associations were not significant for LR-HPV types. In women, their HIV-
positive status and low CD4 count were significantly associated with increased risk of type-
specific HPV concordance, but their male partner’s HIV-positive status and low CD4 counts 
were not significantly associated with type-specific HPV concordance instead male partner’s 
HIV-positive status demonstrated a negative association (Table 3.4). The risk of type-specific 
HPV concordance was not significantly associated with any demographic characteristics or 
reported sexual behaviour, in either men or women (data not shown). 
 
3.3.2 The influence of a sexual partner’s HPV positive status on an individual’s genital HPV 
and the impact of the HIV configuration of the partnership 
 
HPV infection was significantly higher in men with female partners who were HPV positive 
compared to men with female partners who were HPV negative (72% compared to 40%; 
P<0.001, Table 3.5). Similarly more women had genital HPV if their male partners were HPV 
positive compared to women with male partners who were HPV negative (72% compared to 
40%; P<0.001). However, increased HPV prevalence was influenced by HIV co- infection, the 
risk being higher in women and men from a partnership where both partners were HIV-positive 
or where only the female partner was HIV-positive and lower in partnerships where both 
partners were HIV-negative. In HIV-discordant couples where the male partner was HIV-
positive, genital HPV was also more prevalent in women and men with HPV-positive partners 
compared to those whose partners were HPV-negative, although the difference was not 
statistically significant (Table 3.5). 
 
3.3.3 The influence of HIV infection and other factors on HPV prevalence in men  
In the adjusted assessment, for men the risk of having any HPV type and any HR-HPV was 
found to significantly decrease with increasing age (AOR, 0.77 [95% CI: 0.63-0.93] and AOR, 
0.70 [95% CI: 0.57-0.86] respectively, per 10-year increase in age; Table 3.6). In contrast, the 
risk of having LR-HPV did not significantly decrease with increasing age in men (Table 3.6). 
HIV-positive men were found to be at higher risk of any HPV type compared to HIV negative 
men and the risk was found to increase with decreasing CD4 count levels (CD4 counts of 
≥350/mL: AOR, 2.54 [95% CI: 1.41-4.54]; CD4 counts of <350/mL: AOR, 3.32 [95% CI:  
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Table 3.4. The association between type-specific HPV concordance and HIV variables in couples (multivariate analysis). 
 
  All HPV types  Only HR-HPV types  Only LR-HPV types 
 men  women  men  women  men  women 
  AOR 95% CI P-value   AOR 95% CI P-value   AOR 95% CI P-value   AOR 95% CI P-value   AOR 95% CI P-value   
 
AOR 95% CI P-value 
                        
HIV- ref  0.06  ref  <0.0001  ref  0.023  ref  0.0001  ref  0.42  ref  <0.0001 
HIV+, CD4 ≥350 1.12 0.61-2.1   2.99 1.63-5.48   1.02 0.49-2.14   2.64 1.28-5.45   1.22 0.61-2.42   3.5 1.46-8.37  
HIV+, CD4 <350 2.02 1.12-3.6   5.82 3.1-10.1   2.23 1.21-4.13   4.24 2.19-8.23   1.72 0.77-3.85   8.4 3.46-20.4  
                        
Partner HIV- ref  0.005  ref  0.08  ref  0.027  ref  0.14  ref  0.1  ref  0.17 
Partner HIV+, 
CD4 ≥350 1.81 0.98-3.4   0.61 0.34-1.1   1.84 0.9-3.74   0.64 0.32-1.28   1.69 0.64-4.47   0.58 0.28-1.18  
Partner HIV+, 
CD4 <350 2.76 1.51-5.1     0.55 0.33-0.97     2.6 1.29-5.22     0.55 0.29-1.02     2.71 1.02-7.22     0.58 0.29-1.17   
ref: Reference. HIV-: HIV-negative. HIV+: HIV-positive. AOR: adjusted odd ratio. Sexual behavior and demographic variables were not statistically significant and were 
therefore not included in the analysis. 
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Table 3.5. The influence of a sexual partner’s HPV status on genital HPV in men and women 
and the impact of the HIV configuration of the partnership. 
      Men   Women      
      n % with HPV   n % with HPV   OR* 95% CI* P-value 
All couples (n = 469)          
Partner HPV-negative 194 40%  194 40%  ref   
Partner HPV-positive 275 72%  275 72%  3.76 2.55-5.54 <0.001 
HIV-negative couples (n = 155)        
Partner HPV-negative 103 32%  96 27%  ref   
Partner HPV-positive 52 50%  59 44%  2.12 1.07-4.2 0.031 
HIV-positive couples (n = 112)        
Partner HPV-negative 28 61%  18 39%  ref   
Partner HPV-positive 84 92%  94 82%  7.12 2.41-21.0 <0.001 
HIV-discordant couples, female HIV-positive (n = 158)     
Partner HPV-negative 40 40%  63 62%  ref   
Partner HPV-positive 118 67%  95 83%  3.04 1.45-6.37 0.003 
HIV-discordant couples, male HIV-positive (n = 44)      
Partner HPV-negative 23 52%  17 35%  ref   
Partner HPV-positive 21 71%   27 56%   2.29 0.66-8.01 0.194 
* Odds ratio for the association between male HPV and female HPV. ref- reference 
 
1.82-6.04]); this was also the case for both HR-HPV types (CD4 counts of ≥350/mL: AOR, 
2.91 [95% CI: 1.7-4.98]; CD4 counts of <350/mL: AOR, 3.1 [95% CI: 1.82-5.28])  and LR-  
HPV types (CD4 counts of ≥350/mL: AOR, 2.46 [95% CI: 1.45-4.17]; CD4 counts of 
<350/mL: AOR, 3.18 [95% CI: 1.86-5.42], Table 3.6).  
 
None of the sexual behaviour characteristics were included in the multivariate analysis, these 
included total number of sexual partners, new sex partners last year, age at first sex, number of 
sexual acts with the study partner last month, duration of relationship with the study partner 
and condom use, as they did not significantly affect male HPV risk. Men with HIV-positive 
female partners were found to be at higher risk of any HPV, HR-HPV and LR-HPV infection 
compared to men with HIV-negative female partners. In men with HIV-positive female 
partners the risk of any HPV type was found to increase with decreasing CD4 count levels of 
their partner compared to men with HIV-negative female partner (CD4 counts of ≥350/mL: 
AOR, 2.37 [95% CI: 1.1.47-3.83]; CD4 counts of <350/mL: AOR, 3.02 [95% CI: 1.86-4.9]); 
this was also true for HR-HPV type (CD4 counts of ≥350/mL: AOR, 2.17 [95% CI: 1.34-3.5]; 
CD4 counts of <350/mL: AOR, 2.32 [95% CI 1.45-3.73]) and LR-HPV type (CD4 counts of 
≥350/mL: AOR, 2.13 [95% CI: 1.33-3.41]; CD4 counts of <350/mL: AOR, 2.37 [95% CI: 
1.49-3.78], Table 3.6).  
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Table 3.6. Risk factors for human papillomavirus (HPV) in men (multivariate analysis).  
 
  All HPV types  Only HR-HPV types  Only LR-HPV types 
            
  AOR 95% CI P-value   AOR 95% CI P-value   AOR 95% CI P-value 
            
Age (per 10 yr increase) 0.77 0.63-0.93 0.009  0.70 0.57-0.86 0.001  0.91 0.75-1.11 0.375 
            
HIV-negative ref  <0.001  ref  <0.001  ref  <0.001 
HIV-positive, CD4 ≥350/mL 2.54 1.41-4.54   2.91 1.7-4.98   2.38 1.4-4.03  
HIV-positive, CD4 <350/mL 3.32 1.82-6.04   3.1 1.82-5.28   3.09 1.81-5.27  
            
Partner HIV-negative ref  <0.001  ref  <0.001  ref  <0.001 
Partner HIV-positive, CD4 
≥350/mL 2.37 1.47-3.83   2.17 1.34-3.5   2.14 1.34-3.42  
Partner HIV-positive, CD4 
<350/mL 3.02 1.86-4.9     2.32 1.45-3.73     2.54 1.59-4.04   
ref: Reference. AOR: adjusted odd ratio. Sexual behavior variables were not statistically significant and were therefore not included in the analysis. 
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3.3.4 The influence of HIV infection and other factors on HPV prevalence in women  
In the adjusted assessment for women the risk of having any HPV type, was found to 
significantly decrease with increasing age, and the same relationship was observed for HR-
HPV and LR-HPV (Table 3.7). HIV-positive women were found to be at higher risk of any 
HPV type compared to HIV-negative women and the risk was found to increase with 
decreasing CD4 count levels among HIV-positive women (CD4 counts of ≥350/mL: AOR, 
3.26 [95% CI: 2.04-5.2]; CD4 counts of <350/mL: AOR, 6.86 [95% CI: 4.08-11.54]); this was 
also the case for HR-HPV type (CD4 counts of ≥350/mL CD4: AOR, 2.89[95% CI: 1.81-4.6]; 
CD4 counts of <350/mL: AOR, 4.22 [95% CI: 2.64-6.76]) and LR-HPV type (CD4 counts of 
≥350/mL CD4: AOR, 4.72 [95% CI: 2.82-7.92]; CD4 counts of <350/mL CD4: AOR, 6.31 
[95% CI: 3.78-10.52]) (Table 3.7). The risk of HPV was not found to differ between women 
with a HIV-positive male partner and women with a HIV-negative male partner, either for HR 
or LR types. Neither the HIV-positive status nor the level of the CD4 count of the male partner 
influenced HPV prevalence in women (Table 3.7). 
 
3.3.5 The effect of female abnormal cervical cytology on the HPV prevalence of a male 
partner and HPV sharing between couples  
 
Men with a female partner with abnormal cervical cytology were found to have a higher 
prevalence of any HPV, HR-HPV and LR-HPV types (67% 88/131; 54% 71/131 and 50% 
66/131), but the prevalence was statistically significant for any HPV and HR-HPV types not 
LR-HPV types, compared to men with a female partner with normal cervical cytology (57% 
178/315; 40% 126/315 and 46% 146/315 respectively, P=0.04 for any HPV type, P=0.006 for 
HR-HPV types and P=0.44 for LR-HPV types; Figure 3.1). The impact of abnormal cervical 
cytology on HPV type-specific concordance was investigated. To do this, couples were 
stratified by HIV status and whether the women had normal or abnormal cervical cytology. 
The degree of HPV type-specific concordance in HIV discordant, HIV-negative and HIV-
positive couples was found to increase where female partners showed abnormal cervical 
cytology (ASCUS, LSIL and HSIL) compared to those where the female partner had normal 
cervical cytology (68% 89/131 compared to 34% 108/314, P<0.0001, Figure 3.1). However, 
the high HPV viral load in women with abnormal cervical cytology must be considered in 
these observations. 
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Table 3.7. Risk factors for human papillomavirus (HPV) in women (multivariate analysis). 
  All HPV types  Only HR-HPV types  Only LR-HPV types 
            
  AOR 95% CI P-value   AOR 95% CI P-value   AOR 95% CI P-value 
            
Age (per 10 yr increase) 0.75 0.61-0.92 0.006  0.74 0.61-0.91 0.005  0.73 0.59-0.92 0.008 
            
HIV-negative ref  <0.001  ref  <0.001  ref  <0.001 
HIV-positive, CD4 ≥350/mL 3.26 2.04-5.2   2.89 1.81-4.6   4.85 2.89-8.13  
HIV-positive, CD4 <350/mL 6.86 4.08-11.54   4.22 2.64-6.76   6.28 3.77-10.49  
            
Partner HIV-negative ref  0.298  ref  0.232  ref  0.779 
Partner HIV-positive, 
CD4≥350/mL 1.58 0.88-2.84   1.54 0.9-2.64   1.06 0.61-1.84  
Partner HIV-positive, CD4 
<350/mL 1.13 0.65-1.98     0.92 0.54-1.56     1.22 0.71-2.1   
ref: Reference. AOR: adjusted odd ratio. Sexual behavior variables were not statistically significant and were therefore not included in the analysis. 
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A significantly higher genital HPV type-specific concordance was observed in HIV-positive 
couples where the female partners had abnormal cervical cytology compared to those where 
female partners had normal cervical cytology (87% 33/38 compared to 59% 41/70, P=0.003). 
A significantly higher genital HPV type-specific concordance was observed in couples that 
were HIV-discordant were the female partner was HIV-positive and had abnormal cervical 
cytology compared to those with female partners with normal cervical cytology (65% 37/57 
compared to 43% 40/93, P=0.009). A significantly higher genital HPV type-specific 
concordance was observed in couples that were both HIV-negative with female partners with 
abnormal cervical cytology compared to those with female partners with normal cervical 
cytology (34% 11/32 compared to 13% 15/112, P=0.007, Figure 3.2). HPV type-specific 
concordance was not statistically different in couples that were HIV-discordant where the male 
partner was HIV-positive with female partners with abnormal cervical cytology compared with 
those with female partners with normal cervical cytology (75% 3/4 compared to 31% 12/39, 
P=0.11). The small number of women with normal cervical cytology in HIV-discordant 
relationships where the male partner was HIV-positive possibly skewed these results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. The effect of abnormal cytology of the female partner on HPV prevalence in men 
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Figure 3.2. Genital HPV type-specific concordance in couples stratified for female cervical 
cytology, normal or abnormal (ASCUS, LSIL and HSIL). HIV disc F+: HIV discordant 
couples where the female partner is HIV-positive. HIV disc M+: HIV discordant couples 
where the male partner is HIV-positive. HIV-: HIV-negative. HIV+: HIV-positive 
 
 
3.4 DISCUSSION 
This study examined, in detail, the relationship between HIV and HPV prevalence among 
sexual couples, and demonstrates the influence of a partner’s HIV positive status on HPV 
prevalence in women and men from HIV-concordant and HIV-discordant relationships. An 
individual’s HIV infection was associated with increased genital HPV in both men and women, 
with a stronger association by decreasing CD4 count in women than men as has been earlier 
reported by others (Riva et al., 2007). Men with HIV-positive female partners were also found 
to have a higher risk of any HPV, HR-HPV and LR-HPV infection compared to men with 
HIV-negative female partners. However, women with HIV-positive male partners were not 
found to have a higher risk of any HR, HR-HPV or LR-HPV infection compared to women 
with HIV-negative male partners. These findings suggest that women’s HPV risk is influenced 
only by their own HIV status, while the HPV prevalence in men is determined by their own 
HIV-positive status and that of their female partner. HIV-positive women are reported to have 
a higher cervical HPV viral load compared to HIV-negative women and this has been 
associated with low CD4 count levels suggesting that HIV co-infection may increase genital 
HPV viral load in women (Lefevre et al., 2004). The finding that a women’s HPV infection 
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risk was not influenced by her male partner’s HIV status may be explained by the low rate of 
male to female HPV transmission compared to female to male HPV transmission, possibly due 
to less virus available for transmission in men (Hernandez et al., 2008). The finding that men’s 
HPV infection risk was influenced by his female partner’s HIV status may also be explained by 
the high rate of female to male HPV transmission compared to female to male HPV 
transmission (Hernandez et al., 2008).  
 
We demonstrated that a partner’s HPV positive status increases the risk of HPV in women and 
men; similar observations have been reported elsewhere (Burchell et al., 2010a). Parada et al., 
(2010) also reported that detection of genital HPV DNA in women and men is associated with 
the detection of HPV in their sexual partner. HIV-negative couples were found to have a 
significantly lower prevalence of type-specific HPV concordance compared to couples in 
which both partners were HIV-positive and HIV-discordant couples in which the female 
partner was HIV-positive. HIV-positive and HIV-discordant couples where the female partner 
was HIV-positive were more likely to share multiple HPV types while HIV-negative couples 
were more likely to share single HPV types. The higher prevalence of type-specific HPV 
concordance in couples that were both HIV-positive and HIV-discordant where female partner 
was HIV-positive could be due to the higher prevalence of HPV observed in HIV-positive 
women and men. It was interesting to note that type-specific HPV sharing did not differ 
between HIV-negative couples and HIV-discordant couples where the male partner was HIV-
positive and the number of HPV types shared was similar.  
 
Hippelainen et al. (1994) showed a lower level of HPV infection in both partners (24.4%) 
compared with our study and the HPV type-specific concordance was only 22.7% despite the 
women in their study having abnormal cervical cytology (Hippelainen et al., 1994). 
Castellsague et al., (2002) described in a Columbian study, a high risk cervical cancer area and 
a Spanish study, a low risk cervical cancer area, that the prevalence of HPV concordance of 
any type in both partners was 9% in Columbia and 4.9% in Spain (Castellsague et al., 1997). 
The Columbian findings were similar to our findings for HIV-negative couples and the 
prevalence was far higher in our HIV-positive and discordant couples. Bleeker et al., (2005a) 
reported that out of all couples screened, 37% (67/181) shared  at least one HPV type; however 
when both partners were HPV positive the HPV type-specific concordance increased to 57.8% 
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(Bleeker et al., 2005a). The HPV concordance in Bleeker et al., (2005a) study was not higher 
than the one observed in our study even though the women partners had cervical intraepithelial 
neoplasia while in our study only 29% of women had abnormal cytology (includes ASCUS, 
LSIL and HSIL). It was also found that among men type-specific HPV concordance was 
influenced by both their own HIV status and their female partner’s HIV-positive status, while 
in women HPV type-specific concordance was associated with their own HIV status and low 
CD4 count but not their male partner’s HIV-positive status. The higher frequency of type-
specific HPV concordance in couples that were HIV-positive or HIV-discordant, specifically 
where the female partner was HIV-positive, could be the result of higher HPV-viral load seen 
in HIV-positive individuals due to immune suppression. It has been demonstrated that women 
and men with high HPV viral load more frequently shared HPV compared to those with a 
lower HPV viral load (Bleeker et al., 2005a).  
 
We observed that men with female partners with abnormal cervical cytology were found to 
have a higher prevalence of HPV and HPV sharing compared to men with female partners with 
normal cervical cytology regardless of HIV status. Castellsague et al., (1997) also reported that 
men with female partners with cervical neoplasia had a higher HPV prevalence compared to 
men with female partners with normal cytology. The observed increased HR-HPV prevalence 
in men with female partner with abnormal cervical cytology compared to those with normal 
cervical cytology but not the LR-HPV prevalence can be explained by the high association of 
HR-HPV types with abnormal cervical cytology compared to LR-HPV types and high HPV 
viral load in women with abnormal cervical cytology. Women with abnormal cervical cytology 
were found to significantly share more HPV types compared to women with normal cervical 
cytology. These findings could be explained by high HPV prevalence and HPV viral load 
found in cervical samples from women with abnormal cervical cytology compared to normal 
cervical cytology. Therefore the high viral load in women with abnormal cervical cytology 
might increase the risk of HPV sharing with the partner and transmission (Bleeker et al., 
2005a).  
 
In conclusion, results from this study demonstrated that men’s HIV status did not influence the 
prevalence of genital HPV (any type), HR-HPV or LR-HPV in their female partner whereas 
women’s HIV-positive status increased the HPV risk of their male partner. We also 
demonstrated that, in men, type-specific HPV concordance with their female partner is 
influenced by their own HIV-status and that of their female partner. However in women type-
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specific HPV concordance is influenced by their own HIV-status and not that of their male 
partner. Abnormal cervical cytology was found to influence HPV prevalence of their male 
partners and type-specific HPV concordance in the partnership. Irrespective of sexual behavior, 
HIV-positive status in women as well as abnormal cervical cytology status influences HPV 
type-specific concordance within the partnership. The data from this study substantially 
increases the very limited data reported on type-specific genital HPV concordance between 
sexually active couples and especially HIV-positive and HIV-discordant couples  
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4.1 INTRODUCTION 
Cervical or penile infection with HR-HPV and its persistence may leads to the development of 
cervical or penile lesions (Castellsague et al., 2006; Munoz et al., 2006). Women who are 
found to harbour HR-HPV but have normal cervical cytology are reported to have a higher risk 
of developing HSIL compared to women with normal cytology and are HR-HPV negative 
(Munoz et al., 2006). Elevated HPV viral load predicts the progression of precancerous lesions 
and cancer in both women and men (Moberg et al., 2005). The HPV viral load significantly 
increase with increasing cervical cytology abnormalities and women with high HPV viral load 
were found to have significantly increased risk of disease progression after 2 years compared to 
women with low HPV viral load (Swan et al., 1999; Lefevre et al., 2004; Moberg et al., 2005; 
Carcopino et al., 2011; Lowe et al., 2011). Ho et al., (2006) followed women with LSIL and 
observed that women with increased viral load by real-time PCR had 7-fold higher risk of 
developing HSIL compared to women with LSIL but without increased HPV viral load.  
 
It has been suggested that high HPV viral load would increase the risk of HPV persistence over 
time and the risk of disease progression (van Duin et al., 2002; Wu et al., 2006; Zhang et al., 
2010). Persistent HR-HPV infection is the risk factor for cervical disease progression (Fontaine 
et al., 2008). A significant clustering of HPV types and species is reported in women with 
abnormal cervical cytology compared to women with normal cervical cytology. It is also 
reported that women with multiple HPV infection have increased risk of HPV persistence and 
cervical disease progression (Ho et al., 1998; Fife et al., 2001; Trottier et al., 2006; Trottier et 
al., 2008, Spinillo et al., 2009). The frequency of HPV DNA integration is also reported to 
increase with increasing HPV viral load (Peitsaro et al., 2002). Women with male sexual 
partners with HPV infection are more likely to acquire HPV infection and develop cervical 
disease (Heard et al., 2000; Burchell et al., 2010b). It was previously reported that men with a 
high HPV viral load more frequently share HPV types with their female partner compared to 
men with low viral load, suggesting that high viral load may enhance viral transmission 
between partners (Bleeker et al., 2005a).  
 
HIV co-infected women progress to cervical cancer about 10 years earlier than HIV-negative 
women (Lomalisa et al., 2000). Even though data on their sexual behaviour including when 
they started sexual activity was not available, however, they find that HIV-positive women 
presented with invasive cervical cancer 10 years earlier than the HIV-negative women 
(Lomalisa et al., 2000). Immune competence plays an important role in cervical disease 
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progression. Women with low CD4 cell counts are reported to have a higher viral load and a 
greater risk of HPV persistent infection (Fontaine et al., 2008; Denny et al., 2008; Luchters et 
al., 2010). That is why after controlling for age and CD4 cell counts, HIV-positive women with 
a HPV-16 viral load of <107 copies/µg were found to have 13.5 month median duration of 
HPV persistent infection compared to women with HPV-16 viral load of ≥107 copies/µg who 
had 21.3 month median HPV duration (Fontaine et al., 2008). Women with a stable HPV viral 
load were less likely to show progressive cervical disease compared to those with HPV viral 
load which increased by 2 logs (Fontaine et al., 2008). Women with low CD4 cell count are at 
increased risk of HPV acquisition and persistence infection making them at risk of progressing 
to cervical cancer. Cervical cancer rate in HIV-positive women has not gone down despite the 
use of ARTs because the use of ARTs only will not reduce the risk of cervical cancer, 
however, the use of ARTs will make HIV-positive women to live longer (Atashili et al., 2011). 
Atashili et al., (2011) suggested that cervical cancer cases will drop in South Africa if HIV-
positive women on ARTs get cervical cancer screening even if once in their lifetime 
 
Delmas et al., (2000) reported a 23% cumulative incidence of LSIL after 2 years in HIV-
positive women with normal cervical cytology and HPV DNA negative results at baseline 
(Delmas et al., 2000). Whereas Harris et al., (2005) reported a 9% cumulative incidence of 
LSIL in HIV-positive women with a CD4 count <200/µl, 9% also in women with CD4 count 
200-500/µl and 4% in women with CD4 count >500/µl. However participants in the Delmas et 
al., (2000) study were younger than those in the Harris et al., (2005) study. It has been reported 
that young age is a risk factor for HPV infection and LSIL, therefore the young age of the 
women in the Delmas et al., (2000) study could account for the increased cumulative incidence 
of HPV observed, compared to women in the Harris et al., (2005) study. 
  
In the present study we detected and quantified genital HPV viral load in men and women 
using the in-house hpVIR assay which detects and quantifies 12 HR-HPV (includes HPV-16, -
18, -31, -33, -35, -39, -45, -51, -52, -56, -58 and -59) types associated with 93.1% of cervical 
cancer cases worldwide (Moberg et al., 2003; Clifford et al., 2006; Gustavsson et al., 2009). 
The HR-HPV types detected by hpVIR assay were then referred to as hpVIR HR-HPV types 
because we previously reported on 15 HR-HPV types detected by Roche assay.  
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The objectives of the study were:  
(i) to investigate the respective hpVIR HR-HPV viral loads in HIV-positive and HIV-negative 
women and men; 
(ii) to investigate the effect of CD4 counts and HIV viral load on hpVIR HR-HPV viral load; 
(iii) to investigate the association of hpVIR HR-HPV viral load with cervical abnormality; 
(iv) to investigate factors associated with cervical abnormalities; and 
(v) to investigate the association between cervical or penile hpVIR HR-HPV viral load and 
HPV sharing between partners. 
 
4.2 MATERIALS AND METHODS 
4.2.1 Study population and specimen collection 
Study participants were recruited from the Manyanani clinic, Empilisweni Centre, Cape Town, 
South Africa. The Research Ethics Committee of the University of Cape Town approved all 
aspects of the investigation. All available samples underwent HPV viral load analyses even if 
they were HR-HPV negative by linear array HPV genotyping. A total of 292 HIV-negative 
women, 258 HIV-positive women, 412 HIV-negative men and 153 HIV-positive men were 
enrolled. However when the participants were grouped with their partners there we 542 couples 
enrolled, of these 246 were both HIV-negative, 103 were both HIV-infected, 155 were HIV-
discordant where the female was HIV-positive and 41 were HIV discordant where the male 
was HIV-positive. The mean age of the women and men were 34 years (range, 18-66 years) 
and 38 years (range, 19-78 years) respectively. Of the men enrolled in the study 94% were 
circumcised. Samples were collected as described in chapter 2 section 2.2.1.  
 
4.2.2 Detection and quantification of HPV DNA 
DNA was extracted from both cervical and penile cells using the MagNA Pure Compact 
Nucleic Acid Isolation Kit (Roche Diagnostics, Mannheim, Germany) and automated MagNA 
Pure Compact machine (Roche Diagnostics, Mannheim, Germany). DNA was stored at -20°C 
and shipped to University of Uppsala, Sweden for detection and quantification of HPV DNA. 
Since the assay that detects and quantifies HPV DNA by real-time (RT) PCR was not set-up in 
Prof A.L Williamson’s laboratory it was arranged for me to go to Prof Ulf Gyllensten’s 
laboratory in Sweden. Inger Gustavsson trained me to perform the assay. HPV was detected 
and quantified by a RT-PCR based assay described by Gustavsson et al., (2009) and is called 
hpVIR. Even though hpVIR is an “in-house method”, it has been reported to have similar 
sensitivity and specificity to Hybrid Capture 2 (HC2), a Food and Drug Administration (FDA) 
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approved assay (Gustavsson et al., 2009). The hpVIR assay detects HR-HPV types individually 
or in groups and includes their viral load, while HC2 identifies 13 HR-HPV types as a group 
(Gustavsson et al., 2009). 
 
The hpVIR assay is based on four parallel real-time PCRs from each DNA sample, one reaction 
to quantify the amount of a human single copy gene (house keeping gene) (HMBS, Homo 
sapiens hydroxymethylbilane synthase; GenBank accession no. M95623.1) and the three other 
reactions to detect and quantify HR-HPVs (includes HPV-16, -18, -31, -33, -35, -39, -45, -51, -
52, -56, -58, and -59. A housekeeping gene must not change with changing conditions of the 
cells. HMBS is reported to be one of the best housekeeping gene (Cicinnati et al., 2008). There 
are difficulties in finding a good housekeeping gene to be used as normalization control for 
example the level of other genes may vary in cells from different cytological cervical lesions 
and normal cytology (Cicinnati et al., 2008). Use of a second housekeeping gene in our study 
would improve or confirm the findings. 
 
 
The results are presented as individual types, except for HPV18 and - 45 which are detected as 
a phylogenetically related group and HPV33, -52, and -58 which are similarly detected. The 
real-time PCR assay was carried out in a final volume of 25 µl, containing 3 µl template DNA 
from cervical cells or 6 µl from penile cells, Taqman® Universal PCR master mix with no 
AmpErase® UNG (Applied Biosystems, Inc, Foster City, CA, USA), 3.1 μg of bovine serum 
albumin (Sigma, St Louis, MO, USA), 200 nM of each primer (Thermo Hybaid, Waltham, 
MA, USA) and probe (Applied Biosystems, Inc, Foster City, CA, USA). Amplification and 
detection steps were performed using 7900 HT Sequence Detection System (Applied 
Biosystems, Inc, Foster City, CA, USA). The primers and probes sequences are according to 
Moberg et al., (2003) and Gustavsson et al., (2009). The amplification ramp includes an initial 
hold program of 10 minutes at 95°C followed by a two-step cycle consisting of 95°C for 15 
seconds and 57°C for 1 minute that was repeated 40 times. The sensitivity of the HPV assay 
was determined using plasmids containing the full genome of different HPV types. Standard 
curves ranging from 102 to 105 copies were established for each HPV type or group of HPV 
types to be detected. A highly significant linear relationship was seen between HPV copy 
number and threshold cycle (Ct) for all HPV types detected by the system. The threshold for a 
positive HPV type was set at 10 copies per PCR. Similarly, a linear relationship was seen 
between copy number of the human HMBS gene and threshold cycle, and as threshold for 
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inclusion in the study a copy number of 10 genomic equivalents were used. The RT-PCR data 
was analysed with the applying software SDS version 2.2. and the HPV copy number and viral 
load (HPV copy number per human genome equivalent) was calculated using Microsoft excel.  
Copies per cell were calculated by dividing HPV copies per sample by copies of house-keeping 
gene HMBS. 
 
4.2.3 Statistical analyses 
Statistical analyses were performed using X2 test (EpiInfo Version 5 Statcalc) and the Mann-
Whitney test (GraphPad Prism® 5) when comparing HPV viral load between groups. Kruskal-
Wallis test was used when analysing the effect of CD4 counts on hpVIR HR-HPV viral load. 
Univariate analyses were conducted using STATA 11.0 (StataCorp, College Station, TX, 
USA). Advanced statistics were performed by Dr Leigh Johnson (Centre for Infectious Disease 
Epidemiology and Research, University of Cape Town). In all analyses P-values ≤0.05 were 
considered significant.  
 
4.3 RESULTS 
4.3.1 hpVIR HR-HPV prevalence in women and men according to HIV status 
To determine if the genital sampling was adequate, a house keeping gene known as HMBS 
copies was quantified in each sample. HMBS copies were found to be <10 in 3/550 (0.5%) 
cervical cells and in 64/565 (11%) penile cells. The samples with <10 HMBS copies were not 
included in the analysis. Both HIV-positive women and men had a significantly higher 
prevalence of hpVIR HR-HPV (51% 131/257; 59% 85/143 respectively) compared to HIV-
negative women and men (21% 61/290; 32% 113/358 respectively, P<0.0001 for both women 
and men, Figure 4.1).  
 
HIV-positive men were found to have a higher hpVIR HR-HPV prevalence compared to HIV-
positive women however the difference was not statistically significant (59% 85/143 compared 
to 51% 131/257, P=0.1). HIV-negative men were found to have a significantly higher hpVIR 
HR-HPV prevalence compared to HIV-negative women (32% 113/358 compared to 21% 
61/290, P=0.003). Among HPV-positive participants, both women and men were found to have 
a significantly higher prevalence of multiple hpVIR HR-HPV infections compared to HIV-
negative women and men (49% 65/131 compared to 28% 17/61, P=0.007 for women and 60% 
51/85 compared 33% 31/113, P=0.0002 for men). HIV-positive women and men were found to 
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have a higher prevalence of all the hpVIR HR-HPV genotypes detected compared to HIV-
negative women and men respectively (Figure 4.2). HIV-positive men and HIV-negative men  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. hpVIR HR-HPV prevalence in women and men according to HIV status.  
 
were found to have a higher prevalence of all hpVIR HR-HPV genotypes detected compared to 
HIV-positive women and HIV-negative women respectively except for HPV-31 in HIV-
positive men and women and HPV-35 in HIV-negative men and women. The HPV33/52/58 
phylogentic group was the most prevalent (Figure 4.2). 
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Figure 4.2. hpVIR HR-HPV genotypes in HIV-positive and HIV-negative women (A) and men 
(B). 
 
The agreement between hpVIR and Roche HPV genotyping assay was investigated using 
kappa analysis. In women the agreement of detecting HPV-16 was k=0.91 and in men it was 
k=0.87. This indicates good agreement between hpVIR assay in this chapter and Roche HPV 
genotyping assay reported in chapter 2 and 3. Even though hpVIR assay uses 3μl of DNA 
template it detects HPV types similar with Roche assay that uses 50μl of DNA template. 
 
4.3.2 hpVIR HR-HPV viral load in men and women 
Genital hpVIR HR-HPV viral load was compared between men and women for each of the 
HPV types studied. Women were found to have a higher number of HPV-16, -18/45, -
33/52/58, -39, -51 copies per sample compared to men and also for combined hpVIR HR-HPV 
groups (Table 4.1). When we look at hpVIR HR-HPV copies per cell, men were found to have 
higher hpVIR HR-HPV copies per cell compared to women for HPV-16 (median: 5.6 range: 0-
7353 compared to: 1.2 range: 0-97.2 respectively, P=0.07), HPV-51 (median: 6.8 range: 0-
2785 compared to: 2.02 range: 0-782.2 respectively, P=0.13) and for all hpVIR HR-HPV 
(median: 2.0 range: 0-23530 compared to: 1.0 range: 0-1866 respectively, P=0.04).  
 
The higher hpVIR HR-HPV viral load we observed in men could be the results of fewer cells 
sampled at penile sites compared to cervical sites, the different cell types sampled at the 
different sites from women (mucosal epithelium) and men (keratinised epithelium) could also 
played a role in this. When participants were stratified according to their HIV status and 
gender; in general HIV-positive women were found to have a higher median hpVIR HR-HPV 
viral load per cell for all types, except HPV-59, compared to HIV-negative women however 
this was only statistically significant for α9 HPV species (HPV-16, -31, -33, -35, -52, -58; 
P=0.022, Table 4.2). HIV-positive men and were found to have a significantly higher number 
of copies per cell for HPV-39 compared to HIV-negative men (P=0.024, Table 4.3). In men, 
HPV viral load of all other types was not found to differ significantly between HIV-positive 
and HIV-negative men.  
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Table 4.1. hpVIR HR-HPV types in women and men and their HPV viral load expressed as 
number of copies per cell and sample.  
Subjects, viral load Women Men P-value 
HPV-16 positive subjects n= 36 n= 41  
No of copies/sample 10860 (29 - 1457000) 1711 (13,2 - 7618000) 0.04 
No of copies/cell 1,2 (0 - 97,2) 5,6 (0 - 7353) 0.07 
HPV-18/45 positive subjects n= 50 n= 45  
No of copies/sample 7919 (9 - 4511000) 1947 (13,5 - 987100) 0.02 
No of copies/cell 3,5 (0 - 411,0) 3,9 (0 - 1921) 0.65 
HPV-31 positive subjects n= 24 n = 17  
No of copies/sample 2591 (25 - 2268000) 552 (16,9 - 1925000) 0.21 
No of copies/cell 0,5 (0 - 256) 1,02 (0 - 66,9) 0.19 
HPV-33/52/58 positive subjects n= 85  n= 102  
No of copies/sample 28290 (12 - 25090000) 636,1 (11 - 44070000) <0,0001 
No of copies/cell 2,8 (0 - 1414) 1,7 (0 - 23530) 0.47 
HPV-35 positive subjects n= 40 n= 32  
No of copies/sample 1710 (26 - 2960000) 5562 (3,1 - 19930000) 0.12 
No of copies/cell 2,8 (0 - 7105) 0,61 (0 - 1866) 0.02 
HPV-39 positive subjects n= 18 n= 24  
No of copies/sample 7192 (2,3 - 5152000) 240,8 (6,1 - 134700) 0.03 
No of copies/cell 0,63 (0 - 1234) 0,85 (0 - 293) 0.92 
HPV-51 positive subjects n= 22 n= 31  
No of copies/sample 32900 (94,8 - 5251000) 3423 (13,3 - 954100) 0.0007 
No of copies/cell 2,02 (0 - 782,2) 6,8 (0 - 2785) 0.13 
HPV-56 positive subjects n= 30 n= 34  
No of copies/sample 1636 (0,6- 16110000) 287,6 (10,2 - 104600) 0.07 
No of copies/cell 0,13 (0 - 384,3) 3,8 (0 - 3655) 0.1 
HPV-59 positive subjects n= 18 n= 28  
No of copies/sample 467 (13,8 - 701600) 253 (13,7 - 1056000) 0.42 
No of copies/cell 0,09 (0 - 305) 0,81 (0 - 707) 0.2 
HPV-16, -18/45, -31 positive subjects n= 110 n= 103  
No of copies/sample 5645 (9 - 4511000) 1611 (13 - 7618000) 0.002 
No of copies/cell 2 (0 - 411) 3 (0 - 7353) 0.23 
HPV-33/52/58, -35, -39, -51, -56, -59 
positive subjects n= 213 n= 251  
No of copies/sample 8162 (0,6 - 25090000) 608 (6 - 44070000) <0,0001 
No of copies/cell 1 (0 - 1866) 2 (0 - 23530) 0.06 
All HPV positive subjects n= 323 n= 354  
No of copies/sample 7013 (0,6 - 25090000) 735 (6 - 44070000) <0,0001 
No of copies/cell 1 (0 - 1866) 2 (0 - 23530) 0.04 
Note: Data are no. (%) of subjects or median (range) and the P-values were calculated by Mann-Whitney test 
(two-tailed), significantly P-values are in bold writing. 
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Table 4.2. hpVIR HR-HPV viral load per sample in women according to HIV-status. 
HPV type   HIV-negative women   HIV-positive women P-value 
    n Median   n Median 
HPV-16 
 
8 0.43 
 
29 2.35 0.238 
HPV-18/45 9 0.27 
 
41 1.33 0.398 
HPV-31 
 
9 0.25 
 
15 0.7 0.698 
HPV-33/52/58 22 1.02 
 
67 3.18 0.220 
HPV-35 
 
16 0.51 
 
24 1.14 0.456 
HPV-39 
 
7 0.1 
 
14 0.36 0.709 
HPV-51 
 
3 1.15 
 
19 2.17 0.363 
HPV-56 
 
9 0.024 
 
25 0.091 0.339 
HPV-59 
 
8 0.089 
 
14 0.009 0.838 
        α5 HPV species 3 1.15 
 
19 2.17 0.363 
α6 HPV species 9 0.024 
 
25 0.091 0.339 
α7 HPV species 24 0.15 
 
58 0.65 0.245 
α9 HPV species 47 0.63   100 3.9 0.022 
 
α5 and α6 HPV species include HPV-51 and -56 respectively; α7 HPV species includes HPV-18, -39, -45 and -
59; α9 HPV species includes HPV-16, -31, -33, -35, -52 and -58. P-values were calculated by Mann-Whitney test 
(two-tailed). Significant P-values are in bold. 
 
 
4.3.3 The effect of CD4 counts on hpVIR HPV viral load in HIV-positive women and men 
HIV-positive women with CD4 counts >350/mL had significantly lower α7 HPV species viral 
loads (median 0.12 copies per cell) than HIV-positive women with CD4 ≤350/mL (median 
1.52 copies per cell, P= 0.008), but none of the median HPV viral loads for other HPV 
types/species were found to be significantly lower in HIV-positive women with CD4 counts 
>350/mL (results not shown). Unexpectedly, HIV-positive men with CD4 counts >350/mL had 
significantly higher HPV-39 viral loads (median 4.29 copies per cell) than HIV-positive men 
with CD4 ≤350/mL (median 0.026 copies per cell, P= 0.017), however HIV-positive men with 
CD4 counts >350/mL and infected with HPV-39 were few (n=3). None of the median HPV 
CD4 counts >350/mL and infected with HPV-39 were few (n=3). None of the median HPV 
viral loads for other HPV types/species were found to be significantly different in HIV-positive 
men according to CD4 level. 
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Table 4.3. hpVIR HR-HPV viral load per sample in men according to HIV-status. 
HPV type   HIV-negative women   HIV-positive women P-value 
    n Median   n Median 
HPV-16 
 
21 3.55 
 
24 0.92 0.666 
HPV-18/45 23 3.94 
 
24 3.05 0.670 
HPV-31 
 
10 0.91 
 
7 1.02 0.845 
HPV-33/52/58 67 0.42 
 
67 1.01 0.193 
HPV-35 
 
17 0.4 
 
27 1.48 0.952 
HPV-39 
 
14 1.28 
 
17 0.04 0.024 
HPV-51 
 
15 8.22 
 
22 1.88 0.370 
HPV-56 
 
30 0.24 
 
23 0.06 0.566 
HPV-59 
 
16 1.01 
 
19 0.11 0.059 
        α5 HPV species 15 8.22 
 
22 1.88 0.370 
α6 HPV species 30 0.24 
 
23 0.06 0.566 
α7 HPV species 46 3.24 
 
45 0.77 0.132 
α9 HPV species 96 1.01   89 1.48 0.228 
α5 and α6 HPV species include HPV-51 and -56 respectively; α7 HPV species includes HPV-18, -39, -45 and -
59; α9 HPV species includes HPV-16, -31, -33, -35, -52 and -58. P-values were calculated by Mann-Whitney test 
(two-tailed). Significant P-values are in bold. 
 
 
 
4.2.4 Prevalence of hpVIR HR-HPV and viral load in women with normal and abnormal 
cervical cytology 
 
When women with valid cervical hpVIR HR-HPV data were stratified according to cervical 
cytology, a total of 374 had normal cervical cytology, 40 had ASCUS, 77 had LSIL, and 11 
had HSIL. Women with normal cervical cytology were on average 35 years of age (range: 18-
66 years), women with ASCUS 34 years (range: 21-61 years), women with LSIL 34 years 
(range: 18-49 years) and women with HSIL 39 years (range: 32-47 years). In women with 
normal cervical cytology 22% (82/374) were found to have hpVIR HR-HPV infection, in 
women with ASCUS 46% (22/48) were found to have hpVIR HR-HPV infection, in women 
with LSIL 79% (61/77) were found to have hpVIR HR-HPV and women with HSIL 100% 
(11/11) were found to have hpVIR HR-HPV infection. The prevalence of hpVIR HR-HPV 
infection was found to increase with increasing cervical disease and thus was positively 
associated with cervical disease (R2=0.993, Figure 4.3).  
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Figure 4.3. Prevalence of hpVIR HR-HPV in women with normal cervical cytology (N=374), 
atypical squamous cell of undetermined significance (ASCUS, N=48), low-grade squamous 
intraepithelial lesion (LSIL, N=77), and high-grade squamous intraepithelial lesion (HSIL, 
N=11). 
 
 
hpVIR HR-HPV prevalence was then further stratified according to age and cervical cytology. 
Women who were ≥30 years were found to have a higher hpVIR HR-HPV prevalence 
compared to women <30 years of age (normal cervical cytology: 25% 20/59 compared to 17% 
23/137, P=0.08; ASCUS:  47% 14/30 compared to 44% 8/18, P=0.88 and LSIL: 66% 21/32 
compared to 89% 39/44, P=0.015) however the difference was only statistically significant for 
women with LSIL. Women with HSIL were all above the age of 30 years (Figure 4.4). Women 
with ASCUS, LSIL and HSIL were found to have significantly higher hpVIR HR-HPV copies 
per sample and copies per cell compared to women with normal cervical cytology (Table 4.4), 
while a comparison between women with different grades of cervical disease showed no 
significant difference. Women with ASCUS, LSIL and HSIL were found to have significantly 
higher α9 HPV copies per sample and copies per cell compared to women with normal cervical 
cytology, for α7 HPV species viral load was statistically different between women with normal 
cervical cytology and ASCUS and women with LSIL while for α5/6 HPV species viral load 
was statistically different between women with normal cervical cytology and LSIL not ASCUS 
(Table 4.4). Women with abnormal cervical cytology were found to have a higher hpVIR HR-
HPV viral load compared to women with normal cervical cytology.  
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Figure 4.4. Prevalence of hpVIR HR-HPV in women with normal cytology, atypical squamous 
cell of undetermined significance (ASCUS) low-grade squamous intraepithelial lesion (LSIL), 
and high-grade squamous intraepithelial lesion (HSIL) according to age. 
 
 
Table 4.4. hpVIR HR-HPV viral load in women with normal and abnormal cervical cytology 
according to species level. 
 
HPV Species Cytology No of copies/samples P-value No of copies/cell P-value 
α5/6      
 Normal 978 (0-320800) ref 0.1 (0-75) ref 
 ASCUS 338200 (2-5251000) 0.19 71 (0-782) 0.09 
 LSIL 31840 (20-16110000) 0.009 2 (0-384) 0.01 
 HSIL … … … … 
α7      
 Normal 941 (2-5152000) ref 0.01 (0-485) ref 
 ASCUS 18670 (73-861500) 0.008 3 (0-411) 0.008 
 LSIL 16930 (1-4511000) 0.03 2 (0-1234) 0.05 
 HSIL … … … … 
α9      
 Normal 2424 (3-25090000) ref 0.2 (0-1414) ref 
 ASCUS 31610 (6-3328000) 0.05 1.8 (0-519) 0.02 
 LSIL 76269 (12-19930000) <0.0001 9 (0-1866) <0.0001 
 HSIL 73290 (29-10970000) 0.02 18 (0-870) 0.003 
All      
 Normal 2123 (0.6-25090000) ref 0.12 (0-1414) ref 
 ASCUS 25140 (2-5251000) 0.0009 2.2 (0-782) 0.0002 
 LSIL 41140 (1-19930000) <0.0001 4 (0-1860) <0.0001 
  HSIL 60280 (29-10970000) 0.002 14 (0-870) 0.002 
Note: Data are median (range) and the P-values were calculated by Mann-Whitney test (two-tailed), significantly 
P-values are in bold writing. Ref- reference. α5/6 HPV species includes HPV-51 and -56; α7 HPV species 
includes HPV-18, -39, -45 and -59; α9 HPV species includes HPV-16, -31, -33, -35, -52 and -58.  
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Factors that are associated with abnormal cervical cytology are presented in Table 4.5. 
Predictors of abnormal cervical cytology were found to be HIV-positive status, <5 years of 
relationship with the study partner, infected with α5, α6, α7 or α9 HPV species. Women 
infected with α7 HPV species with ≥0.6 HPV copies per cell were at greater risk of having 
abnormal cervical cytology (odds ratio (OR), 7.08 [95% confidence interval (CI): 3.51-14.31]) 
followed by women with <0.6 HPV copies per cell  (OR, 3.01 [95% CI: 1.52-5.97]) when 
compared with women with no α7 HPV infection. Women infected with α9 HPV species with 
≥2.5  HPV copies per cell were at greater risk of having abnormal cervical cytology (OR, 15.80 
[95% CI: 8.56-29.14]) followed by women with <2.5 HPV copies per cell  (OR, 3.27 [95% CI: 
1.89-5.75]) when compared with women with no α9 HPV infection (Table 4.5). However, in 
multivariate analysis HIV status and duration of relationship with the study partners were not 
significant predictors of abnormal cytology only high α α6, α7 and α9 HPV species viral loads 
remain to be predictors of abnormal cytology (Table 4.5). 
 
4.3.5 The relationship between genital hpVIR HR-HPV viral load and type-specific HPV 
concordance in couples 
 
Type-specific HPV concordance among couples was defined as the presence of the same HPV 
genotypes in cervical and penile cells of a couple. To investigate the association of hpVIR HR-
HPV viral load on type-specific hpVIR HR-HPV concordance study participants were grouped 
according to couples. Samples from couples that were hpVIR HR-HPV positive by hpVIR were 
analysed to determine the relationship between cervical HPV viral load and type-specific HPV 
concordance with male partners. Women infected with hpVIR HR-HPV and type-specific HPV 
concordance with their male partner were found to have significantly higher copies of hpVIR 
HR-HPV per cell compared to women that were not having type-specific HPV concordance 
with their male partner (6 median value, range: 0-1866 compared to 0.4 median, range: 0-1234, 
P<0.0001). Women with type-specific HPV concordance with their male partner were also 
found to have significantly higher copies of HPV-16/18/45/31 (four most common hpVIR HR- 
HPV types) and HPV-33/52/58/35/39/51/56/59 per cell compared to women that were not 
having type-specific HPV concordance with their male partners (P=0.003 and P=0.0002 
respectively, Table 4.6).  
 
Women infected with hpVIR HR-HPV and type-specific HPV concordance with their partner 
were found to have a higher hpVIR HR-HPV viral load compared to women that were not 
having type-specific HPV concordance with their male partners, suggesting that a high HPV  
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Table 4.5. The predictors of abnormal cervical cytology in women, (univariate analysis) 
 Variable   n HPV% OR 95% CI P-value 
Age group       
<30 years  196 27% ref  0.07 
30-39 years  187 33% 1.31 0.84-2.03  
≥40 years  151 21% 0.73 0.44-1.2  
HIV status       
Negative  279 19% ref  <0.0001 
Positive  255 36% 2.35 1.59-3.48  
CD4 count (if HIV-positive)     
≥350/mL  128 32% ref  0.18 
<350/mL  127 40% 1.42 0.85-2.38  
HIV viral load (if HIV-positive)     
<4 log  86 34% ref  0.36 
≥4 log  138 40% 1.3 0.74-2.29  
Living together with study partner     
No  202 28% ref  0.7 
Yes  330 27% 0.93 0.63-1.37  
Duration of relationship with study partner    
<5 years  112 29% ref  0.04 
≥5 years  84 17% 0.48 0.24-0.97  
Age at first sex      
<18 years  266 24% ref  0.09 
≥18 years  265 31% 1.39 0.95-2.04  
Lifetime number of sexual partners      
1-2  231 30% ref  0.50 
3-5  227 25% 0.79 0.52-1.19  
>5  73 26% 0.83 0.46-1.5  
Number of sex acts with study partner  
in last month    
<5  367 26% ref  0.36 
≥5  160 30% 1.21 0.8-1.82  
Ever used a condom with current  
study partner    
No  166 25% ref  0.34 
Yes  359 29% 1.23 0.81-1.87  
Experienced genital discharge in 
last 12 months    
No  443 27% ref  0.73 
Yes  90 29% 1.09 0.66-1.81  
Experienced genital ulcer in  
last 12 months    
No  502 27% ref  0.31 
Yes  31 35% 1.5 0.7-3.2  
α5 HPV infection      
No   510 26% ref  0.006 
Yes  22 55% 3.4 1.44-8.06  
α6 HPV infection      
No   498 25% ref  <0.0001 
Yes  34 65% 5.59 2.69-11.62  
α7 HPV infection      
None  456 22% ref  <0.0001 
HPV VL <0.6 copies/cell 37 46% 3.01 1.52-5.97  
HPV VL ≥0.6 copies/cell 39 67% 7.08 3.51-14.31  
α9 HPV infection      
None  396 17% ref  <0.0001 
HPV VL <2.5 copies/cell 68 43% 3.27 1.89-5.75  
HPV VL ≥2.5 copies/cell 68 72% 15.80 8.56-29.14   
Note: VL: viral load per cell, α5 HPV species is HPV-51; α6 HPV species is HPV-56; α7 HPV species are HPV-
18, -39, -45 and -59; α9 HPV species are HPV-16, -31, -33, -35, -52 and -58.  
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viral load in women may play role in HPV transmission to their male partner. Men that were 
positive for any hpVIR HR-HPV type were then selected and analysed for the relationship 
between penile hpVIR HR-HPV viral load and type-specific HPV concordance with their 
female partner. There was no significant difference in viral load between men that were type-
specific HPV concordance with their female partner and those that were not having type-
specific HPV concordance with their female partner. Therefore no clear association was 
observed between penile hpVIR HR-HPV viral load and type-specific HPV concordance in 
couples (Table 4.7).  
 
4.4 DISCUSSION  
In this study we investigated the hpVIR HR-HPV viral load in HIV-positive and HIV-negative 
women and men. HIV-positive women and men were found to have higher hpVIR HR-HPV 
prevalence, more total hpVIR HR-HPV and a greater hpVIR HR-HPV viral load compared to 
HIV-negative women and men. Similar findings were previously reported elsewhere (Palefsky 
et al., 1999; Gomousa-Michael et al., 2000; Viscidi et al., 2003; Strickler et al., 2005). HIV 
infection was found to be the predictor of abnormal cytology. The high hpVIR HR-HPV 
prevalence and viral load in HIV-positive women and men could be due to suppressed immune 
system caused by HIV infection that could also result to reactivation of latent infection and 
high susceptibility to HPV acquisition. The role played by immune system on HPV viral load 
can also be explained by the increasing hpVIR HR-HPV viral load with decreasing CD4 count 
among HIV-positive women and men. High hpVIR HR-HPV viral load in HIV-positive 
individuals seem to be influenced by the CD4 count level as the hpVIR HR-HPV viral load was 
found to significantly increase with decreasing CD4 counts, similar observations have been 
reported elsewhere (Swan et al., 1999; Fontaine et al., 2008; Denny et al., 2008). When 
comparing women and men, we found that hpVIR HR-HPV viral load was higher in women 
compared to men regardless of HIV-status. However comparing HPV viral load between 
women and men may not be accurate because fewer cells were collected in penile samples 
from men compared to the cervical samples from women and would account for the low hpVIR 
HR-HPV viral load/sample in men compared to women. Also, the different cervical cells 
present in women may provide a different environment for HPV replication; the cervical cells 
are more favourable for producing high HPV viral loads compared to penile cells (Bleeker et 
al., 2005a; Flores et al., 2006). 
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Table 4.6. The relationship between cervical hpVIR HR-HPV viral load and type-specific HPV 
concordance with a male partner 
 
Note: Data are no. (%) of subjects or median (range) and the P-values were calculated by Mann-Whitney test 
(two-tailed 
 
 
 
Viral load for female 
partner 
type-specific HPV concordance 
with male partner 
not type-specific HPV 
concordance with male partner P-value 
HPV-16 positive subjects n=14 n= 18  
No of copies/sample 21270 (188 - 630400) 10830 (129 - 1093000) 0.86 
No of copies/cell 5.2 (0 - 97) 0.8 (0 - 31) 0.48 
HPV-18/45 positive 
subjects n= 16 n= 30  
No of copies/sample 99140 (17 - 2955000) 5645 (19 - 4511000) 0.03 
No of copies/cell 19 (0 - 411) 0.2 ( 0 - 152) 0.004 
HPV-31 positive subjects n= 8 n= 13  
No of copies/sample 8084 (31 - 2268000) 2600 (25 - 514500) 0.32 
No of copies/cell 1.3 (0 - 225) 0.2 (0 - 256) 0.25 
HPV-33/52/58 positive 
subjects n=46 n= 28  
No of copies/sample 82780 (155 - 25090000) 8816 (16 - 6591000) 0.06 
No of copies/cell 9.2 (0- 1414) 0.87 (0 - 255) 0.04 
HPV-35 positive subjects n= 11 n= 24  
No of copies/sample 44020 (72 - 19930000) 5629 (13 - 4344000) 0.36 
No of copies/cell 4.4 (0 - 1866) 0.6 (0 - 802) 0.29 
HPV-39 positive subjects n= 3 n= 12  
No of copies/sample 8900 (133 - 161700) 11210 (17 - 5152000) 0.9 
No of copies/cell 15 (0 - 70) 1.3 (0 - 1234) 0.83 
HPV-51 positive subjects n= 8 n= 12  
No of copies/sample 289800 (6465 - 2060000) 8894 (95 - 5251000) 0.03 
No of copies/cell 10 (1 - 193) 0.4 (0 - 782) 0.04 
HPV-56 positive subjects n= 15 n= 12  
No of copies/sample 1242 (28 - 16110000) 1636 (20 - 2387000) 0.51 
No of copies/cell 0.2 (0 - 384) 0.08 (0 - 283) 0.29 
HPV-59 positive subjects n= 4 n= 12  
No of copies/sample 117500 (6209 - 701600) 195 (14 - 604200) 0.02 
No of copies/cell 30 (1 - 305) 0.02 (0 - 31) 0.02 
HPV-16, -18/45, -31 
positive subjects n= 38 n= 61  
No of copies/sample 34930 (17 - 2955000) 4145 (19 - 4511000) 0.03 
No of copies/cell 7 (0 - 411) 0,5 (0 - 256) 0.003 
HPV-33/52/58, -35, -39, -
51, -56, -59 positive 
subjects n= 87 n= 100  
No of copies/sample 45570 (28 - 25090000) 3752 (13 - 6591000) 0.0004 
No of copies/cell 6 (0 - 1866) 0,3 (0 - 1234) 0.0002 
All HPV positive subjects n= 125 n= 161  
No of copies/sample 37970 (17 - 25090000) 3983 (13 - 6591000) <0,0001 
No of copies/cell 6 (0 - 1866) 0,4 (0 - 1234) <0,0001 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 4  
 
 
86 
Table 4.7. The relationship between penile hpVIR HR-HPV viral load and type-specific 
concordance with female partner 
 
Viral load for male 
partner 
type-specific concordance with 
female partner 
not type-specific concordance with 
female partner P-value 
HPV-16 positive subjects n= 12 n= 25  
No of copies/sample 3866 (157 – 174200) 1711 (13 - 923200) 0.47 
No of copies/cell 13 (0.17 - 188) 4 (0 - 7353) 0.34 
HPV-18/45 positive 
subjects n=16 n= 26  
No of copies/sample 1798 (30 – 142300) 2985 (14 - 987100)  0.77 
No of copies/cell 4.4 (0 - 238) 3.3 (0 - 1921) 0.92 
HPV-31 positive subjects n= 10 n= 7  
No of copies/sample 301 (17 - 10930) 779 (189 - 1925000) 0.23 
No of copies/cell 0.6 (0 - 20) 1.6 (0 - 67) 0.47 
HPV-33/52/58 positive 
subjects n= 40 n= 55  
No of copies/sample 850 (16 - 804800) 397 (11 - 1196000) 0.33 
No of copies/cell 2.3 (0 - 334) 1.4 (0 - 23530) 0.9 
HPV-35 positive subjects n= 11 n= 17  
No of copies/sample 2464 (47 – 2960000) 464 (26 - 435900) 0.45 
No of copies/cell 3.4 (0.2 - 5305) 2.7 (0 - 7105) 0.4 
HPV-39 positive subjects n= 3 n= 19  
No of copies/sample 12970 (332 - 134700) 198 (13 - 72200) 0.06 
No of copies/cell 10 (6 - 19) 0.6 (0 - 29) 0.08 
HPV-51 positive subjects n= 9 n= 18  
No of copies/sample 31960 (66 – 954100) 1472 (38 - 22660) 0.11 
No of copies/cell 13 (0 - 2785) 6 ( 0 - 105) 0.37 
HPV-56 positive subjects n= 14 n= 19  
No of copies/sample 380 (10 - 31570) 235 (19 - 104600) 0.99 
No of copies/cell 5.5 (0 - 92) 2 (0 - 3655) 0.9 
HPV-59 positive subjects n= 4 n= 23  
No of copies/sample 176 (42 - 359600) 541 (14 - 1056000) 0.97 
No of copies/cell 1 (0 - 153) 0.8 (0 - 707) 0.81 
HPV-16, -18/45, -31 
positive subjects n= 38 n= 58  
No of copies/sample 1630 (17 – 174200) 1661 (13 - 1925000) 0.73 
No of copies/cell 4 (0 - 238) 2,5 (0 - 7353) 0.99 
HPV-33/52/58, -35, -39, -
51, -56, -59 positive 
subjects n= 81 n= 151  
No of copies/sample 855 (10 – 2960000) 400 (11 - 1196000) 0.05 
No of copies/cell 3 (0 - 5305) 1,5 (0 - 23530) 0.14 
All HPV positive subjects n= 119 n= 209  
No of copies/sample 1611 (10 – 2960000) 694 (11 - 1925000) 0.09 
No of copies/cell 3 (0 - 5305) 2 (0 - 23530) 0.22 
Note: Data are median value (range) and the P-values were calculated by Mann-Whitney test (two-tailed).  
 
 
Cervical hpVIR HR-HPV infection (R2=0.993) and HPV viral load were positively associated 
with cervical abnormality and all women with HSIL were found to have hpVIR HR-HPV 
infection at their cervix, similar observation we observed when HPV types were grouped 
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according to species. HPV viral load is predicted as a marker for HPV persistent infection and 
risk of developing precancerous lesions and cancer (Sun et al., 2002; Moberg et al., 2005; 
Gravitt et al., 2007; Guo et al., 2010).  hpVIR HR-HPV prevalence was significantly increasing 
with age among women with LSIL while in women with normal cervical cytology and ASCUS 
it did not. Peak prevalence of precancerous lesion is been reported in women older than 30 
years compared to young age women (Schiffman & Castle, 2005). The positive association 
between hpVIR HR-HPV and cervical precancerous lesions has been reported in numerous 
studies which concluded that persistence HPV infection is necessary for the development of 
cervical cancer (Andersson et al., 2005). According to Fontaine et al., (2008) women who did 
not develop cervical abnormalities during follow up were those with stable HPV viral load 
while those who developed cervical disease were more likely to be those with increased HPV 
viral load. Women with ASCUS or LSIL or HSIL had a higher viral load of α7 and α9 HPV 
species compared to women with normal cervical cytology. Clustering of different HPV 
species was more likely to be observed in women with abnormal cervical cytology compared to 
women with normal cervical cytology. A high prevalence of HPV types and species clustering 
in women with abnormal cervical cytology has been previously reported and the clustering of 
different HPV species in women is associated with increased risk of HPV persistence and 
cervical disease progression (Ho et al., 1998; Trottier et al., 2008; Spinillo et al., 2009).  
 
The high HPV viral load in women with abnormal cervical cytology and the high prevalence of 
HIV infection among women with abnormal cervical cytology might increase the risk of HPV 
sharing with the partner and transmission. We observed that women have higher HPV viral 
load per sample compared to men. Bleeker et al., (2005a) also reported that female cervical 
scrape specimens have a higher HPV viral load compared to male penile scrape specimens. 
However, comparing HPV viral load between women and men may not be accurate because 
the number of cells obtained in female cervical samples is higher than those obtained in male 
penile samples (Bleeker et al., 2005a; Flores et al., 2006). As previously mentioned, the 
different type of genital cell epithelium observed in women and men may provide a different 
environment for HPV replication and cervical specimen has more than epithelial cells (Flores 
et al., 2006). We reported that women with high HPV viral load frequently shared HPV 
compared to those with lower HPV viral load, similar observations were reported elsewhere 
(Bleeker et al., 2005a). The present study provides biological support that immune suppressed 
conditions increase hpVIR HR-HPV prevalence as well as viral load and among sexually active 
partners increased HPV viral load could increase the probability of HPV sharing and 
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transmission among partners. Measuring HPV viral load may identify HPV persistence and 
also identify those women and men at risk of developing intraepithelial neoplasia. 
 
In conclusion, HIV co-infection significantly influenced HR-HPV prevalence in both men and 
women; and HR-HPV viral load in women. High HR-HPV viral load were found to be the 
predictors of cervical abnormal cytology. Measuring HPV viral load may identify HPV 
persistence and also identify those women and men at risk of developing intraepithelial 
neoplasia. Data from this study will assist policy-makers in management of cervical 
abnormalities in South African HIV-positive women. 
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5.1 INTRODUCTION  
HPV serology is an important tool in sero-epidemiology studies. Its specificity is determined by 
the type of assay used. HPV antibody detection can be very useful in assessing present and past 
HPV infection in both women and men (Stanley, 2006). Sero-epidemiology has been 
successfully used as the basis of the design of HPV vaccination programmes (Ryding et al., 
2008). HPV DNA detection at a particular site provides information about HPV at that specific 
site while HPV serology determines HPV past and present HPV exposure at any anatomic sites. 
HPV antibodies can be detected in individuals who are not HPV infected or infected with HPV 
type other than the antibody detected, demonstrating past infection or possible cross reactivity 
between types (Touze et al., 1998; Dillner, 1999; Stanley 2006). After HPV infection only a 
certain proportion of women will seroconvert and seroconversion can take 7 months or longer 
to be detected (Carter et al., 2000; Stanley, 2006). Among women who were HPV-16 infected, 
56.7% seroconverted within 8.3 months for IgG and 37.0% for IgA within 14 months (Ho et 
al., 2004). HPV DNA detection is not the optimum test to determine new infections especial in 
sexual experienced individuals; because the presence of new HPV DNA during a follow up 
visit does not always demonstrate new infections. It can demonstrate reactivation of latent HPV 
infection or sampling error of previous sampling (Carter et al., 1996; Thompson et al., 2004). 
The combination of serology and DNA detection could provide the maximum information on 
HPV infection. HPV serology is not a best tool to detect HPV infection because it determines 
HPV past and present HPV exposure at any anatomic sites. HPV antibodies can be detected in 
individuals who are not HPV infected or infected with HPV type other than the antibody 
detected, demonstrating past infection or possible cross reactivity between types. HPV serology 
is different from serology for other STDs, for example HSV serology can be used to 
management of patients with first incident of genital herpes infection (Page et al., 2003). 
 
In the early 90s, an HPV virus-like particles (VLP) serological assay was established 
(Kirnbauer et al., 1992; Kirnbauer et al., 1994). In order to produce HPV virions, xenografts of 
human tissue in mice were initially used, however, the technique was very time consuming and 
lab-intensive and produced few HPV virions. VLPs are non-infectious and resemble the HPV 
virion with regards to the morphology and immunogenicity of each specific type and also 
resemble the authentic virions (Kirnbauer et al., 1992; Roden et al., 1996). VLPs can be 
produced in different cell culture systems including mammalian, insect, plant and yeast cells 
(Kirnbauer et al., 1994). The production of VLPs in insect cells using recombinant baculovirus 
to yield substantial amounts of VLPs allowing the development of VLP-based enzyme-linked 
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immunosorbent assay (ELISA) in which HPV VLPs were used as antigens (Kirnbauer et al., 
1994). Antibody results from ELISA were consistent with HPV DNA results by PCR. This was 
a breakthrough in humoral immune response studies as detecting antibody responses using 
bacterially expressed fusion proteins or synthetic peptides as an antigen in ELISA was complex 
(Kirnbauer et al., 1994). Preparation of high quality VLPs is an important factor in the VLP 
based ELISA to limit cross reactivity between HPV types (Wang et al., 2003). 
  
More recently, pseudovirions were produced which allowed the development of a 
pseudovirion-based papillomavirus neutralisation assay. High yields of HPV pseudovirions 
consisting of capsid protein and reporter gene can be produced using 293TT cells (Pastrana et 
al., 2004; Buck et al., 2005). During HPV pseudovirons production L1 and L2 capsid proteins 
are co-transfected together with a reporter gene into 293TT cells (Buck et al., 2004). In 
pseudovirion-based papillomavirus neutralisation assay the presence of HPV neutralising 
antibodies in a sample are determined by the intensity of the secreted alkaline phosphatase in 
cell supernatant (Pastrana et al., 2004; Buck et al., 2005). According to Pastrana et al., (2004) 
the pseudovirus-based neutralisation assay is more sensitive and more genotype-specific than 
the VLP-based ELISA. Cervical and serum HPV-16 neutralising antibodies detected using 
pseudovirion-based neutralisation assay are associated with HPV-16 infection but not with 
cervical disease (Mbulawa et al., 2008). HPV ELISA detects both binding and neutralising 
antibodies while pseudovirus-based neutralisation assay detects only neutralising antibodies 
(Pastrana et al., 2004). 
 
HPV multiplex serology technique permits the detection of more than 100 different HPV types 
simultaneous (Opalka et al., 2003; Waterboer et al., 2005). Multiplex serology allows data 
generation of large epidemiologic studies in a few days as 1000 samples per day can be tested. 
a low volume of sample is required (2μl) and risk of cross contamination between samples is 
reduced in multiplex serology technique. The HPV multiplex serology has been used 
extensively in monitoring HPV vaccines. HPV multiplex serology testing for vaccine efficacy 
is needed even though there are only 2 or 4 HPV types in current HPV vaccines so that 
immunity to non-vaccine HPV types can be studied. There are different multiplex serology 
assays. The multiplex serology used in the current study is the same as the one described by 
Waterboer et al., (2005) and is based on glutathione S-transferase fusion-L1 protein not VLPs. 
High concordance between glutathione S-transferase (GST) capture ELISA and multiplex 
serology was observed and samples that were only positive by multiplex serology and not by 
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ELISA demonstrated very low titres. HPV seropositivity by multiplex serology is not found to 
correlate very well with HPV DNA at both genital and oral sites but associated with age at 
onset of sexual activity, number of sexual partners and history of genital warts (Syrjanen et al., 
2009).  
 
HPV IgA and IgG antibodies have been detected in cervical mucus; IgA is detected in cervical 
mucus even in the absence of serum HPV IgA while cervical HPV IgG is frequently detected 
in those women with high titres of serum HPV IgG (Lorincz et al., 1992, Marais et al., 2000). 
It is possible that through transudation, the IgG antibodies from serum can enter mucosal 
surfaces (Bontkes et al., 1999). HPV persistence and HSIL were associated with serum HPV 
IgG responses while HPV clearance and persistence were observed in women with Th1 
responses (Carter et al., 1996; de Gruijl et al., 1999). Antibody titres produced in natural 
infection are of lower titre and probably do not always reach the level required to provide 
protection. The high antibody titres observed in vaccinated candidates are associated with 
complete protection against HPV infection (Harper et al., 2006; Villa et al., 2006). However, 
the minimum level of HPV antibody correlating with protection against infection is unknown. 
 
When comparing serum antibody responses between women and men, it was found that 
antibodies to HR-HPV types in women are initially detected after puberty indicating initiation 
of sexual activity, and increase between 25-34 years. In men, a significant increase between 
25-34 years was not observed (Michael et al., 2008). The antibody increase and peak in young 
women has been reported elsewhere (Marais et al., 1997; Stone et al., 2002; Shin et al., 2003). 
Sasagawa et al., (2003) observed that women between 40-49 years of age had a high 
prevalence of HPV IgG responses against HPV-16, -18, -31 or -45 compared to women 
between 25-29 years of age even though cervical HPV DNA prevalence was found to decrease 
with increasing age. Cumulative exposure to HPV in older women could result in a high 
prevalence of HPV IgG responses in older women (Wang et al., 2000; Onda et al., 2003). HIV-
positive women are reported to have a higher prevalence of HPV IgG antibodies compared to 
HIV- negative women (Viscidi et al., 2003). According to Marais et al., (2009), after HIV 
seroconversion in women, the prevalence of serum HPV-16 IgA, cervico-vaginal IgA and IgG 
declined while the prevalence of serum HPV-16 IgG was found to increase. IgG is the most 
abundant isotype in serum followed by IgA, however IgA at mucosal sites is reported to play a 
very significant role in protection against pathologic agents (Mestecky & Fultz 1999). 
Antibody responses to HPV infection are determined as a key of protective immunity (Stanley 
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et al., 2006). According to Ho et al., (2004), the ability of a host to develop a strong humoral 
immunity may be detected by the presence of IgA antibodies. 
 
The aims of the study were:  
i) to determine the distribution of HPV antibodies in South African women and men; 
ii) to investigate factors that are associated with HPV seropositivity such as genital HPV DNA 
positivity, HIV status, CD4 counts, use of antiretroviral (ARV) therapy, age, cervical 
abnormalities, marital status, smoking, number of sexual partners, age at first sexual 
intercourse and genital ulcers; and 
iii) to investigate HPV seroconversion over a 12-month period in women and men and 
predictors of HPV seroconversion. 
 
5.2 METHODS AND METHODS 
5.2.1 Study population and specimen collection 
Study participants were recruited from the Manyanani clinic, Empilisweni Centre, Cape Town, 
South Africa. The Research Ethics Committee of the University of Cape Town approved all 
aspects of the investigation.  Study participants were 171 HIV-negative women, 265 HIV-
positive women, 277 HIV-negative men and 159 HIV-positive men. The mean ages were 35 
years (range, 18-65 years) and 38 years (range, 19-67 years) for women and men respectively. 
Of the men enrolled in the study 94% (404/428) were circumcised and 7 men had missing data 
on circumcision. Blood specimens were taken from all participants at both baseline and 12-
months for measurement of serum antibody responses to HPV-11, -16, -18, -31, -33, -35, -45, -
52, and -58. After collection, the blood samples were centrifuged at 1500rpm for 5 minutes to 
separate serum. The sera samples were aliquoted and stored at -80°C. Genital samples were 
collected and stores as described in section 2.2.1.   
 
5.2.2 HPV serology  
Serum was stored at -80°C and shipped on dry ice to German Cancer Research Centre (DFKZ), 
Heidelberg, Germany for detection of antibodies by multiplex serology. Since the multiplex 
serology technology was not available in South Africa it was arranged for the investigator 
(ZZA Mbulawa) to travel to DFKZ laboratory to train. HPV serology data was performed with 
the assistance of Dr Tim Waterboer and Dr Michael Pawlita of DFKZ. Detection of serum 
antibodies to the L1 major capsid protein of HPV-11, HPV-16, HPV-18, HPV-31, HPV-33, 
HPV-35, HPV-45, HPV-52 and HPV-58 was performed using multiplex serology based on 
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glutathione S-transferase fusion-L1 protein capture on fluorescent beads as described by 
Watertboer et al., (2005 and 2006) and serum was tested at 1:100 dilution. The secondary 
antibody used in this assay recognizes IgA, IgG and IgM together. Cut-off for positivity was 
determined using serum obtained from Korean female students who were HPV DNA negative 
(by Pap smears) and self-reported virgins and the cut-off was 400 median fluorescence 
intensity (MFI) for the L1 antigen of the 9 individual HPV types. Each sample was duplicated 
and averaged. Seroconverters were define as participants whose serum samples had a ≤400MFI 
at baseline and who at the 12-month visit showed a 2-fold increased MFI over the baseline visit 
which was also >400MFI (Syrjanen et al., 2009).  
 
5.2.3 HPV genotyping 
Samples were collected as described in chapter 2 section 2.2.1. DNA was extracted from both 
cervical and penile cells using the MagNA Pure Compact Nucleic Acid Isolation Kit (Roche 
Diagnostics, Mannheim, Germany) and automated MagNA Pure Compact machine (Roche 
Diagnostics, Mannheim, Germany). HPV typing was performed on DNA extracted from 
cervical and penile cells as described in section 2.2.2. 
 
5.2.4 Statistical analyses 
Statistics analyses were performed using X2 test (EpiInfo Version 5 Statcalc) and Mann-
Whitney test (GraphPad Prism® 5) when comparing HPV antibody magnitudes. Advanced 
statistics was performed by Dr Henri Carrara (Department of Public Health and Family 
Medicine, Faculty of Health Sciences, University of Cape Town) using STATA 11.0 
(StataCorp, College Station, TX, USA). HPV prevalence data were tabulated by key 
demographic and behavioural variables. Univariate analyses to estimate Odds Ratios and 95% 
confidence intervals were performed using logistic regression. All univariate analyses were all 
adjusted for age as a continuous variable because age is such an important confounder. 
Multivariate model building included age as a continuous variable and factors that 
demonstrated significant trend in the univariate analyses.  
 
5.3 RESULTS  
 
5.3.1 Serum HPV antibody prevalence in women and men 
More women were found to have antibody responses to all of the 9 HPV types tested compared 
to men (53% 232/435 compared to 31% 137/436, P<0.0001). In women seroprevalence for 
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HPV-11 (34%) was the highest followed by HPV-31 (30%), HPV-16 (24%), HPV-18 (24%), 
HPV-45 (22%), HPV-35 (18%), HPV-52 (14%), HPV-58 (11%) and antibodies to HPV-33 
(8%) were less prevalent. In men seroprevalence for HPV-11 (14%) was the highest followed 
by HPV-31 (11%), HPV-35 (10%), HPV-16 (7%), HPV-52 (7%), HPV-58 (7%), HPV-18 
(5%), HPV-45 (5%) and antibodies to HPV-33 (3%) were less prevalent (Figure 5.1). Multiple 
seroprevalence was defined as antibody reactivity to more than one HPV type. Women were 
found to have a 2.8-fold significantly higher seroprevalence of multiple types (2-9) compared 
to men (34%, 150/435 compared to 12%, 54/436, P<0.0001, Figure 5.1).  
 
Women were found to have a 2-fold to 4-fold higher seroprevalence compared to men and 
similar findings were observed when stratified according to the age (Figure 5.2). HPV 
seroprevalence was found to increase in both women and men with increasing age, from age 
18-29 years to 30-40 years, however seroprevalence decreased amongst those aged 41-67 years 
[women: 30-40 years (58% 93/161) compared to 18-29 years (48% 76/160, P=0.07) and 
compared to 41-67 years (49% 56/114); men:  30-40 years (32% 62/191) compared to 18-29 
years (19% 16/84, P=0.02) and compared to 41-67 years (22% 35/161, P=0.02) Figure 5.2]. 
Multiple seroprevalence in women was also found to increase with increasing age but 
decreased at 41-67 years; however, in men aged 41-67 no decrease was observed (Figure 5.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Human papillomavirus (HPV) serum antibody prevalence in women and men. 
Significantly more women had antibodies to all 9 types tested and more women had antibodies 
to multiple types compared to men. Note: * p<0.05, ***p=0.001, ****p<0.0001. 
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Figure 5.2. Human papillomavirus (HPV) serum antibody prevalence and multiple 
seroprevalence in women and men according to age. 
 
5.3.2 HPV type-specific seroprevalence according to genital HPV DNA infection in women 
and men  
 
HPV type-specific seroprevalence according to genital HPV DNA infection in women is 
demonstrated in Table 5.1. HPV-11 seropositivity was 40% in HPV DNA negative women, 
29.6% in women HPV DNA positive for types other than HPV-11 and 60% in women HPV-11 
DNA positive. Women that were HPV-11 DNA positive were found to have a 2.3 risk (95% 
CI: 0.4-14.4) of having HPV-11 antibodies compared to HPV DNA negative women. HPV-16 
seropositivity was 25.6% in HPV DNA negative women, 22.6% in women HPV DNA positive 
for types other than HPV-16 and 25% in women HPV-16 DNA positive. Women that were 
HPV-16 DNA positive were not more likely to have HPV-16 antibodies compared to HPV 
DNA negative women. HPV-18 seropositivity was 25.6% in HPV DNA negative women, 
20.5% in women HPV DNA positive for types other than HPV-18 and 35.7% in women HPV-
18 DNA positive. Women that were HPV-18 DNA positive had 1.6 risk (95% CI: 0.7-3.8) of 
having HPV-18 antibodies compared to HPV DNA negative women.  
 
HPV α7 species seropositivity was 27.3% in HPV DNA negative women, 22.4% in women 
HPV DNA positive for types other than α7 HPV species and 36.5% in women α7 HPV species 
DNA positive. The risk of having α7 HPV species antibodies in women that were α7 HPV 
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species positive was 1.5 times (95% CI: 0.8-2.9) greater compared to HPV DNA negative 
women. α9 HPV species seropositivity was 42.4% in HPV DNA negative women, 44.2% in 
women HPV DNA positive for types other than α9 HPV species and 39.1% in women α9 HPV 
species DNA positive. Antibody responses were not found to differ between women that were 
α9 HPV species positive compared to HPV DNA negative women (OR: 0.9, 95% CI: 0.5-1.4; 
Table 5.1). 
 
Table 5.1. HPV type-specific seroprevalence as related to genital HPV DNA at the baseline 
visit in women 
Cervical DNA status 
n seroposositive/ n total  
(% seropositive) OR (95% CI) P-value 
 HPV-11   
HPV DNA negative 67/172 (40.0) ref  
HPV pos but HPV-11 negative 76/257 (29.6) 0.7 (0.4-1.0) 0.04 
HPV-11 positive 3/5 (60.0) 2.3 (0.4-14.4) 0.36 
 HPV-16   
HPV DNA negative 44/172 (25.6) ref  
HPV pos but HPV-16 negative 51/226 (22.6) 0.8 (0.5-1.3) 0.49 
HPV-16 positive 9/36 (25) 1.0 (0.4-2.2) 0.94 
 HPV-18   
HPV DNA negative 44/172 (25.6) ref  
HPV pos but HPV-18 negative 48/234 (20.5) 0.8 (0.5-1.2) 0.23 
HPV-18 positive 10/28 (35.7) 1.6 (0.7-3.8) 0.27 
 α7 HPV species   
HPV DNA negative 47/172 (27.3) ref  
HPV pos but α7 HPV negative 47/210 (22.4) 0.8 (0.5-1.2) 0.27 
α7 HPV positive 19/52 (36.5) 1.5 (0.8-2.9) 0.2 
 α9 HPV species   
HPV DNA negative 73/172 (42.4) ref  
α9 HPV pos but HPV negative 57/129 (44.2) 1.1 (0.7-1.7) 0.76 
α9 HPV positive 52/133 (39.1) 0.9 (0.5-1.4) 0.56 
ref: reference. α7 HPV spec es includes HPV-18 and -45. α9 HPV species includes HPV-16, -31, -33, -35, -52 
and -58. 
 
HPV type-specific seroprevalence according to genital HPV DNA infection in men is 
demonstrated in Table 5.2. HPV-11 seropositivity was 12.6% in HPV DNA negative men, 
13.8% in men HPV DNA positive for other types but not HPV-11 and 40% in men HPV-11 
DNA positive. Men that were HPV-11 DNA positive had 1.6 risk (95% CI: 1.2-17.7) of having 
HPV-11 antibodies compared to HPV DNA negative men. HPV-16 seropositivity was 5.7% in 
HPV DNA negative men, 9% in men HPV DNA positive for types other than HPV-16 and 0% 
in men HPV-16 DNA positive. HPV-18 seropositivity was 3.4% in HPV DNA negative men, 
5.5% in men HPV DNA positive for types other than HPV-18 and 4.6% in men HPV-18 DNA 
positive. Men that were HPV-18 DNA positive had 1.3 risk (95% CI: 0.3-11.7) of having 
HPV-18 antibodies compared to HPV DNA negative men. α7 HPV species seropositivity was 
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5.1% in HPV DNA negative men, 7.7% in men HPV DNA positive for other types but not α7 
HPV species and 4.1% in men α7 HPV species DNA positive. Men that were α7 HPV species 
positive were more likely to have antibody responses compared to α7 HPV DNA negative men. 
α9 HPV species seropositivity was 22.3% in HPV DNA negative women, 23.8% in women 
HPV DNA positive for types other than α9 HPV species and 23.7% in women α9 HPV species 
DNA positive. Women that were α9 HPV species positive were not more likely to have 
antibody responses compared to HPV DNA negative women (OR: 1.1, 95% CI: 0.6-2.0; Table 
5.2). 
 
Table 5.2. HPV type-specific seroprevalence as related to genital HPV DNA at the baseline 
visit in men 
Penile DNA status 
n seroposositive/ n total  
(% seropositive) OR (95% CI) P-value 
 HPV-11   
HPV DNA negative 22/175 (12.6) ref  
HPV pos but HPV-11 negative 34/247 (13.8) 1.1 (0.6-2.0) 0.72 
HPV-11 positive 4/10 (40) 1.6 (1.2-17.7) 0.03 
 HPV-16   
HPV DNA negative 10/175 (5.7) ref  
HPV pos but HPV-16 negative 20/223 (9.0) 1.6 (0.7-3.6) 0.23 
HPV-16 positive 0/34 (0.0) .. .. 
 HPV-18   
HPV DNA negative 6/175 (3.4) ref  
HPV pos but HPV-18 negative 13/235 (5.5) 1.6 (0.6-4.4) 0.32 
HPV-18 positive 1/22 (4.6) 1.3 (0.2-11.7) 0.79 
 α7 HPV species   
HPV DNA negative 9/175 (5.1) ref  
HPV pos but α7 HPV  negative 16/208 (7.7) 1.5 (0.7-3.6) 0.32 
α7 HPV positive 2/49 (4.1) 0.8 (0.2-3.8) 0.76 
 α9 HPV species   
HPV DNA negative 39/175 (22.3) ref  
HPV  pos but α9 HPV negative 38/160 (23.8) 1.1 (0.7-1.8) 0.75 
α9 HPV positive 23/97 (23.7) 1.1 (0.6-2.0) 0.79 
       ref: reference. Neg: negative, pos: positive 
5.3.3 HPV antibody response according to cervical cytology 
HPV seroprevalence was found to be similar in women with normal cytology, ASCUS, LSIL 
and those with HSIL (43% 121/284; 39% 15/38; 40% 30/75 and 42% 5/12 respectively). 
Among women that were HPV seropositive, multiple seroprevalence was higher in women 
with abnormal cervical cytology (includes ASCUS, LSIL and HSIL) compared to women with 
normal cervical cytology (64% 32/50; 47% 57/121, P=0.04). Multiple seroprevalence was 
found to increase as cervical cytology abnormalities increased in severity and then decrease in 
women with HSIL (normal cervical cytology: 47% 57/121, ASCUS: 67% 10/15, LSIL: 70% 
21/30 and HSIL: 20% 1/5).  
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Antibody titres were defined as the level of MFI. Women with abnormal cervical cytology 
were found to have higher antibody titres compared to women with normal cervical cytology 
and this was found to be significant for HPV-16 (median: 77 MFI, range: 0- 5366 MFI 
compared to median: 46 MFI, range: 0-4290 MFI, P=0.04), HPV-45 (median: 43 MFI, range: 
0- 6230 MFI compared to median: 27 MFI, range: 0- 3098 MFI, P=0.035, Table 5.3) and all 
HPV types (median: 53 MFI, range: 0- 7145 MFI compared to median: 42 MFI, range: 0- 5430 
MFI, P=0.0002). There was no difference in seroprevalence to all HPV types tested between 
women with normal cervical cytology with those with abnormal cervical cytology.  
 
Table 5.3. HPV seroprevalence and antibody titres (MFI) for women with normal and 
abnormal cervical cytology 
  
Normal cytology N=284 
  
Abnormal cytology N=125 
 
Antibodies n (%) 
MFI median 
(range) 
 
n (%) 
MFI median  
(range) P-valuea P-valueb 
HPV-11 71 (25) 122 (0-4997)  29 (23) 137 (0-3161) 0.7 0.74 
HPV-16 40 (14) 46 (0-4290)  20 (16) 77 (0-5366) 0.61 0.04 
HPV-18 35 (12) 37 (0-4290)  22 (18) 51 (0-5291) 0.16 0.2 
HPV-31 55 (19) 59 (0-5430)  25 (20) 77 (0-7145) 0.88 0.06 
HPV-33 12 (4) 19 (0-2232)  11 (9) 29 (0-2034) 0.06 0.07 
HPV-35 30 (11) 45 (0-2626)  21 (17) 54 (0-5527) 0.08 0.31 
HPV-45 37 (13) 27 (0-3098)  19 (15) 43 (0-6230) 0.56 0.035 
HPV-52 29 (10) 41 (0-3924)  14 (11) 52 (0-3855) 0.76 0.12 
HPV-58 21 (7) 30 (0-5068)  12 (10) 37 (0-3084) 0.45 0.18 
All HPV 
types 
121 (43) 42 (0-5430)  50 (40) 53 (0-7145) 0.55 0.0002 
a compare seroprevalence, b compare median antibody titre between women with normal and abnormal cytology. 
 
5.3.4 HPV antibody response according to HIV status 
HIV-positive women were found to have a significantly higher HPV-16 antibody titre 
compared to HIV-negative women (median: 135 MFI, range: 0- 5987 MFI compared to 
median: 88 MFI, range: 0- 5366 MFI; P=0.03, Figure 5.3a).  The titres of antibody to HPV-11, 
-18, -31, -33, -35, -45, -52 and -58 were not found to differ significantly between HIV-negative 
women and HIV-positive women (Table 5.4). HIV-positive women were found to have higher 
antibody titre of combined HPV compared to HIV-negative women (median: 100 MFI, range: 
0- 5987 MFI compared to median: 87 MFI, range: 0- 8024 MFI; P=0.07, Table 5.4), however it 
was not found to be significantly higher. HIV-positive men were found to have significantly 
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higher HPV-45 antibody titres compared to HIV-negative men (median: 16 MFI, range: 0- 
2173 MFI compared to median: 8 MFI, range: 0- 3804 MFI; P=0.003, Figure 5.3b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. HPV-16 (A) and HIV-45 (B) antibody titres in HIV-positive and HIV-negative 
women and men. HIV+: HIV-positive, HIV-: HIV-negative. 
 
The antibody titres to HPV-11, -16, -18, -31, -33, -35, -52 and -58 were not found to differ 
significantly between HIV-negative men and HIV-positive men (Table 5.5). However, for all 
HPV types HIV-positive men demonstrated higher antibody titres compared to HIV-negative 
men (median: 24 MFI, range: 0- 12510 MFI compared to median: 20 MFI, range: 0- 5455 
MFI; P=0.02, Table 5.5). HPV antibody titres for all types were found to be significantly 
higher in women compared to men regardless of HIV-status.  When women and men were 
grouped according to HIV status, HIV-positive women were found to have significantly higher 
antibodies titres for all HPV types investigated compared to HIV-positive men. HIV-negative 
women were also found to have significantly higher antibodies titres for all HPV types 
investigated compared to HIV-negative men (Table 5.5).  
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Table 5.4. HPV antibody titres in HIV-positive and HIV-negative women  
 
  Women 
 HIV-positive (n=265)  HIV-negative (n=170) P-value 
Antibody median range   median range   
HPV-11 200 0-3007  289 1-8024 0.07 
HPV-16 135 0-5987  88 0-5366 0.03 
HPV-18 116 0-3294  92 0-5291 0.21 
HPV-31 140 1-4060  158 0-7145 0.97 
HPV-33 41 0-1535  31 0-2034 0.06 
HPV-35 76 0-3650  79 0-5527 0.79 
HPV-45 112 0-3850  76 0-6230 0.2 
HPV-52 81 0-2566  66 0-3855 0.26 
HPV-58 56 1-1542   17 0-6758 0.70 
All HPV types 100 0-5987  86 0-8024 0.07 
 
Table 5.5. HPV antibody titres in HIV-positive and HIV-negative men.  
 
 Men  
 HIV-positive (n=160)  HIV-negative (n=277) P-value 
Antibody median range   median range   
HPV-11 79 0-2231  70 0-5455 0.65 
HPV-16 20 0-3764  18 0-3265 0.31 
HPV-18 16 0-1666  14 0-3859 0.18 
HPV-31 28 0-5430  27 0-4420 0.94 
HPV-33 9 0-2232  9 0-1773 0.95 
HPV-35 34 0-12510  23 0-2603 0.26 
HPV-45 16 0-2173  8 0-3804 0.004 
HPV-52 25 0-3934  8 0-3376 0.21 
HPV-58 21 0-5086   17 0-3363 0.40 
All HPV types 24 0-12510  20 0-5455 0.02 
 
5.3.5 Factors associated with HPV seropositivity in women 
Investigation of factors associated with HPV seropositivity was only restricted to HPV-11, -16, 
-18, α7 and α9 HPV species in both women and men. Table 5.6 demonstrates the determinants 
of HPV-11, -16 and -18 seropositivity at baseline in women (univariate analysis). HPV-11 
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seropositivity was associated with the use of ARVs among the HIV-positive women (OR: 0.2, 
95% CI: 0.1-0.6, P=0.004); being unmarried (OR: 2.0, 95% CI: 1.1-3.6, P=0.02); having 
developed a genital ulcer 1+ month ago (OR: 1.9, 95% CI: 0.5-7.7, P=0.38) but not 
significantly; current smoking (OR: 1.6, 95% CI: 1.0-2.6, P=0.04) and previous smoking (OR: 
1.9, 95% CI: 0.9-3.9, P=0.08). In women, HPV-16 seropositivity was also associated with 
being unmarried (OR: 2.7, 95% CI: 1.3-5.7, P=0.007); having 3-4 lifetime sexual partners (OR: 
1.9, 95% CI: 1.1-3.2, P=0.015), having developed a genital ulcer 1+ month ago (OR: 6.3, 95% 
CI: 1.1-38.9, P=0.04);  and previous smoking (OR: 2.1, 95% CI: 1.0-4.5, P=0.08) but not 
significantly. In HIV-positive women, HPV-18 seropositivity was associated with increased 
CD4 counts (OR: 3.1, 95% CI: 1.1-8.3, P=0.03); being unmarried (OR: 2.1, 95% CI: 1.0-4.1, 
P=0.04) having developed a genital ulcer 1+ month ago (OR: 3.7, 95% CI: 0.6-22.5, P=0.15) 
but not significantly; and current smoking (OR: 1.7, 95% CI: 1.1-2.9, P=0.03). Factors such as 
HIV status, age at first sexual intercourse, number of sexual partners over the previous year, 
number of new sexual partners over the previous year, sexual frequency over the last month, 
genital ulcer and abnormal cytology were not significantly associated with HPV-11, -16 or -18 
seropositivity in women (Table 5.6). 
 
In women, α9 HPV (HPV-16, -31, -33, -35,-52 and/ or -58) seropositivity was significantly 
associated with being unmarried (OR: 1.9, 95% CI: 1.1-3.2, P=0.02) and having developed a 
genital ulcer ≥1 month ago (OR: 5.3, 95% CI: 1.3-21.7, P=0.02). α7 HPV (HPV-18 and/ or 
HPV-45) seropositivity was associated with CD4 counts ≥500/mL among HIV-positive women 
(OR: 2.7, 95% CI: 1.1-7.1, P=0.04) and having developed a genital ulcer ≥1 month ago (OR: 
3.5, 95% CI: 0.7-17.1, P=0.13) however the latter association was not significant. α9 HPV 
seropositivity was not significantly associated with any factor assessed in women. 
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Table 5.6. The HPV-11, -16 and -18 antibodies in women and factors associated with seropositivity, adjusted for age as a continuous variable 
    Women: HPV-11   Women: HPV-16   Women: HPV-18 
Variable n Ab % OR (95% CI)  P-value   Ab % OR (95% CI)  P-value   Ab % OR (95% CI)  P-value 
Age             
<30 years 144 31.3 1.0   1.0 1.0   1.0 1.0  
30-39 years 162 38.3 1.4 (0.8 - 2.2)  0.12  28.4 1.2 (0.8-1.8) 0.34  29.0 1.7 1.0-2.9) 0.05 
40-49 years 97 33.0 1.1 (0.6 - 1.9)  0.78  20.6 0.9 (0.5-1.4) 0.59  23.7 1.3 (0.7-2.4) 0.43 
50+ years 31 22.6 0.6 (0.26 - 1.6)  0.34  12.9 0.5 (0.2-1.4) 0.22  12.9 0.6 (0.2-1.9) 0.40 
HIV             
negative 169 38.5 1.0   23.8 1.0   24.3 1.0  
positive 265 30.6 0.7 (0.5 - 1.0)    0.07  24.2 1.0 (0.6-1.6) 0.97  23.0 0.9 (0.6-1.5) 0.73 
CD4 count*             
<200/mL 45 40.0 1.0   20.0 1.0   13.3 1.0  
200 – 349/mL 84 22.6 0.4 (0.2 - 1.0)  0.04  27.4 1.5 (0.6-3.6) 0.36  22.6 1.9 (0.7-5.1) 0.21 
350 – 499/mL 63 31.8 0.7 (0.32 - 1.6) 0.42  20.6 1.1 (0.4-2.8) 0.9  19.1 1.6 (0.5-4.5) 0.42 
500+/mL 72 21.9 0.7 (0.33 - 1.6)  0.41  25.0 1.4 (0.5-3.3) 0.51  31.9 3.1 (1.1-8.3) 0.03 
ARV status*             
yes 15 66.8 1.0   40.0 1.0   33.3 1.0  
no 206 29.0 0.2 (0.1 - 0.6)  0.004  25.2 0.5 (0.2-1.5) 0.21  23.8 0.6 (0.2-1.9) 0.39 
Married            1.00 
yes 77 22.1 1.0   11.7 1.0   14.3 1.0  
no 356 36.2 2.0 (1.1-3.6) 0.02  26.7 2.7 (1.3-5.7) 0.007  25.6 2.1 (1.0-4.1) 0.04 
Age at first sex            
<15 years 26 38.5 1.0   23.0 1.0   23.1 1.0  
15+ 407 33.4 0.8 (0.4-1.9) 0.63  24.1 1.1 (0.4-2.8) 0.87  23.6 1.0 (0.4-2.7) 0.94 
Number of sex partners           
1- 2 163 38.0 1.0   19.6 1.0   21.5 1.0  
3 - 4 153 34.0 0.8 (0.5 - 1.3)  0.47  31.4 1.9 (1.1-3.2) 0.015  28.8 1.5 (0.9-2.5) 0.13 
5 - 9 89 29.2 0.7 (0.4 - 1.2)  0.18  19.1 1.0 (0.5-1.9) 0.98  20.2 0.9 (0.5-1.8) 0.83 
10+ 28 21.4 0.5 (0.2 - 1.2)  0.1  25.0 1.4 (0.6-3.6) 0.469  17.9 0.8 (0.3-2.3) 0.68 
Sex partners previous year           
0 or 1 379 32.7 1.0   23.2 1.0   23.5 1.0  
3+ 52 38.5 1.3 (0.7 - 2.3)   0.44  28.9 1.3 (0.7-2.5) 0.42  25.0 1.1 (0.6-2.1) 0.83 
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    Women: HPV-11   Women: HPV-16   Women: HPV-18 
Variable n Ab % OR (95% CI)  P-value   Ab % OR (95% CI)  P-value   Ab % OR (95% CI)  P-value 
New sex partners previous year           
0 or 1 378 31.5 1.0   24.1 1.0   23.0 1.0  
3+ 17 41.2 1.5 (0.55 - 4.0)  0.43  11.8 0.4 (0.1-1.8) 0.23  23.5 1.0 (0.3-3.2) 0.97 
Sex frequency previous month           
0 37 35.1 1.0   29.7 1.0   29.7 1.0  
1 121 33.1 0.9 (0.5 - 1.9)  0.77  26.5 0.8 (0.4-1.8) 0.62  21.5 0.6 (0.3-1.5) 0.29 
2 135 31.9 0.8 (0.4 - 1.8)  0.64  19.3 0.5 (0.2-1.2) 0.13  21.5 0.6 (0.3-1.4) 0.28 
3 57 36.8 1.0 (0.4 - 2.5)   0.92  22.8 0.7 (0.3-1.7) 0.39  28.1 0.9 (0.4-2.2) 0.83 
4 80 32.5 0.8 (0.4 - 1.9)  0.69  26.3 0.8 (0.3-1.8) 0.56  25.0 0.8 (0.3-1.8) 0.55 
Genital ulcer             
no 387 34.9 1.0   24.0 1.0   24.6 1.0  
yes 47 23.4 0.6 (0.3-1.1) 0.11  23.4 0.9 (0.5-1.9) 0.86  14.9 0.5 (0.2-1.2) 0.14 
Genital ulcer recency           
<1 month 25 20.0 1.0   8.0 1.0   8.0 1.0  
≥1 month 19 31.6 1.9 (0.5-7.7) 0.38  36.8 6.3 (1.1-38.9) 0.04  26.3 3.7 (0.6-22.5) 0.15 
Cervical cytology            
normal 284 34.5 1.0   23.6 1.0   25.0 1.0  
ASCUS 38 36.8 1.1 (0.5 - 2.2)  0.78  18.4 0.7 (0.3-1.7) 0.48  29.0 1.2 (0.6-2.6) 0.60 
LSIL 75 26.7 0.7 (0.37 - 1.18)   0.16  25.3 1.0 (0.6-1.9) 0.88  16.0 0.6 (0.3-1.1) 0.09 
HSIL 12 25.0 0.7 (0.2 - 2.5) 0.53  33.3 1.7 (0.5-5.8) 0.4  16.7 0.6 (0.1-2.9) 0.53 
Smoking             
never 277 30.0 1.0   21.7 1.0   20.2 1.0  
previously 35 42.9 1.9 (0.9-3.9) 0.08  34.3 2.1 (1.0-4.5) 0.06  28.6 1.7 (0.7-3.7) 0.21 
current 122 39.3 1.6 (1.0-2.6) 0.04  26.2 1.4 (0.8-2.4) 0.18  29.5 1.7 (1.1-2.9) 0.03 
Numbers will not always add up to 437 because of some of the participants did not provide all required information, n: number, Ab%: percentage of women with positive 
antibody response. Ab: antibodies. *: HIV-positive. Age adjusted as a continuous variable. 
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Multivariate analysis included variables such as age, HIV status, CD4 count, ARVs, marital 
status, total number of sex partners and smoking habit. Table 5.7 demonstrates the determinants 
of HPV-11, -16 and -18 seropositivity at baseline in women (multivariate analysis). HIV-
positive women were more likely to have antibodies to HPV-11 (OR: 4.7, 95% CI: 1.6-16.7, 
P=0.02) and HPV-16 (OR: 1.8, 95% CI: 0.5-6.2, P=0.36) compared to HIV-negative women 
but not for HPV-18, α7 and α9 HPV species. HIV-positive women with ≥500/mL CD4 counts 
were more likely to have antibodies to HPV-18 (OR: 3.5, 95% CI: 1.1-10.9, P=0.03) and α7 
HPV species (OR: 3.0, 95% CI: 1.0-8.8, P=0.05) compared to HIV-positive women with 
<200/mL CD4 counts but not for HPV-11, HPV-16 and α9 HPV species. Women that were 
HIV-positive and not using ARVs were found to be significantly less likely to develop 
antibodies to HPV-11 (OR: 0.2, 95% CI: 0.1-0.7, P=0.01) compared to those using ARVs but 
not for HPV-16, HPV-18, α7 and α9 HPV species. Women that were married were found to be 
more likely to have detectable antibodies compared to married women and this was significant 
for HPV-16 (OR: 2.7, 95% CI: 1.2-6.1, P=0.01) and α9 HPV species (OR: 1.9, 95% CI: 1.1-
3.5, P=0.02). Women that were previously smoking were more likely to have HPV-11 
antibodies compared to women who never smoked (OR: 2.6, 95% CI: 1.1-539, P=0.03, Table 
5.7).  
 
Surprisingly the level of antibodies was found to decrease with increasing number of total sex 
partners for HPV-11, -16 and -18 (Table 5.7). When the number of sex partners or new sex 
partners in previous year was used in multivariate analysis instead of total number of sex 
partners, HPV-11 seropositivity was found to be influenced by HIV-positive status in women 
(OR: 3.1, 95% CI: 0.8-12.0; and OR: 3.6, 95% CI: 1.0-12.9 respectively, data not shown). 
Factors that were found to have an association with HPV seropositivity for HPV-11, -16, -18, 
α7 and α9 HPV species in multivariate analysis when total number of sex partners was included 
in the analysis were also found to have an association when the number of sex partners or new 
sex partners in previous year were used instead of total number of sex partners. 
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Table 5.7. The HPV-11, -16 and -18 antibodies in women and factors associated with seropositivity in multivariate analysis 
    WOMEN: HPV-11   WOMEN: HPV-16     WOMEN: HPV-18 
Variable n % OR (95% CI)  P-value   % OR (95% CI)  P-value   % OR (95% CI)  P-value 
Age* 434 33.6 1.0 (0.9-1.0) 0.08  24.0 1.0 (0.2-1.0) 0.17  23.5 1.0 (0.9-1.0) 0.29 
HIV             
negative 169 38.5 1.0   23.8 1.0   24.3 1.0  
positive 265 30.6 4.7 (1.3-16.7) 0.02  24.2 1.8 (0.5-6.2) 0.36  23 0.9 (0.2-3.5) 0.86 
CD4 count+             
<200/mL 45 40.0 1.0   20.0 1.0   13.3 1.0  
200 - 349/mL 84 22.6 0.4 (0.2-1.0) 0.05  27.4 1.4 (0.5-4.0) 0.48  22.6 2.0 (0.6-6.5) 0.23 
350 - 499/mL 63 31.8 0.7 (0.3-1.8) 0.44  20.6 1.2 (0.4-3.4) 0.78  19.1 1.9 (0.3-6.2) 0.31 
500+/mL 72 21.9 0.7 (0.5-1.8) 0.49  25.0 1.5 (0.5-4.1) 0.46  31.9 3.5 (1.1-10.9) 0.03 
ARV status+             
yes 15 66.8 1.0   40.0 1.0   33.3 1.0  
no 206 29.0 0.2 (0.1-0.7) 0.01  25.2 0.5 (0.1-1.4) 0.18  23.8 0.5 (0.1-1.6) 0.24 
Married             
yes 77 22.1 1.0   11.7 1.0   14.3 1.0  
no 356 36.2 1.8 (1.0-3.5) 0.07  26.7 2.7 (1.2-6.1) 0.01  25.6 1.8 (0.9-3.8) 0.12 
Total number of sex partners          
1- 2 163 38.0 1.0   19.6 1.0   21.5 1.0  
3 - 4 153 34.0 0.9 (0.5-1.5) 0.61  31.4 1.6 (0.9-2.8) 0.09  28.8 1.5 (0.9-2.7) 0.15 
5 - 9 89 29.2 0.7 (0.4-1.3) 0.27  19.1 0.8 (0.4-1.7) 0.60  20.2 1.0 (0.5-2.0) 0.97 
10+ 28 21.4 0.3 (0.1-1.0) 0.05  25.0 0.8 (0.3-2.4) 0.68  17.9 0.6 (0.2-2.0) 0.44 
Smoking             
never 277 30.0 1.0   21.7 1.0   20.2 1.0  
previously 35 42.9 2.6 (1.1-5.9) 0.03  34.3 1.8 (0.8-4.4) 0.18  28.6 1.9 (0.8-4.6) 0.17 
current 122 39.3 1.5 (0.9-2.5) 0.13   26.2 1.3 (0.8-2.3) 0.30   29.5 1.5 (0.9-2.7) 0.12 
                  * Age was included as a continuous variable. Only variables that appear on this table were included in multivariate analysis. +:HIV-positive 
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5.3.6 Factors associated with HPV seropositivity in men 
Table 5.8 shows the determinants of HPV-11, -16 and -18 seropositivity at baseline in men 
(univariate analysis). In men, HPV-11 seropositivity was associated with the use of ARVs 
among the HIV-positive men (OR: 0.2, 95% CI: 0.1-0.8, P=0.03); but not significantly 
associated with the number of new sexual partners over the previous year (OR: 2.2, 95% CI: 
0.6-7.9, P=0.21); or having developed a genital ulcer ≥1 month ago (OR: 2.0, 95% CI: 0.2-20.7, 
P=0.56). In men, HPV-16 seropositivity was not significantly associated with any factors 
assessed, (Table 5.8). In men, HPV-18 seropositivity was significantly associated with the use 
of ARVs among the HIV-positive men (OR: 0.1, 95% CI: 0.0-1.0, P=0.05) and the number of 
new sexual partners over the previous year (OR: 6.8, 95% CI: 1.2-37.3, P=0.03). The number 
of sexual partners over the previous year did not demonstrated a significant association with 
HPV-18 seropositivity (OR: 3.5, 95% CI: 0.7-17.1, P=0.12).  
 
Factors such as HIV status, age at first sexual intercourse, number of sexual partners, sexual 
frequency over the last month, and smoking were not significantly associated with HPV-11, -16 
or -18 seropositivity in men (Table 5.8). In men α7 HPV seropositivity was associated with 
number of new sexual partners over the previous year (OR: 7.2, 95% CI: 1.4-35.5, P=0.02); 
genital ulcer (OR: 2.6, 95% CI: 1.0-6.9, P=0.05) and number of sexual partners over the 
previous year (OR: 2.8, 95% CI: 0.7-11.6, P=0.16) but the latter not significantly. In men, α9 
HPV seropositivity was not significantly associated with any factor assessed. In determining 
predictors of HPV seropositivity some of the possible confounding factors were excluded 
including oral and injectable contraceptives because few participants used contraceptives (data 
not shown). 
 
Multivariate analysis for men included; variables such as age, HIV status, CD4 count, ARVs, 
marital status, total number of sex partners and smoking habits. Table 5.9 demonstrates the 
determinants of HPV-11, -16 and -18 seropositivity at baseline in men (multivariate analysis). 
HIV-positive men were found to be more likely to have antibodies to HPV-11 (OR: 4.2, 95% 
CI: 0.8-23.3, P=0.10), HPV-18 (OR: 6.3, 95% CI: 0.5-82.3, P=0.16) and α7 HPV species (OR: 
5.5, 95% CI: 0.6-47.2, P=0.12) compared to HIV-negative men but the associations were not 
significant. In men HIV-positive status was found not to show any association with α9 HPV 
species (OR: 1.2, 95% CI: 0.3-6.1, P=0.79). HIV-positive men with ≥500/mL CD4 counts were 
also found to be more likely to have antibodies compared to HIV+ women with <200/mL CD4
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Table 5.8. The HPV-11, -16 and -18 antibodies in men and factors associated with seropositivity, adjusted for age as a continuous variable 
    Men: HPV-11   Men: HPV-16   Men: HPV-18 
Variable n Ab % OR (95% CI)  P-value   Ab % OR (95% CI)  P-value   Ab % OR (95% CI)  P-value 
Age             
<30 years 84 11.9 1.0   4.8 1.0   6.0 1.0  
30-39 years 177 13.6 1.1 (0.5 - 2.4) 0.73  6.2 1.3 (0.4-4.0) 0.64  4.0 0.7 (0.2-2.0) 0.46 
40-49 years 106 17.9 1.5 (0.7 - 3.2) 0.3  9.4 2.0 (0.6-6.1) 0.23  4.7 0.8 (0.3-2.5) 0.69 
50+ years 65 10.8 0.9 (0.34 - 2.4) 0.84  7.7 1.1 (0.6-5.8)   4.6 0.8 (0.2-3.0) 0.71 
HIV             
negative 277 15.2 1.0   6.5 1.0   5.1 1.0  
positive 155 11.6 0.7 (0.4 - 1.3)   0.3  7.7 1.3 (0.59-2.8) 0.53  3.9 0.7 (0.3-2.0) 0.56 
CD4 count*             
<200/mL 31 9.7 1.0   3.2 1.0   3.2 1.0  
200 – 349/mL 48 12.5 1.3 (0.31 - 5.8)  0.7  6.3 2.2 (0.2-23.2) 0.51  4.2 1.3 (0.1-15.0) 0.83 
350 – 499/mL 35 8.6 0.8 (0.1 - 4.4)  0.8  5.7 2.3 (0.2-28.2) 0.51  0.0   
500+/mL 38 15.8 1.7 (0.4 - 7.7)  0.46  15.8 6.1 (0.7-56.1) 0.11  7.9 2.6 (0.3-26.0) 0.42 
ARV status*             
yes 12 33.3 1.0   16.7 1.0   16.7 1.0  
no 111 9.9 0.2 (0.1 - 0.8)   0.03  6.3 0.4 (0.1-2.3) 0.3  2.7 0.1 (0.0-1.0) 0.05 
Married             
yes 77 11.7 1.0   6.5 1.0   3.9 1.0 1.00 
no 354 14.4 1.3 (0.6 - 2.7)  0.54  7.1 1.1 (0.4-3.1) 0.8  4.8 1.2 (0.3-4.3) 0.76 
Age at first sex            
<15 years 53 20.8 1.0   3.8 1.0   3.8 1.0  
15+ 377 13.0 0.6 (0.3 - 1.2)   0.13  7.2 1.9 (0.4-8.3) 0.38  4.8 1.3 (0.3-5.8) 0.73 
Number of sex partners           
1- 2 82 14.6 1.0   6.1 1.0   6.1 1.0  
3 - 4 71 16.9 1.2 (0.49 - 2.8)  0.72  9.9 1.8 (0.5-6.0) 0.33  8.5 1.4 (0.4-4.8) 0.60 
5 - 9 128 10.9 0.7 (0.3 - 1.6)   0.43  8.6 1.5 (0.5-4.4) 0.47  2.3 0.4 (0.1-1.6) 0.18 
10+ 148 14.9 1 .1 (0.5 - 2.2)    0.95  4.1 0.6 (0.2-2.1) 0.44  4.1 0.7 (0.2-2.2) 0.51 
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    Men: HPV-11   Men: HPV-16   Men: HPV-18 
Variable n Ab % OR (95% CI)  P-value   Ab % OR (95% CI)  
P-
value   Ab % OR (95% CI)  P-value 
Sex partners previous year           
0 or 1 137 11.7 1.0   3.7 1.0   2.2 1.0  
3+ 49 18.4 1.6 (0.7 - 4)      0.29  10.2 2.9 (0.8-10.7) 0.1  8,2 3.5 (0.7-17.1) 0.12 
New sex partners previous year           
0 or 1 171 12.3 1.0   4.7 1.0   2.3 1.0  
3+ 15 26.7 2.2 (0.6 - 7.9)   0.21  13.3 
3.0 (0.54-
16.0) 0.21  20.0 6.8 (1.2-37.3) 0.03 
Sex frequency previous month           
0 33 15.2 1.0   9.1 1.0   9.1 1.0  
1 93 18.3 1.2 (0.4 - 3.7)  0.69  3.2 0.3 (0.1-1.8) 0.21  5.4 0.5 (0.1-2.4) 0.43 
2 106 9.4 0.6 (0.18 - 1.8)   0.35  7.6 0.9 (0.2-3.5) 0.85  2.8 0.3 (0.1-2.5) 0.13 
3 76 7.9 0.5 (0.13 - 1.7)   0.25  9.2 1.1 (0.3-4.5) 0.92  5.3 0.5 (0.1-2.5) 0.43 
4 119 18.5 1.3 (0.43 - 3.65)  0.67  6.7 0.8 (0.2-3.2) 0.75  4.2 0.4 (0.1-1.8) 0.25 
Genital ulcer             
no 383 14.4 1.0   6.3 1.0   4.4 1.0  
yes 46 10.9 0.7 (0.3-1.9) 0.52  13.0 2.4 (0.9-6.2) 0.08  6.5 1.5 (0.4-5.3) 0.54 
Genital ulcer recency            
<1 month 15 6.7 1.0   6.7 1.0   0.0   
≥1 month 30 13.3 2.0 (0.2-20.7) 0.56  16.7 3.7 (0.4-38.3) 0.28  10.0 .. .. 
Smoking             
never 70 18.6 1.0   5.7 1.0   8.6 1.0  
previously 62 11.3 0.6 (0.2 - 1.5)   0.25  9.7 1.5 (0.4-5.7) 0.56  3.2 0.4 (0.1-1.9) 0.24 
current 297 13.1 0.7 (0.3 - 1.3)  0.25  6.7 1.1 (0.4-3.3) 0.88  4.0 0.5 (0.2-1.2) 0.14 
 Numbers will not always add up to 437 because of missing information, n: number, Ab%: percentage of women with positive antibody response. Ab: antibodies. *: HIV-
positive. Age adjusted as a continuous variable. 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
                                                                                                                                            
Chapter 5      
 110 
counts for HPV-11 (OR: 2.9, 95% CI: 0.5-13.1, P=0.29), HPV-18 (OR: 5.1, 95% CI: 0.3-95.1, 
P=0.28), α7 HPv species (OR: 1.9, 95% CI: 0.2-14.5, P=0.52) and α9 HPV species (OR: 2.2, 
95% CI: 0.6-8.4, P=0.24) but the association was not statistically significant. HIV-positive men 
not on ARVs treatment were significantly more likely to have HPV-11 (OR: 0.1, 95% CI: 0.0-
5.8, P=0.01) and HPV-18 (OR: 0.1, 95% CI: 0.0-0.7, P=0.03) antibodies but not α7 and α9 
HPV species compared to those on ARVs.  Men that were not married showed an increased 
likelihood of α9 HPV species antibodies compared to married men (OR: 2.4, 95% CI: 1.1-5.1, 
P=0.02) but not for HPV-11, -18 and α7 HPV species. Smoking in men was found not to 
influence HPV antibodies response (Table 5.9). 
 
 
Table 5.9. The HPV-11, -16 and -18 antibodies in men and factors associated with 
seropositivity in multivariate analysis 
      MEN: HPV-11   MEN: HPV-18 
Variable n % OR (95% CI)  P-value   % OR (95% CI)  P-value 
Age 432 13.9 1.0 (1.0-1.0) 0.98  4.63 1.0 (0.9-1.0) 0.74 
HIV         
negative 277 15.2 1.0   5.1 1.0  
positive 155 11.6 4.2 (0.8-23.6) 0.10  3.9 6.3 (0.5-82.3) 0.16 
CD4 count+         
<200/mL 31 9.7 1.0   3.2 1.0  
200 - 349/mL 48 12.5 0.7 (0.1-3.7) 0.67  4.2 1.0 (0.1-14.2) 0.99 
350 - 499/mL 35 8.6 0.9 (0.1-5.4) 0.91  0.0   
≥500/mL 38 15.8 2.5 (0.5-13.1) 0.29  7.9 5.1 (0.3-95.1) 0.28 
ARV status+         
yes 12 33.3 1.0   16.7 1.0  
no 111 9.9 0.1 (0.0-5.8) 0.01  2.7 0.1 (0.0-0.7) 0.03 
Married         
yes 77 11.7 1.0   3.9 1.0  
no 354 14.4 1.2 (0.5-2.7) 0.66  4.8 1.2 (0.3-4.5) 0.82 
Total number of sex partners      
1- 2 82 14.6 1.0   6.1 1.0  
3 - 4 71 16.9 0.8 (0.3-2.0) 0.60  8.5 0.9 (0.2-3.5) 0.88 
5 - 9 128 10.9 0.6 (0.3-1.5) 0.28  2.3 0.4 (0.1-1.9) 0.25 
≥10 148 14.9 1.0 (0.5-2.3) 0.91  4.1 0.7 (0.2-2.6) 0.64 
Smoking         
never 70 18.6 1.0   8.6 1.0  
previously 62 11.3 0.5 (0.2-1.5) 0.24  3.2 0.3 (0.1-2.0) 0.23 
current 297 13.1 0.6 (0.3-1.3) 0.20   4.0 0.4 (0.1-1.3) 0.14 
         * Age was included as a continuous variable. Only variables that appear on this table were included in  
             multivariate analysis +: HIV-positive. 
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5.3.7 HPV seroconversion at 12 months period in women and men 
HPV seroconversion (over 12 months) was analysed in those women and men (201 and 217 
respectively) that were HPV antibody positive for less than 9 HPV antibodies at the baseline 
visit. Women had a significantly higher seroconversion rate than men (24.8% 52/201, 14.7% 
32/217 respectively, P=0.009, Table 5.10). In women who seroconverted, antibodies to HPV-
11 (7.1% 9/127) were the most common, followed by HPV-31 (6.5% 9/138),  HPV-18 (4.7% 
7/149), HPV-16 (4.6% 7/151), HPV-45 (4% 6/150), HPV-52 (2.9% 5/173), HPV-58 (2.2% 
4/182), HPV-35 (1.8% 3/168) and HPV-33 (1.1% 2/188). In men who seroconverted, -11 
(4.3% 8/186) was also the most common antibody type, followed by HPV-16 (2.1% 4/195), 
HPV-31 (2.1% 4/190), HPV-18 (2.0% 4/203), HPV-35 (2.0% 4-196), HPV-52 (2.0 % 4/199), 
HPV-58 (1% 2/196), HPV-45 (0.5% 1/199), and HPV-33 (0.5% 1/206; Table 5.10). 
 
HPV seroconversion was observed in 65 participants, of which 74% (48/65) seroconverted to 
one HPV type while 26% (17/65, P<0.0001) seroconverted to multiple (2-6) HPV types. 
Participants in whom HPV seroconversion was observed were not always those with genital 
HPV DNA at the baseline, 6-month or 12-month visits. This observation probably indicates an 
infection at another site. Factors associated with HPV seroconversion was also investigated, 
however, due to small number of seroconverters conclusion on factors associated with HPV 
seroconversion was not made. 
 
Table 5.10. Human papillomavirus (HPV) seroconversion in women and men after 12-
months  
Variable Women  Men  P-value 
  n/t % n/t % 
      HPV-11 9/127 7.1 8/186 4.3 0.29 
      HPV-16 7/151 4.6 4/195 2.1 0.15 
      HPV-18 7/149 4.7 4/203 2.0 0.13 
      HPV-31 9/138 6.5 4/190 2.1 0.04 
      HPV-33 2/188 1.1 1/206 0.5 0.46 
      HPV-35 3/168 1.8 4/196 2.0 0.58 
      HPV-45 6/150 4.0 1/199 0.5 0.03 
      HPV-52 5/173 2.9 4/199 2.0 0.41 
      HPV-58 4/182 2.2 2/196 1.0 0.31 
      Total 52/210 24.8 32/217 14.7 0.009 
                                n: number of participants that seroconverted at 12 month visit.  
                                t: total number of participants that were HPV antibody negative at baseline visit 
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5.4 DISCUSSION 
In this chapter we present seroprevalence data of South African black women and men. 
Seroprevalence was assessed by HPV type, gender, age, HIV status, cervical cytology and 
some sexual behaviour variables. To our knowledge this is the first study to investigate serum 
antibody responses in men and women to nine different HPV types using the multiplex 
serology, in South Africa. It is important to note that comparing our data with published data 
from other laboratories is difficult because of different assays used and different cut-off 
definitions which many significantly influence seroprevalence and factors associated with 
seropositivity in different studies. It has been reported that 59% of sera collected from Africans 
directly bind to beads of the assay used in this study, thus interfering with the assay (Waterboer 
et al., 2006). It was interesting to note that in our study only one study participant was found to 
have serum that directly binds to the beads in the assay. 
 
We observed that women have higher HPV seropositivity compared to men (53% compared to 
31%, P<0.0001), as well as HPV seroconversion over 12-months. For individual HPV types 
and multiple seropositivity, women were found to have up to a 4-fold higher HPV 
seroprevalence compared to men. When stratified according to age similar observations were 
observed. Michael et al., (2008) also reported a 5.8-fold and 2.8 fold higher seroprevalence in 
women respectively compared to men of the same age. The low HPV seroprevalence in men 
does not necessary mean less HPV infection as we demonstrated higher genital HPV 
prevalence in HIV-negative men compared to HIV-negative women.  In studies in which VLP-
based ELISA has been used a lower HPV seroprevalence in men compared to women has been 
reported (Hopfl et al., 2003; Thompson et al., 2004). The low seroprevalence in men compared 
to women can also be explained by the fact that the immune system is less accessible in 
keratinized epithelium of the penis in men compared to mucosal epithelium of the cervix in 
women resulting to lower prevalence of seroconversions in heterosexual men compared to 
women (Stone et al., 2002; Thompson et al., 2004). HPV antibodies were not associated with 
HPV clearance in both women and men (chapter 6). The majority of men in our study were 
circumcised (even though their circumcision was traditionally) an indication that the mucosal 
epithelium on the penile shaft was removed. A higher rate of transient HPV infection in male 
genitalia than in female vagina and cervix may also be the reason for the lower prevalence of 
antibodies in men as persistent exposure to HPV is required for seroconversion (Ho et al., 
2004). 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
                                                                                                                                            
Chapter 5      
 113 
In our study HPV-16 and -18 seroprevalence was found to be 24% for each type. Vaccarella et 
al., (2010) reported similar observations for HPV-16 and -18 (27% and 24.8% respectively) 
among Nigerian women. Firnhaber et al., (2011) reported a similar HPV-16 seroprevalence 
(29.3%) and lower HPV-18 seroprevalence (15.9%) in HIV-positive women from 
Johannesberg South Africa compared to the one observed in our study. HPV-16 and -18 
seroprevalence among women from Spain, Argentina, Korea, Thailand and Vietnam were 
found to be lower than observed in our study (0.8-20.9% for HPV-16 and 0.2-12.2% for HPV-
18). Syrjanen et al., (2009) presented their data using two different cut-offs, 200 and 400 MFI. 
When comparing our study with Finnish study, seroprevalence in our study was higher for all 
HPV types investigated (HPV-11: 34% compared to 13%, HPV-16: 24% compared to 19%, 
HPV-18: 24% compared to 8% and HPV-45: 22% compared to 2%).  
 
In our study in women we observed a weak association between HPV seroprevalence and HPV 
DNA and number of sexual partners over the previous year. According to Clifford et al., (2007) 
the presence of genital HPV DNA demonstrated a very strong association with HPV 
seroprevalence in women (OR: 14.0, 95% CI: 4.7-42.0), even stronger than the association with 
the number of sexual partners (within the past 12 months, OR: 2.9, 95% CI: 1.8-4.7). Findings 
from our study and those from Clifford et al., (2007) are different probably due to the different 
demographics of the study participants. In the Clifford et al., (2007) study participants had only 
initiated sexual activity within 12 months before the start of the study. Thus, HPV antibody 
response they observed was the responses to new infections. Our study participants had been 
sexually active for more than a year and up to decades. Thus, the antibody responses we 
observed are probable responses to past and current HPV infection. It is interesting to note that 
in a study reported by Clifford et al., (2007) in which multiplex serology was used to detected 
antibodies, overall and type-specific HPV seroprevalence in women was not found to differ 
significantly compared to that of men (15% and 12% respectively). However, in women who 
were sexually experienced overall HPV seroprevalence was found to be higher compared to 
that of sexually inexperienced women (25% and 13% respectively). In men sexual experience 
did not increase HPV seroprevalence.  It is interesting to note that when looking at sexually 
experienced women and men, women displayed significantly higher overall HPV 
seroprevalence (25% and 13% respectively). In contrast, no difference in seroprevalence was 
observed (13% compared to 11%) among the sexually inexperienced women and men. Study 
participants in the Clifford et al., (2007) study were between the ages of 15 and 19 years and 
many of them reported never having had penetrative sexual intercourse or recent (<12 months) 
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penetrative sexual intercourse. In our study all participants had been sexually active for years or 
decades. 
 
In our study HPV seroprevalence was associated with the increased number of sexual partners 
over the previous year in men. It is interesting to note that in the men in Clifford et al., (2007) 
study, higher number of sexual partners (OR: 1.2, 95% CI: 0.6-2.5) and genital HPV DNA 
(OR: 1.6, 95% CI: 0.4-6.3) had no significant effect on HPV seroprevalence, even though men 
in their study reported higher sexual activity compared to women. Since the study participants 
in the Clifford et al., (2007) study only recently participated in sexual activities and we know 
months are required to develop detectable antibodies, the keratinized epithelium of the penis 
may contribute to the delayed immune response (Thompson et al., 2004; Clifford et al., 2007). 
In a Finnish study in which antibodies were detected in the DFKZ laboratory with the same 
multiplex assay as in our study, type-specific concordance between genital HPV DNA 
detection and seropositivity was poor. When DNA positivity of oral and genital sites were 
combined (positive at genital and/or oral site) the type-specific concordance for HPV-16 was 
improved even though it was still poor (Syrjanen et al., 2009).  
 
Unmarried women in our study were found to more likely to be HPV seropositive compared to 
married women, however, this was not observed in men. Vaccarella et al., (2010) also reported 
that single women were more likely to develop HPV-16 antibodies compared to married 
women (OR: 1.6, 95% CI: 1.1-2.4). Unmarried women have been previously reported to be 
more likely to seroconvert compared to married women (Shin et al., 2003; Syrjanen et al., 
2009). These observations can also be explained by increased number of sex partners in single 
women compared to married women (Shin et al., 2003; Syrjanen et al., 2009). In our study 
marital status in men was not associated with seropositivity. However, Lu et al., (2010) 
reported that men, who were divorced, separated or widows were more likely to be HPV-16 or 
-18 seropositive. In our study increasing numbers of sexual partners over the previous year and 
a greater number of new sexual partners over the previous year were associated with HPV 
seroprevalence in men but not in women. It has been reported in several studies that as the 
number of sexual partners increase in women, the HPV seroprevalence was found to increase 
significantly as well, while in men it was not (Carter et al., 1996; Clifford et al., 2007; Sitas et 
al., 2007; Porras et al., 2010).  
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In our study, age at first sexual intercourse and number of sexual partners were not significantly 
associated with HPV seropositivity. Syrjanen et al., (2009) reported an association between 
HPV seropositivity and age at first sexual intercourse and number of sexual partners, however, 
the cut-off used in their study was lower than ours (200 MFI compared to 400 MFI) and the 
study participants in Syrjanen et al., (2009) study were a high risk sexual cohort compared with 
populations analysed in other serological studies where women had about 5 lifetime sex 
partners. Women who developed a genital ulcer ≥1 month ago and who were smoking were 
more likely to have detectable antibody. HIV-positive status was not associated with HPV 
seropositivity in univariate analysis but in multivariate analysis HIV-positive status was found 
to influence HPV antibody response in both women and men. Other studies have also reported 
an increased seropositivity among HIV-positive individuals (Viscidi et al., 2003; Marais et al., 
2009).  
 
It was interesting to note that HIV-positive men and women who were using ARVs had a 
higher HPV-11 and -18 seroprevalence compared to those not using ARVs but not for HPV-16. 
However, these results should be interpreted with caution as there were too few study 
participants who were using ARVs to be conclusive on this observation. Hopfl et al., (2003) 
reported that HIV-positive men using highly active antiretroviral therapy (HAART) were more 
likely to be HPV-16/18/31 seropositive compared to men not using HAART (43.7% compared 
to 33.3%, OR: 1.6, 95% CI: 0.8-2.9) even though the difference was not statistically significant. 
These observations may demonstrate the role played by ARVs to restore the immune system 
(Minkoff et al., 2010). The data reporting on the association of HAART on HPV and HPV-
associated lesions is not consistent. Some studies have found HAART significantly reducing 
the burden of HPV infection and HPV-associated lesions (Minkoff et al., 2010). Others studies 
have found no effect (Moodley et al., 2009; Shrestha et al., 2010). The period since the 
participants started using HAART would significantly influence the finding. In this study, the 
information on period the participants started using ARVs was not available. The role played 
by ARVs on the prevalence of HPV antibodies still needs further investigation.  
 
Women and men who had acquired a genital ulcer ≥1 month ago were found to be more likely 
to have antibodies compared to those who had genital ulcer <1 month ago. Mbwana et al., 
(2007) also reported a high HPV seroprevalence among women and men with genital ulcer 
disease. These observations may indicate high exposure of the virus to the immune system 
resulting in the elicitation of antibody responses (Mbwana et al., 2006). HSV-2 is identified as 
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the cause of genital ulcer disease (Ahmed et al., 2003). HSV-2 data is not yet available in our 
cohort. This will be generated in future work and the association of HSV2 infection on HPV 
antibodies in our cohort will be investigated. 
 
Age and cervical abnormal cytology were not found to be associated with HPV seropositivity 
in our study. Similar observations were reported elsewhere (Syrjanen et al., 2009). Firnhaber et 
al., (2011) also did not observe any association between abnormal cervical cytology and HPV 
seropositivity in South African women from Johannesburg. However, in our study women with 
abnormal cytology demonstrated seropositivity to multiple types compared to women with 
normal cytology (64% compared to 47%) and multiple seroprevalence was found to increase 
with increasing severity of cervical abnormalities. These observations are the reflection of the 
high prevalence of multiple HPV types detected at the cervix of women with abnormal 
cytology compared to women with normal cervical cytology (Porras et al., 2010).  
 
The multiplex serology method used in this study uses L1 proteins expressed in bacteria as a 
GST fusion proteins as antigen and these L1 proteins have been reported to display 
conformational epitopes (Rizk et al., 2008). All epitopes displayed on VLPs are also displayed 
on these L1 antigens (Rizk et al., 2008). The HPV antibodies detected by this assay target the 
L1 major capsid protein of HPV and the L1 major capsid protein is a marker of infection 
(Zumbach et al., 2000). However, antibody cross-reactivity and non-specificity cannot be 
excluded entirely. Like VLPs, GST fusion L1 proteins present conformational and neutralising 
epitopes but also display more linear or cross-reacting epitopes than VLPs (Kirnbauer et al., 
1996; Rizk et al., 2008). Michael et al., (2008) reported that the assay used in this study detects 
mainly type-specific antibodies while VLP-based ELISA may detect a higher ratio of specific 
to non-specific antibodies. These could be the reasons why we observed that some of the 
factors that were previously found to be positively associated with seropositivity in VLP-based 
ELISA in other studies, while, in GST-based multiplex serology they are not positively 
associated with seropositivity. However, a good correlation between GST-L1 fusion protein 
ELISA and VLP-based ELISA for HPV-16 and -18 antibodies has been reported elsewhere 
(Sehr et al., 2002; Waterboer et al., 2005; Rizk et al., 2008). 
 
The high antibody response to HPV-11, 16 and 18 in young and old sexual active women and 
men indicate that they have been exposed to infection.  The high HPV-6, -11, α7 and α9 HPV 
species prevalence and acquisition (chapter 2 and 6) in our cohort indicate that in South Africa 
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even young women and men are highly exposed to these HPV types indicating that vaccination 
against HPV-6, -11, -16 and -18 will be of great benefit to women and men’s health in our 
country. The current HPV vaccine are found to be very effective in both women and men 
(Stanley, 2008). In an ideal situation HPV vaccines should be given before people become 
sexually active. These are prophylactic vaccines and are not known to have therapeutic 
activity. HPV sero-epidemiology may inform vaccine policy and although there are misgivings 
as to what HPV serology actually reflects in terms of HPV exposure, HPV infection and 
immunity, the more data is available, especially for men where data is very limited the better 
will be our understanding (Schiffman et al., 2009b). Serological data underestimates the 
exposure to HPV due to low rate of seroconversion after infection; however it is a good 
epidemiological tool that can be used in young women and men to assess HPV infection and in 
monitoring the effect of vaccines.  
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6.1 INTRODUCTION 
 
The HPV life cycle is linked to the differentiation of the cells which HPV has infected. HPV 
gains access to basal epithelial cells resulting in productive or abortive infection (Culp et al., 
2006; Doorbar, 2006). In a productive infection, HPV follows its normal life cycle as described 
in chapter 2 section 1.4, in which HPV enters the basal cells, genome amplification occurs 
followed by virus assembly associated with the various layers of differentiating cells and virus 
release within cells sloughing off the epithelial surface. In an abortive infection HPV gains 
access to basal cells but some time during replication the viral life cycle stops leaving some 
cells infected with a low HPV copy number. This condition is referred to as latency. However, 
the mechanism involved in HPV latency is not yet clear. HPV in a state of latency may get 
reactivated to resume replication especially in immune suppressed individuals. HPV can also 
be found in cells in low copy numbers but not sheeding (Stanley, 2006; Doorbar, 2006; Theiler 
et al., 2010; Nicol et al., 2010). According to Insinga et al., (2010) the risk of HPV 
reappearance within 3 years of follow-up ranges from 0 - 16% in women. 
 
HPV prevalence and acquisition in both women and men is significantly associated with young 
age, increased lifetime number of sexual partners, increased number of recent sexual partners, 
smoking, early age of sexual debut, high-risk sexual partners and the consumption of alcohol 
(Kjaer et al., 2002; Svare et al., 2002; Shin et al., 2004; Vaccarella et al., 2006; Nielson et al., 
2007; Partridge et al., 2007; Goodman et al., 2008; Fukuchi et al., 2009; Lu et al., 2009). A 
high prevalence of new HPV infections and persistent infections are reported in immuno-
compromised individuals such as in HIV-positive individuals (Piketty et al., 2003). 
Circumcised men have lower HPV prevalence and acquisition rates compared to 
uncircumcised men (Castellsague et al., 2002; Tobian et al., 2009; Lu et al., 2009).  
 
In a Zimbabwean study of HIV-negative women, HPV acquisition of any type after 12-months 
was reported to be 23.3%. HPV-58 was reported to be the most prevalent type followed by 
HPV-16 (Fukuchi et al., 2009). Factors that were associated with HPV acquisition in women 
include young age, multiple lifetime sexual partners, not using condoms, HSV-2 co-infection, 
other STIs and having HPV infection at the baseline visit (Fukuchi et al., 2009). Goodman et 
al., (2008) reported that the incidence of HR-HPV is not statistically different from that of LR-
HPV. It is not yet clear if there is a biological interaction between various HPV types. Possible 
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infection with a certain type increases the likelihood of acquiring another type in the future or 
there is a genetic susceptibility to HPV infection (Rousseau et al., 2001).  
 
Goodman et al., (2008) reported that of all HR-HPV infections observed in women at 
screening, 69% of HR-HPV and 81% of LR-HPV infections were cleared after 12-months. The 
α9 HPV species demonstrated lower clearance rate compared to other species types. Women 
co-infected with multiple HPV types demonstrated lower clearance when compared with 
women infected with one HPV type. Men with multiple HPV infection also have an elevated 
risk of HPV persistent infection (Kjaer et al., 2002). Women with HPV-16 and/or multiple 
HPV infection demonstrate lower rates of clearance compared to women infected with other 
types and with single HPV infection respectively. Women with HPV-16 infection demonstrate 
a 20% lower clearance than women infected with other HPV genotypes (Louvanto et al., 
2010). HPV clearance is reported to be lower in uncircumcised men compared to circumcised 
men (Hernandez et al., 2010). According to Hernandez et al., (2010) HPV duration is longer in 
uncircumcised men compared to circumcised men (154 days compared to 91 days, P=0.04). 
 
Older women clear their HPV infection faster than younger women (<25 years). HPV 
prevalence is found to decrease with increasing age but HPV clearance is reported to increase 
with increasing age (Castle et al., 2005; Louvanto et al., 2010). This may indicate that older 
women may have been exposed to HPV for a longer period of time compared with young 
women and probably due to immune memory their immune system clears the HPV infection 
faster than young women who are more likely to be newly infected (Goodman et al., 2008). In 
a study reported by Lu et al., (2009) a greater number of lifetime sexual partners (>16) was 
associated with HPV clearance. People with high number of lifetime sex partners have been 
highly exposed to genital HPV infection over time resulting in immune responses that clear the 
infection (Olsen et al., 1997; Slavinsky et al., 2001). It has been reported that 12-months after 
HPV infection ~70% of women clear their infection (Ho et al., 1998; Dillner, 1999; Giuliano et 
al., 2008a; Oh et al., 2008); and after 2 years ~90% of HPV infections are cleared (Moscicki et 
al., 2008). 
 
Castle et al., (2009) reported that women that were HR-HPV positive for one year have a 3 
year HSIL cumulative incidence of 17% to 22%, while women that were HR-HPV negative 
and then HR-HPV positive over one year have a 3.4% to 6.8% HSIL incidence. Women that 
were HR-HPV positive and then HR-HPV negative had an HSIL incidence of 1.2% to 2.5% 
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and women who remain HR-HPV negative for one year had a 3 years HSIL cumulative 
incidence of 0.5% to 0.9% (Castle et al., 2009). The relative risk of developing cervical 
neoplasia is reported to be 14.7 among women with transient HPV infection and 42.9 among 
women with HR-HPV persistent infection for about 1 year (Koshiol et al., 2008). Some studies 
have found that women who tested HR-HPV positive at a first visit and then HPV negative at 
follow up had a similar risk of developing neoplasia compared to those that were negative at 
both visits. This may indicate false positive results at the first visit or HPV clearance (Castle et 
al., 2009). In contrast, Kjaer et al., (2006) reported a higher risk of developing precancerous 
lesions in women who tested HR-HPV positive and then negative compared to those who 
tested HR-HPV negative at both visits. However, the observed risk was still lower than that 
observed in women who tested HR-HPV positive at both visits. Following HPV in women for 
one or more years may assist in determining those at higher risk of developing precancerous 
lesion and thus requiring intervention.  
 
The natural history of different HPV genotypes and factors associated with clearance of 
different HPV genotypes in men are not well known (Ho et al., 1998; Giuliano et al., 2008b). 
Data on the type distribution of HPV and HPV natural history in sub-Saharan Africa is limited 
and there are no published reports on HPV natural history studies on heterosexually active 
couples in Africa. The study described here is the first such report in Africa. This is also the 
first study to describe HPV natural history on HIV-positive; HIV-negative and HIV-discordant 
couples investigated over a period of 24-months. HPV natural history studies in women are not 
as limited as those in men. It is important to study HPV in men because of the direct influence 
men have on genital HPV acquisition and the development of cervical neoplasia and cancer in 
their female partners. 
 
The aims of the study described below were:  
(i) to investigate the rate of HPV acquisition and clearance over a period of 24-months in HIV-
positive and HIV-negative women and men;  
(ii) to investigate the proportion of HPV acquisition events from the study partner; and 
(iii) to investigate factors associated with HPV acquisition and clearance. 
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6.2 MATERIALS AND METHODS 
6.2.1 Study population, specimen collection and HPV genotyping 
Cervical and penile specimens were collected as described in chapter 2 section 2.2.1. For the 
present study, samples from a total of 209 HIV-negative women, 277 HIV-positive women, 
333 HIV-negative men and 153 HIV-positive men were available. There were 486 couples in 
total, 162 couples were both HIV-negative, 115 couples were both HIV-infected, 163 were 
HIV-discordant where the female partner was HIV-positive and 46 were HIV-discordant where 
the male partner was HIV-positive. At the 6-month visit samples from 260 couples were 
available, samples from 197 couples at the 12-month visit, 140 samples from couples at the 18-
month visit and from 62 couples at the 24-month visit. At the baseline visit the mean age of 
women and men participants were 35 years (range: 18-66 years) and 38 years (range: 19-67 
years) respectively. HPV genotyping in cervical and penile cells was detected as described in 
chapter 2 section 2.2.2.  
 
6.2.2 Statistical analysis 
Acquisition of an HPV infection was defined as the first positive result for a specific HPV 
type. HPV clearance was defined as the first time a woman tested negative for HPV following 
the first positive HPV identification. Time to HPV clearance was measured at 6-month 
intervals. Rates of HPV acquisition and HPV clearance were calculated for each HPV type. 
Because follow-up was limited to a maximum of four visits (after baseline), the analysis is 
limited to the rate at which an HPV type is first acquired, or first cleared, over the follow-up 
period. If an HPV type was present at one visit, absent at the next visit, and then present at the 
next visit, the negative result was considered to be a false negative and was treated as a positive 
result for the purpose of calculating rates of HPV clearance. In all other cases, the date of 
clearance was assumed to be the mid-point between the date of the last positive test and the 
first negative test, for a given HPV type. Similarly, the date of HPV acquisition for a specified 
HPV type is assumed to be midway between the last negative visit and the first positive visit. 
For the purpose of calculating the person months at risk in the acquisition rate denominator, the 
period at risk is assumed to start when the individual is first observed to be uninfected with the 
type of interest (or at the second visit at which they are observed to be uninfected if they were 
previously infected). For the purpose of calculating the person months of infection in the 
clearance rate denominator, the period of observation begins when the individual is first 
observed to be infected with the HPV type of interest (and not at the estimated date of 
acquisition if they were previously uninfected). HPV transmission from the study partner is 
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defined to be HPV acquisition where the partner is known to be infected with the type of 
interest at the estimated date of HPV acquisition. This definition of transmission may 
understate the true proportion of acquisition events that are transmissions from study partners, 
since it excludes cases in which both partners acquire the same HPV type between two visits, 
and it excludes cases in which the partner’s HPV status was left- or right-censored at the time 
of the individual’s HPV acquisition. 
 
Poisson regression models were used to assess predictors of acquisition rates and clearance 
rates. Because of the low numbers of acquisition and clearance events for individual HPV 
types, the regression models were run for all HPV types combined, with variance calculations 
adjusted to allow for clustering of observations at the individual level. All regression models 
were controlled for HPV type. All predictors of clearance rates and acquisition rates were 
defined according to values measured at baseline, with the exception of the partner HPV 
infection status, which was treated as a time-varying covariate (and calculated separately for 
each HPV type). All statistical analyses were conducted by Dr Leigh Johnson (Centre for 
Infectious Disease Epidemiology and Research, University of Cape Town) using STATA 11.0 
(StataCorp, College Station, TX, USA). In all analyses P-values ≤0.05 were considered 
significant. 
 
6.3 RESULTS 
6.3.1 Cervical and penile HPV genotype and species incidence and infection  
The initial analysis of HPV prevalence was done on women and men regardless of their HIV 
status. At the baseline visit the prevalence of genital HPV infection in women and men was not 
found to differ significantly between women and men (58% 281/484 compared to 58% 
275/471, P=0.92). In women a total of 293 incident cervical HPV infections were observed 
during follow-up (24-months), 133 incident infections were HR-HPV types and 160 were LR-
HPV types. Among men, a total of 459 incident penile HPV infections were observed during 
follow-up, 211 incident infections were HR-HPV types and 248 were LR-HPV types. There 
were 42 HPV incident infections in women and 66 in men due to transmission from the study 
partners. We observed significantly more HR-HPV transmission events in men from their 
female partner compared to women (18% 38/211 compared to 7% 9/133, P=0.003). In contrast, 
significantly more LR-HPV transmission events were observed in women from their male 
partner compared to men (21% 33/160 compared to 11% 28/248, P=0.01; Table 6.1). 
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The rate of acquiring any type of HPV infection on the cervix was 1.82 (95% CI: 1.53-2.14) 
per 1000 person months in women. The incidence of HR-HPV types was 1.65 (95% CI: 1.30-
2.08) and of the LR-HPV types was 1.98 (95% CI: 1.64-239) per 1000 person-months in 
women. The rate of acquiring any penile HPV infection was 3.07 (95% CI: 2.65-3.54) per 1000 
person-months in men. The incidence of HR-HPV types was 2.80 (95% CI: 2.32-3.36) and of 
the LR-HPV types was 3.34 (95% CI: 2.81-3.95) per 1000 person-months in men. The most 
common HR-HPV type acquired in women during follow-up was HPV-35 (2.76 per 1000 
person-months) followed by HPV-52 (2.58 per 1000 person-months). While in men, HPV-66 
(5.49 per 1000 person-months) was the most acquired type followed by HPV-58 (4.64 per 
1,000 person-months) during follow-up. When looking at LR-HPV types, HPV-62 was the 
most acquired type in both women (5.71 per person-months) and men (10.55 per 1000 person-
months) followed by HPV-61 in both women (4.42 per 1000 person-months) and men (7.55 
per person-months) during follow-up. Men were found to have a higher rate of acquiring any 
HPV, HR-HPV or LR-HPV infection during follow-up compared to women (P<0.001 for each; 
Table 6.1). 
 
When we look at HPV types individually, among HR-HPV types men were found to have a 
significantly high rate of acquiring HPV-18 compared to women (3.36 per 1000 person-months 
compared to 1.13 per 1000 person-months, P=0.04); HPV-58 (4.64 per 1000 person-months 
compared to 2.09 per 1000 person-months, P=0.05); HPV-66 (5.49 per 1000 person-months 
compared to 2.22 per 1000 person-months, P=0.02) and HPV-68 (4.42 per 1000 person-months 
compared to 0.89 per 1000 person-months, P=0.004). Among LR-HPV types men were found 
to have a significantly high rate of acquiring HPV-55 compared to women (3.46 per 1000 
person-months compared to 0.65 per 1000 person-months, P=0.01); HPV-62 (10.55 per 1000 
person-months compared to 5.71 per 1000 person-months, P=0.004); HPV-70 (4.68 per 1000 
person-months compared to 2.04 per 1000 person-months, P=0.004) and HPV-89 (3.16 per 
1000 person-months compared to 1.10 per 1000 person-months, P=0.05, Table 6.1).  
 
During follow-up in women, α3 HPV species contributed the most incident cervical infection 
(97 events of HPV acquisition) followed by α9 HPV species (49 events of HPV acquisition) 
and α7 HPV species (41 events of HPV acquisition). Among men, α3 HPV species (144 events 
of HPV acquisition) contributed the most incident infection followed by α7 HPV species (90 
events of HPV acquisition) and α6 HPV species (43 events of HPV acquisition). Men were 
found to have a significantly higher rate of HPV species acquisition compared to women for α3  
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Table 6.1. The incidence rate of genital HPV infection by genotype and species in women and men 
   WOMEN      MEN    
 Variable 
rate/1000 
PM 95% CI 
Events of 
acquisition 
transm. From* 
study partner PM   
rate/1000 
PM 95% CI 
Events of 
acquisition 
transm. from 
study partner PM P-value 
HR-HPV             
HPV-16 2.04 1.06-3.95 9 0 4407.8  3.16 1.83-5.43 13 4 4113.0 0.32 
HPV-18 1.13 0.47-2.73 5 0 4437.7  3.36 1.98-5.66 14 3 4170.3 0.04 
HPV-26 0.43 0.11-1.74 2 0 4648.4  0.00 - 0 0 4394.2 - 
HPV-31 0.44 0.11-1.74 2 1 4580.5  1.40 0.63-3.10 6 2 4294.1 0.15 
HPV-33 1.10 0.46-2.65 5 0 4553.2  0.92 0.35-2.44 4 0 4343.3 0.79 
HPV-35 2.76 1.56-4.87 12 1 4346.1  3.37 1.98-5.71 14 2 4151.1 0.61 
HPV-39 2.21 1.19-4.11 10 2 4524.7  3.08 1.77-5.33 13 2 4215.8 0.43 
HPV-45 1.79 0.89-3.57 8 1 4474.6  3.63 2.17-6.07 15 5 4135.5 0.11 
HPV-51 2.00 1.03-3.83 9 2 4508.2  3.18 1.85-5.49 13 1 4090.0 0.29 
HPV-52 2.58 1.42-4.68 11 0 4264.9  3.17 1.83-5.49 13 3 4106.3 0.62 
HPV-53 2.31 1.24-4.28 10 0 4334.3  4.33 2.67-6.98 17 2 3929.7 0.11 
HPV-56 1.53 0.73-3.23 7 1 4570.4  0.92 0.34-2.47 4 1 4358.1 0.42 
HPV-58 2.09 1.09-4.03 9 0 4315.3  4.64 2.92-7.34 19 5 4097.0 0.05 
HPV-59 1.11 0.46-2.67 5 0 4503.1  2.62 1.45-4.72 11 2 4194.5 0.11 
HPV-66 2.22 1.19-4.15 10 1 4496.8  5.49 3.57-8.35 22 2 4009.1 0.02 
HPV-68 0.89 0.33-2.37 4 0 4482.3  4.42 2.78-7.05 18 2 4068.1 0.004 
HPV-73 1.96 1.02-3.79 9 0 4588.5  1.87 0.93-3.75 8 1 4279.3 0.92 
HPV-82 1.30 0.58-2.92 6 0 4609.8  1.61 0.77-3.40 7 1 4339.1 0.70 
All HR-HPV 1.65 1.30-2.08 133 9 80646.7  2.80 2.32-3.36 211 38 75288.8 <0.001 
LR-HPV             
HPV-6 1.77 0.88-3.57 8 0 4516.7  1.65 0.78-3.50 7 2 4239.3 0.89 
HPV-11 0.43 0.11-1.72 2 0 4670.0  1.85 0.93-3.68 8 1 4332.4 0.07 
HPV-40 0.65 0.21-2.02 3 1 4650.5  1.39 0.62-3.07 6 1 4330.9 0.28 
HPV-42 1.09 0.45-2.62 5 1 4581.8  1.38 0.61-3.07 6 0 4361.0 0.70 
HPV-54 2.29 1.24-4.28 10 1 4367.5  3.15 1.83-5.43 13 3 4128.2 0.45 
HPV-55 0.65 0.21-2.04 3 0 4581.0  3.46 1.86-5.54 14 1 4042.6 0.01 
HPV-61 4.42 2.81-6.98 19 4 4299.3  7.55 5.17-11.05 28 2 3706.4 0.07 
HPV-62 5.71 3.83-8.52 24 11 4203.4  10.55 7.56-14.63 37 3 3506.1 0.02 
HPV-67 0.21 0.03-1.53 1 0 4690.5  0.23 0.03-1.62 1 0 4421.0 0.97 
HPV-69 1.75 0.87-3.50 8 1 4571.7  1.61 0.77-3.36 7 1 4337.2 0.88 
HPV-70 2.04 1.05-3.95 9 1 4407.0  4.68 2.95-7.41 19 3 4061.8 0.04 
HPV-71 2.29 1.22-4.28 10 0 4368.0  2.88 1.62-5.12 12 3 4167.0 0.60 
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   WOMEN      MEN    
Variable  
rate/1000 
PM 95% CI 
Events of 
acquisition 
transm. From* 
study partner PM   
rate/1000 
PM 95% CI 
Events of 
acquisition 
transm. from 
study partner PM P-value 
             
HPV-72 3.66 2.23-6.01 16 5 4374.8  5.19 3.36-8.03 21 4 4049.8 0.30 
HPV-81 1.56 0.74-3.26 7 1 4486.1  3.22 1.86-5.60 13 2 4033.1 0.12 
HPV-83 2.73 1.56-4.82 12 3 4387.8  3.23 1.86-5.60 13 0 4024.5 0.68 
HPV-84 3.14 1.85-5.33 14 4 4458.6  4.72 3.01-7.41 19 1 4022.9 0.25 
HPV-89 1.10 0.46-2.65 5 0 4540.9  3.16 1.83-5.43 13 0 4118.7 0.05 
HPV-IS39 0.87 0.32-2.32 4 0 4613.0  2.54 1.41-4.59 11 1 4331.9 0.07 
All LR-HPV 1.98 1.64-2.39 160 33 80768.5  3.34 2.81-3.95 248 28 74214.7 <0.001 
All HPV 1.82 1.53-2.14 293 42 161415.2  3.07 2.65-3.54 459 66 149503.4 <0.001 
HPV species             
α1 1.09 0.45-2.62 5 1 4581.8  1.38 0.61-3.07 6 0 4361.0 0.70 
α3 3.15 2.54-3.91 97 28 30750.9  5.24 4.32-6.38 144 12 27461.4 0.001 
α5 1.26 0.85-1.86 29 3 22951.0  1.77 1.26-2.47 38 4 21492.5 0.20 
α6 2.01 1.29-3.14 27 2 13401.6  3.50 2.57-472 43 5 12296.8 0.05 
α7 1.53 1.05-2.21 41 4 26829.4  3.62 2.87-4.59 90 17 24846.1 <0.001 
α8 0.65 0.21-2.02 3 1 4650.5  1.39 0.62-3.07 6 1 4330.9 0.28 
α9 1.57 1.15-2.14 49 2 31158.3  2.37 1.83-307 70 16 29526.0 0.05 
α10 0.94 0.53-1.69 13 0 13767.7  2.30 1.51-3.26 29 4 12614.3 0.02 
α11 1.96 1.02-3.79 9 0 4588.5  1.87 0.93-3.75 8 1 4279.3 0.92 
α13 2.29 1.24-4.28 10 1 4367.5  3.15 1.83-5.43 13 3 4128.2 0.45 
α15 2.29 1.22-4.28 10 0 4368.0   2.88 1.62-5.12 12 3 4167.0 0.60 
PM: person-months of follow-up for subject at risk of acquiring HPV infection. *  indicates number of acquired events that we possible transmitted from the study partner. α1 HPV species 
includes HPV-42.  α3 HPV species includes HPV-61, -62, -72, -81, -83, -84 and -89. α5 HPV species includes HPV-26, -51, 69, -82 and –IS39. α6 HPV species includes HPV-53, -56 and -66. α7 
HPV species includes HPV-18, -39, -45, -59, -68 and -70. α8 HPV species includes HPV-40 . α9 HPV species includes HPV-16, -31, -33, -35, -52, -58 and -67. α10 HPV species includes HPV-6, 
-11 and -55. α11 HPV species include HPV-73.  α13 HPV species includes HPV-54. α15 HPV species includes HPV-71.
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HPV species (5.24 per 1000 person-months compared to 3.15 per 1000 person-months, 
P=0.001); α6 HPV species (3.50 per 1000 person-months compared to 2.01 per 1000 person-
months, P=0.05); α7 HPV species (3.62 per 1000 person-months compared to 1.53 per 1000 
person-months, P<0.001); α9 HPV species (2.37 per 1000 person-months compared to 1.57 per 
1000 person-months, P=0.05); and α10 HPV species (2.30 per 1000 person-months compared 
to 0.94 per 1000 person-months, P=0.02, Table 6.1). The proportion of HPV species 
acquisition that was due to transmission from the study partner was generally higher in men 
than in women, with the exception of α3 HPV species which was substantially higher in 
women. 
 
6.3.2 Factors associated with genital HPV acquisition in women and men 
Table 6.2 presents factors associated with acquisition of genital HPV infection during follow-
up in the univariate analysis. HIV infection was significantly associated with increased risk of 
acquiring new HPV types during follow-up in both women (RR: 2.98, 95% CI: 2.1-4.3) and 
men (RR: 2.0, 95% CI: 1.49-2.69). Having an HIV-positive partner was also significantly 
associated with increased risk of acquiring a new HPV type during follow-up in both women 
(OR: 1.67, 95% CI: 1.2-2.3) and men (RR: 1.56, 95% CI: 1.16-2.08). The risk of acquiring 
genital HPV infection during follow-up was significantly increased in women (RR: 5.71, 95% 
CI: 3.9-8.4) and men (RR: 9.06, 95% CI: 6.49-12.7) with a sexual partner that was infected 
with an HPV type similar to the one acquired compared to those with a sexual partner not 
infected with the same HPV types. Women initiating sexual intercourse at a younger age were 
found to have an increased risk of acquiring HPV infection compared to those starting sexual 
intercourse later (P=0.002). In contrast, the risk of acquiring HPV infection during follow-up in 
men was found to increase with an older age of initiating sexual intercourse. However, the 
observations were not statistically significant (P=0.06, Table 6.2) but seem to increase with 
increasing age of sexual debut. Women with an HIV viral load of ≥10 000 copies per mL were 
found to have a significantly higher risk of acquiring HPV infection during follow-up (RR: 
1.46, 95% CI: 1.0-2.2) compared to women with an HIV viral load of <10 000 copies per mL; 
while in men a significant difference was not observed. Living with the study partner was 
found to increase the risk of acquiring HPV infection during follow-up in women (RR: 1.45, 
95% CI: 1.0-2.1), but not in men. An increased number of lifetime sexual partners was 
significantly associated with HPV acquisition during follow-up in women (P=0.015), but not in 
men (Table 6.2). 
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Table 6.2. Factors associated with genital HPV acquisition in women and men, in the univariate analysis 
    WOMEN   MEN 
Variable   
acquisition  
rate/ 1000 PM Events PM RR 95% CI P-value  
acquisition 
rate/ 1000 PM Events PM RR 95% CI P-value 
Age group              
<30 years  1.83 76 41426.4 1.0  0.161  3.48 94 26985.6 1.0  0.538 
30-39 years 2.18 121 55474.8 1.18 0.77-1.83   2.80 148 52765.2 0.80 0.53-1.19  
40+ years  1.49 96 64513.2 0.81 0.53-1.25   3.11 217 69753.6 0.89 0.63-1.26  
HIV status              
Negative  1.01 95 94480.8 1.0  <0.001  2.50 285 114080.4 1.0  <0.001 
Positive  2.96 198 66934.8 2.98 2.07-4.29   4.91 174 35422.8 2.00 1.49-2.69  
CD4 count (if HIV-positive)             
≥350/mL  2.89 96 33187.2 1.0  0.774  5.37 99 18418.8 1.0  0.449 
<350/mL  3.02 102 33747.6 1.05 0.74-1.51   4.46 75 16801.2 0.83 0.51-1.34  
HIV viral load (if HIV-positive)             
<10 000 copies/mL 2.45 71 28950 1.0  0.05  4.37 58 13268.4 1.0  0.395 
≥10 000 copies/mL 3.57 108 30254.4 1.46 0.99-2.16   5.43 107 19688.4 1.23 0.77-1.96  
Partner HIV status              
Negative  1.57 193 123090 1.0  0.003  2.49 215 86326.8 1.0  0.003 
Positive  2.61 100 38325.6 1.67 1.2-2.33   3.86 244 63176.4 1.56 1.16-2.08  
Partner CD4 count (if partner HIV-positive)            
≥350/mL  2.36 45 19092 1.0  0.419  4.05 126 31094.4 1.0  0.685 
<350/mL  2.88 55 19100.4 1.22 0.75-2.0   3.68 118 32082 0.92 0.6-1.40  
Partner HIV viral load (if partner HIV-positive)           
<10 000 copies/ mL 1.80 75 41623.2 1.0  0.844  2.74 48 17546.4 1.0  0.556 
≥10 000 copies/mL 1.85 66 35720.4 1.03 0.74-1.45   2.96 74 25006.8 1.11 0.78-1.59  
Partner infected with specific HPV type             
No  1.59 251 157828.8 1.0  <0.001  2.67 393 147144 1.0  <0.001 
Yes  11.71 42 3585.6 5.71 3.88-8.40   27.98 66 2359.2 9.06 6.49-12.65  
Living together with study partner             
No  1.42 84 59197.2 1.0  0.039  2.94 159 54006 1.0  0.732 
Yes  2.05 209 101784 1.45 1.02-2.07   3.10 294 94867.2 1.06 0.77-1.46  
Duration of relationship with study partner            
<5 years  2.81 68 24206.4 1.0  0.989  3.71 79 21271.2 1.0  0.823 
≥5 years  2.78 61 21978 1.00 0.58-1.71   3.47 75 21598.8 0.94 0.54-1.63  
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    WOMEN   MEN 
Variable   
acquisition  
rate/ 1000 PM Events PM RR 95% CI P-value  
acquisition 
rate/ 1000 PM Events PM RR 95% CI P-value 
Age at first sex              
<16 years  3.12 74 23691.6 1.0  0.002  2.30 90 39163.2 1.0  0.062 
16-18 years 1.78 178 99800.4 0.57 0.36-0.90   3.43 265 77242.8 1.48 1.06-2.07  
>18 years  1.11 40 36018 0.36 0.2-0.62   3.30 102 30949.2 1.43 0.93-2.20  
Number of lifetime sexual partners             
1-2  1.49 103 69134.4 1.0  0.015  3.29 105 31921.2 1.0  0.906 
3-5  1.81 125 69226.8 1.22 0.84-1.77   3.06 112 36655.2 0.93 0.62-1.41  
>5  3.03 64 21150 2.05 1.26-3.33   3.02 240 79506 0.92 0.64-1.34  
Number of sex act with study partner in last month           
<5  1.49 173 115839.6 1.0  <0.001  3.14 251 79890 1.0  0.762 
≥5  2.72 112 41233.2 1.84 1.31-2.58   2.98 196 65685.6 0.95 0.7-1.29  
Ever used a condom with current study partner            
No  1.81 110 60834 1.0  0.955  3.08 175 56859.6 1.0  0.947 
Yes  1.78 174 97548 0.99 0.69-1.42   3.08 273 88768.8 1.01 0.75-1.36  
Experienced genital discharge in last 6 months            
No  1.78 251 140631.6 1.0  0.618  3.10 452 145725.6 1.0  0.073 
Yes  2.02 42 20784 1.13 0.7-1.82   1.85 7 3777.6 0.60 0.35-1.05  
Experienced genital ulcer in last 6 months            
No  1.75 267 152943.6 1.0  0.029  3.07 438 142612.8 1.0  0.901 
Yes  3.07 26 8472 1.76 1.06-2.93   3.11 18 5791.2 1.04 0.6-1.8  
Parity (number of live births)             
0  2.59 69 26606.4 1.0  0.028        
1  1.24 61 49317.6 0.47 0.29-0.77         
2  1.90 68 35739.6 0.73 0.46-1.16         
3+  1.91 95 49752 0.73 0.46-1.17         
Current use of injectable or oral contraceptives            
No  1.98 208 105039.6 1.0  0.111        
Yes   1.48 78 52665.6 0.74 0.51-1.07                 
Acq: acquisition, PM: person-months of follow-up for subject at risk of acquiring HPV infection, RR: relative risk. 
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Increased numbers of sexual acts with the study partner in the last month prior to a study visit 
was associated with an increased risk of acquiring HPV infection during follow-up in women 
(RR: 1.84, 95% CI: 1.3-2.6), but not in men. The presence of a genital ulcer in the last 6 
months before the study visit was associated with an increased risk of acquiring HPV infection 
during follow-up in women (RR: 1.76, 95% CI: 1.1-2.9) but not in men. Increased parity (only 
number of live births were considered) was associated with a decreased risk of HPV 
acquisition during follow-up (P=0.028). Age at the baseline visit, CD4 counts among HIV-
positive individuals, partner’s CD4 count and the HIV viral load if the partner if HIV-positive, 
duration of relationship with the study partner, ever use of condom with the study partner, 
experience of genital discharge in last 6 month prior to the study visit and current use of 
injectable or oral contraceptives were not associated with acquiring infection during follow-up 
in both women and men (Table 6.2). 
 
Table 6.3 presents factors that were associated with genital HPV acquisition during follow-up 
in women and men in the multivariate analysis. HIV-positive individuals with a HIV viral load 
of ≥ 10 000 copies per mL were found to have an increased risk of acquiring any HPV 
infection during follow-up in women (RR: 3.29, 95% CI: 2.18-4.95) and men (RR: 2.14, 95% 
CI: 1.46-3.12) compared to those with a HIV viral load of <10 000 copies per mL The risk of 
acquiring any HPV infection during follow-up was significantly increased in women (RR: 
5.25, 95% CI: 3.52-7.81) and men (RR: 8.71, 95% CI: 6.19-12.24) with a study partner 
infected with an HPV type identical to the one acquired compared to those with a study partner 
not infected with a similar HPV type. Low age of sexual debut in women was significantly 
associated with the higher the risk of acquiring any HPV infection during follow-up (P=0.002). 
The current use of injectable or oral contraceptives was significantly associated with a reduced 
risk of LR-HPV acquisition during follow-up (OR: 0.54, 95% CI: 1.3-2.6, Table 6.3). 
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Table 6.3. Factors significantly associated with genital acquisition in both women and men, in multivariate analysis 
    Any HPV types   HR types   LR types 
 Variable   RR 95% CI P-value   RR 95% CI P-value   RR 95% CI P-value 
WOMEN 
HIV status & viral load            
Negative  1.0  <0.0001  1.0  <0.0001  1.0  0.0003 
Positive, VL<10,000 copies 2.31 1.49-3.58   2.58 1.41-4.7   1.95 1.16-3.28  
Positive, VL≥10,000 copies 3.29 2.18-4.95   4.12 2.27-7.46   2.45 1.6-4.02  
             
Partner infected with same  HPV type           
No  1.0  <0.0001  1.0  0.01  1.0  <0.0001 
Yes  5.25 3.52-7.81   2.69 1.27-5.7   6.88 4.4-10.77  
             
Age at first sex             
<16 years  1.0  0.002  1.0  0.01  1.0  0.015 
16-18 years  0.6 0.39-0.93   0.55 0.31-0.98   0.58 0.36-0.94  
>18 years  0.4 0.24-0.66   0.31 0.15-0.66   0.43 0.24-0.77  
             
Current use of injectable or oral contraceptives          
No          1.0  0.007 
Yes          0.54 0.34-0.84  
MEN 
HIV status & viral load            
Negative  1.0  0.0001  1.0  0.002  1.0  0.001 
Positive, VL<10,000 copies 1.73 1.14-2.62   1.76 1.02-3.03   1.69 0.97-2.95  
Positive, VL≥10,000 copies 2.14 1.46-3.12   2.24 1.4-3.59   2.08 1.38-3.15  
             
Partner infected with same HPV type           
No  1.0  <0.0001  1.0  <0.0001  1.0  <0.0001 
Yes   8.71 6.19-12.24     11.43 7.57-17.26     6.61 4.06-10.75   
Note: multivariate analysis for men and women was done separately
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6.3.3 HPV transmission in sexually active couples  
HPV transmission was defined as the presence of the same HPV type in the partner at next visit 
initially detected in the index partner. HPV transmission analysis was restricted to couples in 
which at least one partner was HPV positive at baseline or HPV discordant. Female to male 
HPV transmission rate per 1000 person-months was 28.0 while male to female HPV 
transmission rate per 1000 person-months was 11.7. In male to female transmission events, 
LR-HPV transmission rate per 1000 person-months was more common (15.8) compared HR-
HPV transmission rate per 1000 person-months (6.0). In contrast in female to male 
transmission events, HR-HPV transmission rate/1000 person-months were similar (29.2) to 
LR-HPV transmission rate per 1000 person-months (26.4). 
 
HIV-positive women were found to be at high risk of HPV infection transmitted from their 
male partners compared to HIV-negative women (RR: 2.31 95% CI: 1.08-4.92, P=0.03). In 
contrast, HIV-positive men were not found to be at high risk of HPV infection transmitted 
from their female partners compared to HIV-negative men (RR: 1.23, 95% CI: 0.58-2.63, 
P=0.585). HIV-positive men with <350mL CD4 counts had high risk of HPV infection 
transmitted from female partners compared to HIV-positive men ≥350/mL CD4 counts (RR: 
3.17, 95% CI: 1.05-9.55, P=0.04). However, HIV-positive women with <350mL CD4 counts 
were not found to have significantly higher risk of HPV infection transmitted from their male 
partners compared to HIV-positive women with 350/mL CD4 counts (RR: 1.57, 95% CI: 0.65-
3.77, P=0.313). In women the risk of HPV transmission from the male partners was 
significantly associated with young age of sexual debut (P=0.03, Table 6.4). In men the risk of 
HPV infection transmitted from the female partner was associated with increasing age but it 
was not statistically significant (P=0.09). Women that have experienced genital ulcers in last 6-
months before the study visit were found to be at higher risk of HPV infection from their male 
partner compared to those who did not (RR: 2.91, 95% CI: 1.05-8.07, P=0.04). Men with 
female partners that were currently using injectable or oral contraceptives were found to be less 
likely to have HPV infection transmitted from their female partner compared to men with 
female partners that were not using injectable or oral contraceptives (RR: 0.39, 95% CI: 0.18-
0.86, P=0.019, Table 6.4).  
 
In women, the risk of HPV infection transmitted from their male partners was found to 
increase with increasing age. While in men the risk of HPV infection transmitted from their 
female partners was found to decrease with increasing age; however these observations were 
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Table 6.4. Factors associated with HPV transmission to female and men over a period of 24 months, in the univariate analysis 
        
  
MALE TO FEMALE#          
  
FEMALE TO MALE+   
Variable    
Transmission 
rate/1000 PM Events PM * RR 95% CI P-value   
Transmission 
rate/1000 PM Events PM* RR 95% CI P- value 
Age group              
<30 years  6.6 6 911 1.0  0.11  36.1 18 499 1.0  0.7 
30-39 years 11.2 15 1338 1.86 0.59-5.88   26.7 21 786 0.74 0.26-2.08  
40+ years  15.7 21 1337 3.01 1.02-8.87   25.1 27 1074 0.69 0.29-1.63  
HIV status              
Negative  7.3 12 1645 1.0  0.03  25.7 44 1710 1.0  0.585 
Positive  15.5 30 1942 2.31 1.08-4.92   33.9 22 649 1.23 0.58-2.63  
CD4 count (if HIV-positive)             
≥350/mL  14.0 16 1139 1.0  0.313  21.5 10 466 1.0  0.04 
<350/mL  17.4 14 803 1.57 0.65-3.77   66.2 12 181 3.17 1.05-9.55  
HIV viral load (if HIV-positive)             
<10 000 copies/mL 21.7 15 691 1.0  0.194  26.5 6 227 1.0  0.316 
≥10 000 copies/mL 14.4 14 972 0.52 0.20-1.39   40.1 17 424 2.03 0.51-8.03  
Partner HIV status              
Negative  13.0 27 2077 1.0  0.612  33.3 20 600 1.0  0.268 
Positive  9.9 15 1510 0.82 0.37-1.79   26.1 46 1759 0.69 0.36-1.33  
Partner CD4 count (if partner HIV-positive)            
≥350/mL  11.0 6 545 1.0  0.363  28.4 24 845 1.0  0.618 
<350/mL  9.4 9 962 1.78 0.52-6.11   24.1 22 913 0.80 0.32-1.96  
Partner HIV viral load (if partner HIV-positive)            
<10 000 copies/mL 14.7 6 408 1.0  0.716  25.4 18 709 1.0  0.671 
≥10 000 copies/mL 10.8 10 925 1.28 0.34-4.90   26.6 23 865 1.22 0.49-3.02  
Living together with study partner             
No  6.9 10 1451 1.0  0.129  23.5 25 1062 1.0  0.472 
Yes  15.0 32 2135 2.02 0.81-5.01   31.6 41 1297 1.32 0.62-2.80  
Duration of relationship with study partner            
<5 years  14.9 11 739 1.0  0.834  17.5 12 688 1.0  0.179 
≥5 years  16.8 8 476 0.89 0.32-2.53   38.3 14 366 2.35 0.68-8.21 
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MALE TO FEMALE#          
  
FEMALE TO MALE+   
Variable    
Transmission 
rate/1000 PM Events PM * RR 95% CI P-value   
Transmission 
rate/1000 PM Events PM* RR 95% CI P- value 
Age at first sex              
<16  21.4 13 607 1.0  0.03  21.1 18 852 1.0  0.092 
16-18  11.2 24 2152 0.44 0.18-1.07   18.6 20 1074 1.32 0.63-2.77  
>18  5.0 4 802 0.21 0.06-0.69   65.1 26 400 2.7 1.10-6.60  
Number of lifetime sexual partners            
1-2  7.8 11 1406 1.0  0.184  42.7 15 352 1.0  0.238 
3-5  14.0 23 1646 2.16 0.94-4.92   22.8 13 571 0.51 0.21-1.25  
>5  13.8 7 509 1.77 0.62-5.03   25.7 36 1403 0.6 0.29-1.23  
Number of sex acts with study partner in last month           
<5  10.0 25 2492 1.0  0.358  24.2 34 1406 1.0  0.479 
≥5  13.4 14 1042 1.42 0.67-2.99   31.2 28 899 1.31 0.62-2.74  
Ever used a condom with current study partner            
No  11.6 15 1290 1.0  0.95  35.8 26 726 1.0  0.343 
Yes  11.1 25 2251 0.98 0.44-2.15   24.0 38 1584 0.72 0.36-1.42  
Experienced genital discharge in last 6 months            
No  10.4 33 3186 1.0  0.075  28.2 63 2238 1.0  0.458 
Yes  22.5 9 400 2.28 0.92-5.62   24.8 3 121 0.64 0.19-2.1  
Experienced genital ulcer in last 6 months            
No  10.2 34 3318 1.0  0.04  28.5 64 2245 1.0  0.995 
Yes  29.9 8 268 2.91 1.05-8.07   23.1 1 43 1.01 0.13-8.09  
Current use of injectable or oral contraceptives            
No  12.4 31 2504 1.0  0.089        
Yes  7.7 8 1037 0.44 0.17-1.13         
Partner's current use of injectable or oral contraceptives           
No         34.0 52 1530 1.0  0.019 
Yes         16.3 13 799 0.39 0.18-0.86  
Partner's cytology              
Normal         24.2 29 1200 1.0  0.64 
Abnormal               33.0 35 1062 1.17 0.60-2.28   
PM*: person-month of exposure to infected partner # In women, factors associated with HPV transmission from male partner.  + In men, factors associated with HPV transmission from female 
partner.
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
                                                                                                                                            
Chapter 6      
 135 
not statistically significant (Table 6.4). The individual’s HIV viral load, partner’s HIV viral 
load partners’ HIV status and CD4 count level, living together with the study partner, duration 
of relationship with the study partner, number of lifetime sexual partners, number of sexual 
acts with study partner in last month, condom usage with study partner and experienced genital 
discharge in last month before the study visit was not significantly associated with HPV 
transmission to women and men. In women the use injectable or oral contraceptives was not 
significantly associated with HPV transmission from their male partners. Men with female 
partners with abnormal cervical cytology were not found to have a significantly higher risk of 
HPV infection transmitted from the female partner compared to men with female partners with 
normal cervical cytology (Table 6.4). 
 
In the multivariate analysis, increasing age in women was significantly associated with HPV 
infection transmitted from their male partner (P=0.003). In women, the risk of HPV 
transmission from the male partner was significantly associated with age at sexual debut 
(P=0.012).  HIV-positive women with ≥350 CD4/mL counts were found to have 1.76 relative 
risk of HPV transmission from male partners (95% CI: 0.7-4.42) and HIV-positive women 
with <350/mL CD4 counts were found to have 3.60 risk of HPV infection transmitted from 
their male partners (95% CI: 1.42-9.09) compared to HIV-negative women (Table 6.5). 
 
Table 6.5. Factors associated with HPV transmission to women, in the univariate analysis 
 
 MALE TO FEMALE* 
Variable RR 95% CI P-value 
Age group    
<30 years 1.0  0.003 
30-39 years 1.74 0.5-6.04  
40+ years 4.44 1.58-12.47  
    
HIV status/CD4 count    
HIV-negative 1.0  0.021 
HIV-positive, CD4 ≥ 350 1.76 0.7-4.42  
HIV-positive, CD4 < 350 3.6 1.42-9.09  
    
Age at first sex    
<16 1.0  0.012 
16-18 0.41 0.17-0.96  
>18 0.18 0.06-0.58   
                          * In women, factors associated with HPV transmission from male partner. RR: relative risk 
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6.3.4 Clearance of genital HPV infection in women and men 
In women a total of 319 clearance events were observed, 166 of them were LR-HPV types and 
153 were HR-HPV types. In men a total of 528 clearance events were observed, 285 of them 
were LR-HPV types and 243 were HR-HPV types. The rate of clearing any HPV infection was 
95.12 (95% CI: 83.3-108.1) per 1000 person-months in men and 66.95 (95% CI: 57.0-78.5) per 
1000 person-months in women. Men demonstrated a significantly higher rate of clearing any 
HPV infection compared to women (P=0.001). The rate of clearing HR-HPV infection was 
significantly higher in men 103.22 (95% CI: 88.5-120.6) per 1000 person-months compared to 
62.28 (95% CI: 51.1-76.2) per 1000 person-months in women (P<0.001). The rate of clearing 
LR-HPV was 89.15 (95% CI: 76.2-10.38) per 1000 person-months in men and 71.92 (95% CI: 
58.1-89.4) per 1000 person-months in women but the difference in the rate of clearing LR-
HPV between women and men was not statistically significant (P=0.111, Table 6.6).  
 
In women, the three HR-HPV types most cleared during follow-up were HPV-26 (258.63 per 
1000 person months) followed by HPV-18 (106.55 per 1000 person-months) and HPV-33 
(100.21 per 1000 person-months). In women HPV-16 was found to be the least cleared when 
compared with other HR-HPV and LR-HPV types during follow up (32.29 per 1000 person-
months). In men, three HR-HPV types most cleared included HPV-82 (290.83 per 1000 
person-months), HPV-33 (148.73 per 1000 person-months) and HPV-18 (133.20 per 1000 
person months). In men HPV-59 was found to be the least cleared when compared with other 
HR-HPV and LR-HPV types during follow up (50.79 per 1000 person-months). When we look 
at HR-HPV types individually, men were found to have a significantly higher clearance rate 
compared to women for HPV-16 (101.23 per 1000 person-months compared to 32.30 per 1000 
person-months, P=0.02); HPV-35 (133.21 per 1000 person-months compared to 48.95 per 
1000 person-months, P=0.014); HPV-45 (110.02 per 1000 person-months compared to 38.52 
per 1000 person-months, P=0.032); HPV-52 (115.26 per 1000 person-months compared to 
52.58 per 1000 person-months, P=0.034) and HPV-82 (290.83 per 1000 person-months 
compared to 99.02 per 1000 person-months, P=0.001, Table 6.6). 
 
In women, the three LR-HPV types most cleared were HPV-54 (105.31 per 1000 person-
months); followed by HPV-42 (94.39 per 1000 person-months) and HPV-84 (92.85 per 1000 
person-months). Among all LR-HPV types, HPV-11 was found to be the least cleared type in 
women (46.29 per 1000 person-months). In men HPV-42 was found to be the most cleared LR-
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Table 6.6. The clearance rate of genital HPV infection by genotype and species in women and men 
  WOMEN   MEN 
 Variable 
Clearance 
rate/ 1000 PM 95% CI 
Events of 
clearance PM   
Clearance 
rate/ 1000 PM 95% CI 
Events of 
clearance PM P-value 
HR-HPV           
HPV-16 32.39 13.9-75.4 7 216.1  101.23 62.3-164.5 17 167.9 0.02 
HPV-18 106.55 71.0-159.6 16 150.2  133.30 91.2-195.0 14 105.0 0.425 
HPV-26 258.63 174.7-384.8 4 15.5  66.90 11.1-404.6 2 29.9 0.104 
HPV-31 66.33 28.3-154.9 5 75.4  108.99 65.6-180.0 9 82.6 0.313 
HPV-33 100.21 38.6-260-6 7 69.9  148.73 88.5-250.3 5 33.6 0.462 
HPV-35 48.95 28.3-85.0 11 224.7  133.21 73.9-240.5 16 120.1 0.014 
HPV-39 71.53 36.0-141.6 7 97.9  132.07 87.6-198.9 15 113.6 0.125 
HPV-45 38.52 15.7-94.0 6 155.8  110.02 74.7-161.2 18 163.6 0.032 
HPV-51 80.68 39.4-164.5 9 111.6  70.94 40.6-124.3 14 197.3 0.777 
HPV-52 52.58 29.8-93.0 15 285.3  115.26 72.4-183.6 21 182.2 0.034 
HPV-53 81.58 47.6-140.2 17 208.4  100.82 68.2-148.8 27 267.8 0.528 
HPV-56 32.45 9.2-113.6 3 92.5  72.38 16.7-312.0 3 41.4 0.394 
HPV-58 54.23 31.0-94.9 14 258.1  76.44 41.4-140.2 14 183.2 0.411 
HPV-59 73.27 39.8-134.7 10 136.5  50.79 22.7-113.6 8 157.5 0.471 
HPV-66 65.12 30.0-141.6 8 122.9  113.91 80.9-161.2 26 228.3 0.187 
HPV-68 44.86 19.5-102.8 7 156.0  99.35 62.4-159.6 18 181.2 0.096 
HPV-73 75.22 23.6-240.5 3 39.9  112.15 61.7-202.9 8 71.3 0.527 
HPV-82 99.02 52.1-189.2 4 40.4  290.83 231.1-366.1 8 27.5 0.001 
All HR-HPV 62.28 51.1-76.2 153 2456.8  103.22 88.5-120.6 243 2354.1 <0.001 
LR-HPV           
HPV-6 68.19 30.7-151.8 7 102.7  84.02 44.8-156.5 10 119.0 0.681 
HPV-11 46.29 4.9-442.7 1 21.6  97.21 28.6-331.2 5 51.4 0.483 
HPV-40 64.01 12.6-324.7 2 31.2  177.11 87.6-358.8 9 50.8 0.229 
HPV-42 94.39 43.5-205.0 6 63.6  188.47 71.0-499.1 5 26.5 0.254 
HPV-54 105.31 67.5-164.5 18 170.9  105.56 66.2-167.8 18 170.5 0.994 
HPV-55 51.38 15.7-167.8 4 77.8  110.90 73.2-167.8 22 198.4 0.207 
HPV-61 66.35 39.0-112.5 16 241.1  71.40 50.0-101.8 32 448.2 0.821 
HPV-62 60.60 37.8-97.8 18 297.0  72.88 54.2-98.8 42 576.3 0.516 
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  WOMEN   MEN 
 Variable 
Clearance 
rate/ 1000 PM 95% CI 
Events of 
clearance PM   
Clearance 
rate/ 1000 PM 95% CI 
Events of 
clearance PM P-value 
HPV-67   1 5.2    1 3.0  
HPV-69 84.23 32.9-215.5 6 71.2  128.97 72.4-228.8 7 54.3 0.435 
HPV-70 91.17 51.6-161.2 17 186.5  117.63 81.7-169.5 22 187.0 0.455 
HPV-71 74.31 41.0-134.7 15 201.9  91.17 55.3-150.3 14 153.6 0.602 
HPV-72 55.51 30.0-101.8 12 216.2  85.53 50.0-147.4 18 210.5 0.293 
HPV-81 47.18 24.6-90.3 7 148.4  97.60 65.6-145.9 22 225.4 0.057 
HPV-83 64.72 36.0-117.1 13 200.9  68.80 39.8-118.3 17 247.1 0.88 
HPV-84 92.85 46.7-183.6 12 129.2  94.54 64.3-138.8 21 222.1 0.964 
HPV-89 81.79 44.4-150.3 8 97.8  71.46 40.6-125.6 15 209.9 0.746 
HPV-IS39 66.72 19.5-228.8 3 45.0  116.62 60.5-224.3 5 42.9 0.416 
All LR-HPV 71.92 58.1-89.4 166 2308.2  89.15 76.2-103.8 285 3196.9 0.111 
All HPV 66.95 57.0-78.5 319 4765.0  95.12 83.3-108.1 528 5551.0 0.001 
HPV species           
α1 94.39 43.5-205-0 6 63.6  188.47 71.0-499.1 5 26.5 0.254 
α3 64.63 50.0-83.3 86 1330.6  78.06 64.9-94.0 167 2139.4 0.241 
α5 91.67 60.5-138.8 26 283.6  102.30 72.4-144.0 36 351.9 0.691 
α6 66.08 43.9-99.8 28 423.7  104.18 79.3-137.4 56 537.5 0.068 
α7 71.37 53.1-95.9 63 882.8  104.63 85.0-128.1 95 907.9 0.038 
α8 64.01 12.6-324.7 2 31.2  177.11 87.6-358.8 9 50.8 0.229 
α9 52.88 40.2-69.6 60 1134.7  107.43 85.0-136.0 83 772.6 <0.001 
α10 59.38 30.4-115.9 12 202.1  100.32 71.0-141.6 37 368.8 0.165 
α11 75.22 23.6-240.5 3 39.9  112.15 61.7-202.9 8 71.3 0.527 
α13 105.31 67.5-164.5 18 170.9  105.56 66.2-167.8 18 170.5 0.528 
α15 74.31 41.0-134.7 15 201.9   91.17 55.3-150.3 14 153.6 0.602 
PM: person-months of follow-up for subject at risk of acquiring HPV infection. α1 HPV species includes HPV-42.  α3 HPV species includes HPV-61, -62, -72, -81, -83, -84 and -89. α5 
HPV species includes HPV-26, -51, 69, -82 and –IS39. α6 HPV species includes HPV-53, -56 and -66. α7 HPV species includes HPV-18, -39, -45, -59, -68 and -70. α8 HPV species includes 
HPV-40 . α9 HPV species includes HPV-16, -31, -33, -35, -52, -58 and -67. α10 HPV species includes HPV-6, -11 and -55. α11 HPV species include HPV-73.  α13 HPV species includes HPV-
54. α15 HPV species includes HPV-71.
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HPV type (188.47 per 1000 person-months) followed by HPV-40 (177.11 per 1000 person-
months) and HPV-69 (128.97 per 1000 person-months). HPV-61 was found to be the least 
cleared LR-HPV type in men during follow-up (71.40 per 1000 person-months). When we look 
at the LR-HPV individually the clearance rate of LR-HPV types was not found to differ 
significantly between women and men (Table 6.6).  
 
When HPV clearance was investigated according to each HPV species types, in women the 
three most cleared HPV species types during follow-up were α13 HPV species (105.31 per 
1000 person-month); α1 HPV species (94.39 per 1000 person-month) and α5 HPV species 
(91.67 per 1000 person-month). In men HPV types within the α1 HPV species (188.47 per 
1000 person-month) were most cleared followed by α8 HPV species (177.11 per 1000 person-
month) and α11 HPV species (112.15 per 1000 person-month). In women α9 HPV species 
were the least cleared HPV species (52.88 per 1000 person-month) and in men α3 HPV species 
(76.06 per 1000 person-month) were the least. Men were found to have significantly higher 
HPV clearance rates compared to women for α7 HPV species types (104.63 per 1000 person-
month compared to 71.37 per 1000 person-month) and for α9 HPV species types (107.43 per 
1000 person-month compared to 52.88 per 1000 person-month, Table 6.6). 
 
6.3.5 Factors affecting clearance of genital HPV infection in women and men 
HIV-positive women were found to have a significantly lower clearance of HPV infection 
compared to HIV-negative women (RR: 0.46, 95% CI: 0.34-0.62, P<0.001). Women with 
abnormal cervical cytology were also found to have a significantly lower HPV clearance when 
compared with women with normal cervical cytology (RR: 0.68, 95% CI: 0.48-0.96, P=0.029). 
HIV-positive men were also found to have a significantly lower clearing of HPV infection 
compared to HIV-negative men (RR: 0.71, 95% CI: 0.55-0.93, P=0.013). All other variables 
demonstrated no statistically significant effect on HPV clearance (Table 6.7). In multivariate 
analysis, the only factor that remained significantly associated with the rate of HPV clearance 
in both men and in women was HIV status. The effect of HIV infection on HPV clearance was 
similar for women infected with HR-HPV types (RR: 0.44, 95% CI: 0.29-0.65) and women 
infected with LR-HPV types (RR: 0.48, 95% CI: 0.33-0.71). However, in men the effect of 
HIV infection on HPV clearance was significant only for high risk types (RR: 0.59, 95% CI: 
0.43-0.81) but not for LR-HPV types (RR: 0.84, 95% CI: 0.61-1.16). The presence of HPV 
antibodies was not significantly associated with the rate of HPV clearance 
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Table 6.7. Factors associated with genital HPV clearance in women and men, in the univariate analysis 
    WOMEN   MEN 
    
 Clearance 
rate/1000 PM Events PM RR 95% CI P-value   
 Clearance 
rate/1000 PM Events PM RR 95% CI P-value 
Age group              
<30  65.4 104 1590.0 1.0  0.133  95.0 119 1252.8 1.0  0.782 
30-39  59.7 114 1910.4 0.9 0.59-1.39   90.8 193 2125.2 0.92 0.64-1.33  
40+  79.9 101 1263.6 1.31 0.88-1.97   99.4 216 2173.2 1.02 0.74-1.42  
HIV status              
Negative  110.1 114 1035.6 1.0  <0.001  106.8 331 3098.4 1.0  0.013 
Positive  55.0 205 3729.6 0.46 0.34-0.62   80.3 197 2452.8 0.71 0.55-0.93  
CD4 count (if HIV-positive)             
≥350/mL  63.8 91 1425.6 1.0  0.155  81.0 82 1012.8 1.0  0.987 
<350/mL  49.5 114 2302.8 0.77 0.53-1.1   79.7 114 1430.4 1.00 0.64-1.56  
HIV viral load (if HIV-positive)             
<10 000 copies 59.9 80 1335.6 1.0  0.211  94.3 61 646.8 1.0  0.063 
≥10 000 copies 48.4 96 1984.8 0.77 0.51-1.16   71.9 116 1612.8 0.67 0.44-1.02  
Partner HIV status              
Negative  73.5 222 3021.6 1.0  0.085  100.7 215 2134.8 1.0  0.373 
Positive  55.6 97 1743.6 0.74 0.52-1.04   91.6 313 3416.4 0.89 0.7-1.14  
Partner CD4 count (if partner HIV-positive)            
≥350/mL  51.4 52 1011.6 1.0  0.73  82.9 134 1616.4 1.0  0.236 
<350/mL  60.7 44 724.8 1.11 0.62-2.0   99.4 179 1800 1.25 0.86-1.80  
Partner HIV viral load (if partner HIV-positive)           
<10 000 copies 55.4 27 487.2 1.0  0.784  103.8 116 1117.2 1.0  0.165 
≥10 000 copies 57.0 69 1209.6 0.92 0.5-1.68   80.6 154 1910.4 0.74 0.49-1.13  
Antibody to HPV strain              
No  57.8 67 1159.2 1.0  0.933  113.2 110 972 1.0  0.114 
Yes  60.9 16 262.8 0.98 0.58-1.65   70.9 12 169.2 0.58 0.29-1.14  
Living together with study partner             
No  64.9 117 1803.6 1.0  0.924  98.9 194 1962 1.0  0.758 
Yes  68.2 202 2960.4 1.02 0.72-1.43   92.7 329 3547.2 0.95 0.71-1.28  
Duration of relationship with study partner            
<5 years  71.9 85 1182 1.0  0.366  111.5 121 1084.8 1.0  0.287 
≥5 years  64.9 63 970.8 0.77 0.44-1.36   137.9 115 834 1.24 0.84-1.83  
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PM: person-months of follow-up for subject at clearing HPV infection, RR: relative risk 
    WOMEN   MEN 
    
 Clearance 
rate/1000 PM Events PM RR 95% CI P-value   
 Clearance 
rate/1000 PM Events PM RR 95% CI P-value 
Age at first sex              
<16  77.4 59 762 1.0  0.595  104.2 161 1545.6 1.0  0.77 
16-18  66.5 206 3097.2 0.84 0.52-1.35   91.4 255 2791.2 0.89 0.64-1.23  
>18  59.6 52 872.4 0.76 0.45-1.28   95.3 109 1143.6 0.90 0.62-1.32  
Number of lifetime  sexual partners             
1-2  69.2 118 1704 1.0  0.961  79.3 98 1236 1.0  0.335 
3-5  65.2 129 1977.6 0.98 0.66-1.44   104.5 155 1483.2 1.27 0.9-1.78  
>5  66.7 70 1050 1.05 0.63-1.75   98.5 272 2762.4 1.23 0.89-1.68  
Number of sex acts with study partner in last month           
<5  68.4 194 2838 1.0  0.622  94.9 306 3225.6 1.0  0.923 
≥5  62.4 115 1842 0.91 0.63-1.31   94.5 206 2180.4 1.01 0.77-1.34  
Ever used a condom with current study partner           
No  76.3 107 1402.8 1.0  0.196  89.5 171 1910.4 1.0  0.816 
Yes  64.0 203 3170.4 0.78 0.54-1.14   96.0 338 3522 1.03 0.78-1.38  
Experienced genital discharge in last 6 months            
No  65.7 278 4232.4 1.0  0.557  94.9 502 5288.4 1.0  0.959 
Yes  77.0 41 532.8 1.15 0.72-1.85   98.9 26 262.8 0.98 0.5-1.94  
Experienced genital ulcer in last 6 months            
No  67.1 297 4426.8 1.0  0.786  96.2 500 5196 1.0  0.336 
Yes  65.2 22 337.2 0.93 0.54-1.60   72.1 23 319.2 0.71 0.35-1.43  
Parity (number of live births)             
0  82.4 84 1018.8 1.0  0.157        
1  60.8 92 1513.2 0.76 0.48-1.20         
2  52.5 54 1028.4 0.57 0.34-0.96         
3+  73.8 89 1206 0.92 0.58-1.45         
Current use of injectable or oral contraceptives            
No  66.7 225 3370.8 1.0  0.946        
Yes  65.5 88 1342.8 1.01 0.72-1.43         
Cervical cytology              
Normal  78.6 193 2454 1.0  0.029        
Abnormal   51.9 113 2175.6 0.68 0.48-0.96                 
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after controlling for HIV status, either in women (RR: 1.05, 95% CI: 0.59-1.86) or in men (RR: 
0.58, 95% CI: 0.29-1.17). 
 
6.4 DISCUSSION 
In this chapter we presented the HPV acquisition and clearance rate data for women and men 
as well as factors associated with HPV acquisition and clearance over a period of 24-months. 
We also demonstrated the effect of a women’s abnormal cervical cytology and the effect of 
HIV co-infection in one or both partners on sexual HPV transmission between partners. To our 
knowledge this is the first study to investigate HPV transmission in heterosexually active 
couples that are both HIV-positive and HIV-discordant.  
 
 
Men demonstrated a higher rate of total HPV acquisition compared to women (459 compared 
to 293 acquisition events). In chapter 2 we demonstrated that HIV-negative men have 
significantly higher HPV prevalence compared to HIV-negative women; however, HIV-
positive men demonstrated higher HPV prevalence compared to HIV-positive women but not 
statistically significant. In our study, HPV prevalence at baseline was not different between 
women and men (58.1% and 58.4% respectively). Giuliano et al., (2008a) also observed 
similar baseline HPV prevalence between women and men (53.8% and 52.8% respectively). 
However, total HPV acquisition during follow-up was higher in our study in men compared to 
women (3.07 per 1000 person-months compared 1.82 per 1000 person-months, P<0.001). In 
contrast, Giuliano et al., (2008a) did not observed similar rates of total HPV acquisition 
between women and men (29.4 per 1000 person-months in both women and men). In our study 
among men, the acquisition of HPV-16 was 3.16 per 1000 person-months and for HPV-6 it 
was 1.65 per 1000 person-months; however Giuliano et al., (2008a) reported a higher HPV-16 
and -6 acquisition during follow-up (4.8 per 1000 person-months and 2.8 per 1000 person-
months respectively).In our study among men, the acquisition of HPV-18 and 11 was (3.36 per 
1000 person-months and 1.85 per 1000 person-months respectively). In a Giuliano et al., 
(2008a) report a far lower HPV-18 and -11 acquisitions compared to our study (0.8 per 1000 
person-months and 0.5 per 1000 person-months respectively). The rate of LR-HPV acquisition 
in men was higher than the rate of HR-HPV acquisition (3.34 per 1000 person-months 
compared to 2.8 per 1000 person-months) in our study; while Giuliano et al., (2008a) reported 
a comparable rate of acquiring LR and HR-HPV types. However other studies reported that 
HR-HPV types are acquired faster compared to LR-HPV types (Franco et al., 1999; Giuliano 
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et al., 2002; Winer et al., 2008). The difference between studies may be caused by the different 
sampling methods used, different HPV genotyping assays and different demographics of the 
cohort. The high rate of LR-HPV acquisition in men in our study also explains the observed 
high LR-HPV prevalence at baseline. The different epithelium on samples site in women and 
men could be the result of different HPV acquisition rate observed in this study. 
 
It was interesting to note that the events of HR-HPV acquisition from the study partner were 
significantly higher in men compared to women (18% compared to 7%, P=0.003) while for 
LR-HPV acquisition were significantly higher in women compared to men (21% compared to 
11%, P=0.01). HR-HPV types were more commonly transmitted from female to male 
transmission events while LR-HPV types were more commonly transmitted from male to 
female transmission events. The findings that LR-HPV types were more prevalent at baseline 
among men compared to women and also the events of LR-HPV acquisition during follow-up 
were higher in men compared to women may also explain the high rate of LR-HPV in male to 
female transmission and the fact that in women only the cervix was sampled while in men the 
penile shaft, glans and foreskin in uncircumcised men were samples. 
 
The female to male HPV transmission rate was found to be higher compared to the male to 
female HPV transmission (28.0 compared to 11.7 HPV transmission rate per 1000 person-
months). Hernandez et al., (2008) observed high female to male HPV transmission and male to 
female HPV transmission compared to our study (174.0 and 49 HPV transmission rate per 
1000 person-months). It is interesting to note that female to male HPV transmission rate is 
higher than male to female HPV transmission rate while for most STIs male to female 
transmission rate is usually higher than female to male transmission rate (Weinstock et al., 
2004; Arora et al., 2011). The different sampling interval in our study compared to Hernandez 
et al., (2008) is probable the reason we observed different HPV transmission rates (6-month 
interval in our study compare to 2-month interval). The high rate of HPV transmission from 
female to male explains the high rate of HPV acquisition observed in men compared to 
women. HPV transmission from male partners to female partners was associated with their 
HIV-positive status and low CD4 count and but HPV transmission from female partners to 
male partners was only associated with low CD4 counts. The high risk of HPV transmission to 
women and men with low CD4 count is due to suppressed immune system condition (Strickler 
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et al., 2005). HPV transmission was not associated with increased number of sexual act with 
study partner a month prior the visit suggesting that the observed transmissions were not just 
HPV deposited by the partner from previous sexual act but true infection.   
 
Women who started participating in sexual debut at young age were found to have high risk of 
HPV infection transmitted by their male partner. Women who engaged in sexual activity at 
young age probably have high number of lifetime sex partners compared to those who started 
at older age, therefore the high risk of HPV transmission we observed in women who started 
participating in sexual debut at young age is the reflection of high number of lifetime sex 
partners. It has been reported that the cervix of young women is still immature with an 
inadequate production of protective cervical mucus and increased cervical ectopy increasing 
the susceptibility to HPV infection; thus they are at increased risk of HPV transmission 
(Collins et al., 2005). However, its not clear if old women who started participating in sexual 
debut at <16 years of age would still be at high risk of HPV transmission compared to those 
who started participating in sexual debut at <18 years of age. 
 
Women who experienced genital ulceration 6-months before the study visit had 2.9 risk of 
acquiring HPV infection transmitted from their male partners compared to women who did not 
experience genital ulceration 6-months before the study visit. The association of genital 
ulcerations with HPV transmission can be explain by the fact that the wounds caused by the 
ulcer provide an easy access to the genital mucosa compared to women without genital ulcers 
(Shafti-Karamat et al., 2003). Ulceration can be a complete loss of the epithelial surface but 
sometimes it can be a lesion, then that lesion will give HPV an access to basal cells (Shafti-
Karamat et al., 2003). Women who experienced genital ulcers in the last 6-months before their 
study visit had an increased risk of acquiring new HPV infection during follow-up. The 
development of a genital ulcer increased the risk of HPV acquisition because HPV is able to 
access the genital mucosa more easily through the wounds caused by ulcers (Shafti-Karamat et 
al., 2003; Culp et al., 2003). However, the development of a genital ulcer over the last 6-
months before the study visit did not influence HPV acquisition in men. 
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It was interesting to note that men with female partners using injectable or oral contraceptives 
were less likely to have HPV transmission compared to those with female partners not using 
injectable or oral contraceptives (P=0.019). However the biological explanation of this still 
needs further investigation. Abnormal cervical cytology was not significantly associated with 
female to male HPV transmission in our study. Since women with abnormal cervical cytology 
have high HPV viral load it was expected that female to male transmission will be high in men 
with female partner with abnormal cervical cytology compared to those with female partner 
with normal cervical cytology. The small number of HPV transmission events and women with 
abnormal cervical cytology observed in our study could be the reason for the lack of statistical 
significance. 
 
It is important to note that in this study samples from women were only collected at the cervix 
while a single swab from men sampled penile shaft, glans and foreskin (in uncircumcised 
men). It has been reported that more LR-types are likely to be detected in specimens from the 
vagina than in samples from the cervix (Jones et al., 2007). Therefore the higher LR-HPV 
prevalence in men compared to women and male to female transmission events which were 
more likely to be LR-HPV types could be due to the fact that women were only sampled at the 
cervix not the vagina. The high rate of LR-HPV acquisition in women due to transmission 
from the study partner can be explained by high prevalence of LR-HPV types observed in men 
and the fact that in men we sampled more than one genital site (penile shaft, glans as well as 
foreskin in uncircumcised men). HPV species α3, α7 and α9 were the most prevalent species in 
both women and me . All transmitted HPV types were higher in men but not for α3 HPV 
species which was higher in women. The α3 HPV species group contains seven LR-HPV types 
and since we find that LR-HPVs were more commonly transmitted from male to female 
women would be expected to harbour more α3 HPV types. 
 
We observed that women and men with HIV-positive partners were found to have a 
significantly increased risk of HPV acquisition. However, the CD4 count and HIV viral load of 
their partner were not found to influence HPV acquisition in either women or men. The risk of 
acquiring HPV infection was significantly increased in women and men with partners infected 
with the same HPV type that was acquired. This possibly indicates that those types acquired 
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were transmitted from their sexual partner. It was interesting to note that women living with 
their male partner had an increased risk of acquiring new HPV types not found in their 
partners. These observations may indicate that even though the couples were staying together 
they may have other partners, as it has been reported that having a high risk partner who has 
other partners, can increase the rate of HPV acquisition (Fukuchi et al., 2009). Among men or 
women in monogamous relationships the rate of HPV acquisition was not increased compared 
with polygamous relationship (Bosch, 2008). Having a new sexual partner apart from the study 
partner was associated with an increased risk of acquiring new HPV infection (Bosch et al., 
2008). Oh et al., (2008) conducted a study on women that were virgins, and women who had a 
first sexual encounter at baseline visit and found a 2.9 higher risk of acquiring new HPV 
infection in those who had new or changed sexual partners compared to those who remained 
virgins. Bosch et al., (2008) suggested that the large age gaps between partners in Africa may 
indicate that staying together with or married to the partner does not necessarily mean “safe 
sex” and that men who might have multiple partners are more likely to be the source of STIs 
transmitted to their partners (Bosch et al., 1996; Castellsague et al., 2002).  
 
The duration of a couple’s relationship was not associated with HPV acquisition for both 
women and men. The more sexual acts a woman had with their study partner in last month 
increased the risk of acquiring new HPV infection. In contrast, the number of sex acts did not 
influence the rate of HPV acquisition in men. In our study condom use was not found to play a 
role in decreasing the rate of HPV acquisition in both women and men. These findings may 
suggest that the study participants were not using condoms for every sexual act. Using 
condoms has been found to provide protection against HPV acquisition in women (Kjaer et al., 
2005; Partridge et al., 2007). Consistent condom use is reported to provide some level of 
protection against HPV infection as well as genital lesions (Bleeker et al., 2005b; Nielson et 
al., 2010).  
 
In our study women initiating sexual intercourse after 16 years had a lower risk of acquiring 
HPV compared to those initiating sex before the age of 16 years. Fukuchi et al., (2009) also 
reported that initiation of sex at age >16 years was associated with HPV acquisition during 12-
months. However, in men we observed that HPV acquisition seem to increase with the age 
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years they initiated sexual intercourse however these finding were not statistically significant. 
These observations are in contrast to what has been reported by Shin et al., (2004) in which 
they observed an increased risk of acquiring HPV with younger age of initiating penetrative 
sexual intercourse. It has been reported that women have their first sexual intercourse at 
younger age compared to men (Bosch et al., 2008). In women we observed that having more 
lifetime sexual partners is associated with increased risk of HPV acquisition, similar findings 
are reported elsewhere (Ho et al., 1998; Winer et al., 2003; Munoz et al., 2004; Goodman et 
al., 2008; Lu et al., 2009). Women with male partners with a large number of other sexual 
partners have a significantly increased risk of cervical disease compared to women in 
monogamous relationships (Bosch et al., 1996; Castellsague et al., 2002). In men, the high 
number of lifetime sexual partners was not associated with HPV acquisition. Our findings are 
in contrast with other studies in which large numbers of lifetime sex partners are associated 
with high risk of HPV acquisition in men (Hippelainen et al., 1993; Franceschi et al., 2002; 
Giuliano et al., 2008a).  
 
In our study the use of injectable or oral contraceptives was not associated with acquisition of 
new HPV during follow-up. Vaccarella et al., (2006) reported that the use of oral 
contraceptives even in long term is not associated with increased risk of HPV acquisition and 
persistence but the association of oral contraceptives, smoking and alcohol drinking with HPV 
acquisition may indicate high risk behaviour (Goodman et al., 2008). The high rate of HPV 
acquisition in women who use injectable or oral contraceptives could be an indication of high 
risk behaviour. It was interesting to note that in the multivariate analysis the use of injectable 
or oral contraceptives was associated with reduced risk of only LR-HPV types (RR: 0.54, 95% 
CI: 0.34-0.84, P=0.007) in our study. The explanation of this will require further investigation. 
It is important to note that in our study the majority of women were using injectable 
contraceptives compared to oral contraceptives and in our analysis we combined both the 
injectable and oral contraceptives as a single variable. In our study, having multiple parity was 
associated with a reduced risk of acquiring HPV infection, however in parity was only 
restricted to women with live births which could impact on HPV risk. In other studies high 
parity has been reported to be associated with cervical cancer (Castellsague & Munoz, 2003). 
An increasing number of pregnancies are associated with an increased risk of cervical cancer 
(Hildesheim et al., 2001; Moreno et al., 2002; Munoz et al., 2002).  
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The increased risk of detection of HPV acquisition in HIV-positive women and men could be 
the result of suppressed immune system or reactivation of latent HPV infections, not new HPV 
acquisition. It is not possible to define whether a new HPV detection is a new infection or 
reactivation of latent HPV infection (Palefsky et al., 1999; Strickler et al., 2005; Bleeker et al., 
2005a). Strickler et al., (2005) reported that 22% of HIV-positive women with a CD4 count 
<200/mL having no sexual activity had new HPV infection during follow-up. This may 
indicate reactivation of latent HPV infection (Theiler et al., 2010). In our study the risk of 
acquiring new HPV infection and the ability to clear HPV infection were not found to differ 
significantly between women or men with CD4 count ≥350/mL and <350/mL. However some 
studies have indicated the risk of acquiring HPV infection among HIV-positive individuals is 
affected by CD4 count (Strickler et al., 2005). HPV infections that persist for longer periods 
are not easy to clear and may lead to the development of precancerous lesions and cancer (Ho 
et al., 1998; Wu et al., 2006). HIV-positive women with a HIV viral load ≥10 000/mL were 
found to have a higher risk of HPV acquisition. However, high HIV viral load was not 
associated with HPV acquisition in our study in men. 
 
The decreased ability to clear HPV infection in HIV-positive women and men may be the 
result of decreased immune competency and the high prevalence of multiple HPV infection. It 
has been reported that women with multiple HPV infections have a reduced HPV clearance 
compared to women with a single HPV infection (Goodman et al., 2001; Rousseau et al., 
2003). Men demonstrated greater total HPV clearance compared to women (528 compared to 
319 HPV clearance events). In men the HPV clearance was found to be greater for HR-HPV 
types compared to LR-HPV types (103.22 per 1000 person-months compared to 89.15 per 
1000 person-months) in our study. This is in contrast to what has been reported by previous 
studies in which LR-HPV are reported to have a higher rate of clearance compared to HR-HPV 
types, and HR-HPV persistence is reported to be higher than that of LR-HPV types (Moscicki 
et al., 1998; Franco et al., 1999; Giuliano et al., 2008a). However, Oh et al., (2008) did not 
find a significant difference in the clearance of LR and HR-HPV. In women, HPV clearance 
was higher for LR-HPV compared to HR-HPV (72.92 per 1000 person-months compared to 
62.28 per 1000 person-months).  Assessing LR-HPV types in women, HPV-11 was the least 
cleared type. This may be explained by the high prevalence of HPV-11 DNA and antibodies at 
baseline (chapter 2 and 5 respectively). It is reported that persistent HPV infection and high 
viral load is required to activate the immune system (Stanley et al., 2006). Among women in 
our study, HPV-16 was found to have a lower rate of clearance compared to other HPV types. 
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Louvanto et al., (2010) reported that women with HPV-16 or with multiple HPV infection are 
less likely to clear HPV infection during follow-up compared to women with single HPV 
infection or not infected with HPV-16.  
 
Amongst women in our study, α9 HPV species were the least cleared HPV types. Trottier et 
al., (2008) reported that α7 and α9 HPV species have a lower clearance rate compared to other 
HPV species. HPV-16 is the most dominant HPV type and is responsible for ~50% cervical 
cancer cases and belongs to the α9 HPV species, while HPV-18 is the second most dominant 
type and is responsible for ~20% cervical cancer cases. HPV-18 belongs to α7 HPV species. 
The eight most common HPV types reported in cervical cancers belong to α9 HPV species 
(HPV-16, -31, -33, -35, -52 and -58) and α7 HPV species (HPV-18 and -45). The lower 
clearance rate of α7 and α9 HPV species could be the reason why they are the most common 
HPV types associated with cervical cancer. The HPV persistence is necessary for the 
development of precancerous lesions and cancer. In men, α3 HPV types were found to be the 
least cleared HPV species followed by α7 and α9 HPV species. The reason for the low 
clearance rate of α3 HPV species in men could be that α3 HPV species contains LR-HPV types 
and in men we observed a higher prevalence of LR-HPV types (as single or multiple 
infections) and a higher rate of LR-HPV acquisition. The rate of HPV clearance in our study 
was higher than the rate of HPV acquisition in both women and men and similar observations 
were observed elsewhere (Goodman et al., 2008). Even though HPV acquisition in men is 
higher compared to women, men are reported to clear their HPV infection faster than women 
(Giuliano et al., 2008a; Lu et al., 2009). The incidence of HPV associated cancer is lower in 
men compared to that observed in women (Parkin & Bray, 2006). The high rate of HPV 
clearance in men could be the reason why there is a low incidence of HPV-associated cancer in 
men compared to that observed in women.  
 
HIV co-infection was found to significantly influence HPV clearance in both women and men 
and these observations were observed in both univariate and multivariate analyses. The 
decreased ability to clear HPV infection in HIV-positive women and men could be the result of 
a suppressed immune system caused by HIV infection, a resultant high prevalence of multiple 
HPV infection and a high HPV viral load (Ho et al., 1998; Goodman et al., 2001; Rousseau et 
al., 2003; Stricker et al., 2005; Wu et al., 2006). When we controlled for HIV status, HPV 
antibodies were not associated with HPV clearance in our study. HPV acquisition and 
clearance was not significantly associated with age in our study for both women and men. 
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Giuliano et al., (2008a) also reported no significant difference in the acquisition of HPV in 
men according to age. Dunne et al., (2006) reported a constant HPV prevalence in men of 
different ages. In our study we also observed that in men HPV prevalence did not significantly 
increase with increasing age. So the lack of association between age and HPV acquisition and 
clearance in men during follow-up was a reflection of what was observed at baseline. In 
women the lack of association between age and HPV acquisition or clearance during follow-up 
in our study was in contrast to what has been reported by several studies (Munoz et al., 2004). 
However, Castle et al., (2005) did not observe a significant increase of HPV acquisition with 
age in women. However in the Syrjanen et al., (2005) study, HPV clearance was reported to be 
greater from 25 years age and older compared to HPV acquisition, HPV acquisition was higher 
in younger women substantiating why clearance can sometimes be associated with increasing 
age.  
 
In our study the number of lifetime sexual partners and recent partners was not associated with 
clearing HPV infection. Lu et al., (2009) found that men with many lifetime sex partners had 
an increased (5-fold higher) likelihood of clearing HPV infection. However, these individuals 
are highly exposed to genital HPV resulting in the elicitation of antibody responses against 
HPV which could assist in HPV clearance. In our study antibody responses were not found 
associated with HPV clearance. In support of our results, HPV persistent infection is associated 
with seropositivity but not with HPV transient infection (Wideroff et al., 1995; Lu et al., 
2009). Persistent HPV infection may elicit a good immune response while transient HPV 
infection may not. According to Trottier et al., (2010) HPV re-infection does not seem to be 
controlled by natural immunity. 
 
It has been reported that traditional and medical circumcision differs. A high percent of 
traditionally circumcised men are incompletely circumcised with some foreskin still covering 
part of the glans; resulting in reduced protection by circumcision against HPV and other STI 
(Morris, 2007; Bailey et al., 2008). In our study 96.6% of men were circumcised and the 
majority of them had had a traditional circumcision, which could mean the presence of some 
residual foreskin. Clearance of HPV infection is reported to be 3-6 times more likely in 
circumcised men compared to uncircumcised men (Lu et al., 2009). According to Auvert et al., 
(2009), HR-HPV prevalence was significantly higher in uncircumcised men (22.3%) compared 
to circumcised men (14.8%, P=0.002) and these observations were not affected by age, sexual 
behaviour, marital status and HIV status. Tobian et al., (2009) also reported a higher 
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prevalence of HR-HPV in uncircumcised men compared to circumcised men (27.9% compared 
to 18%, P=0.009). Circumcision may be of great benefit in men making the penis less 
susceptible to HPV infections due to increased keratinized epithelium, reduced viral shedding 
and viral persistence compared to uncircumcised men (Lu et al., 2009). Monogamous women 
with uncircumcised male partners with ≥6 other sexual partners were found to have a 5.6 times 
greater risk of developing cervical cancer compared to monogamous women with circumcised 
male partners with ≥6 other sexual partner (Castellsague et al., 2002). Clinically confirmed 
circumcision tends to provide protection differently from traditional circumcision. The 
majority of the men in our study were traditionally circumcised and their circumcision was not 
confirmed by clinicians.  
 
It is importantat to note that in this study median duration of HPV infection was not 
investigated because study participants were folowed up for 24-months at 6-month interval, 
therefore the data was available for only four visits after baseline visits. If the study 
participants were followed at 3-month interval the median duration of infection would be 
better. The definition for acquisition and clearence used in this study was very stringent which 
could result in missing some of HPV acqusisition and clearence, this should be taked as one of 
the limitations of the study. It is important to note that there were some study participants with 
2 visits and in first visit there were HPV positive and then HPV negative in second visit. So in 
these study participants it was possible to confirm that it was a true HPV clearence or just a 
false negative. 
 
In conclusion, findings from this study indicate that HIV infection increases the risk of HPV 
acquisition in women and men. HIV-positive women and men with high HIV viral load have 
an increased risk of HPV acquisition. HIV co-infection in women and men also decreased the 
ability to clear genital HPV infection in both women and men. Data from this study also 
indicates that the high rate of HPV transmission between sexual active couples more especially 
in partnerships were one or both partners are HIV-positive. Understanding the natural history 
of HPV in both women and men is important to arm ourselves with the knowledge of who to 
target for the best methods of cervical cancer prevention and other HPV-associated cancers. 
This report will assist in understanding HPV natural history in both women and men. 
Determining factors influencing genital HPV acquisition, clearance and transmission are 
necessary in understanding HPV natural history. Data from this study will also assist in 
informing HPV prevention strategies. 
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CHAPTER 7: SUMMARY OF FINDINGS AND CONCLUSIONS 
 
This thesis constitutes the largest study of the genital transmission of HPV amongst 
heterosexual couples that has been described worldwide. To add to the importance of the study, 
participants were from a local community not an STI clinic. We were able to investigate the 
impact of the co-infection by HIV in one or both members of a partnership on the presence of 
HPV and the ability of participants to clear the virus. This also constitutes the first report on 
type-specific HPV concordance, transmission and factors associated with type-specific HPV 
concordance and transmission in heterosexually active couples and the impact of HIV co-
infection. This is also the first report on the seroprevalence of antibodies to nine different HPV 
types in black South African HIV-positive and HIV-negative women and men. 
 
Data from this project clearly indicates that HIV co-infection increases HPV prevalence, viral 
load and the risk of acquisition in women and men. The risk of HPV infection in men was 
influenced by their own HIV status and that of the female partner. However, in women HPV 
infections was influence by their own HIV status not that of their male partner. The three most 
prevalent HPV types found at baseline infecting HIV-positive men were HPV-62, -61 and -70; 
HIV-negative men HPV-62, -61 and -66; HIV-positive women HPV-62, -52 and -58; and HIV-
negative women HPV-11, -6 and -52. It is important to note that HPV-16 was not the most 
dominant type in our cohort, however, it was the least cleared type in women. LR-HPV types 
were most dominant in our cohort. The α3 HPV species were most prevalent in women but in 
women with abnormal cervical cytology the HPV-16 and HPV-18, α9 and α7 HPV species 
were the second dominant HPV species. Worldwide α9 and α7 HPV species are the most 
prevalent HPV types in cervical cancer cases.  
 
HPV-16 and -18 were not the most dominant types in our study even though they are known to 
be the most dominant HPV types in cervical cancer. Many cross-sectional or longitudinal 
studies have shown that the distribution of HPV types in a normal population does not reflect 
the distribution of HPV types in women with cervical cancer. Franceschi et al., (2005) reported 
that as the lesion severity (LSIL-HSIL-SCC) increases, HPV-16 also increases while other 
HPV types seem to decrease. In our study the majority of women had normal cervical cytology 
and only 2.2% had HSIL so we would not expect to find as HPV-16 the most prominent type. 
A total of 7/12 (58%) of women with HSIL were found to have HPV-16/18 infection. The 
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remaining five women were infected with HPV-31/33/45/52/58. Even though were had few 
women with HSIL in our study, but these findings confirm that HPV-16/18 and HPV types that 
are related to HPV-16 and -18 are more dominant in precancerous lesions. Therefore 
introducing HPV vaccines in our country will reduce the high percentage of precancerous 
HPV-associated lesions in South Africa. 
 
HIV-positive individuals were found to have a higher HPV prevalence compared to HIV-
negative individuals across all age groups. Importantly we noted that HIV co-infection resulted 
in women displaying a second peak of HPV infection 10 years earlier than uninfected women, 
at 36-45 years. The increase of HPV infection in HIV-negative women at >45 years of age is 
thought to be due to immune senescence. Clearly the reduced immune competence of HIV-
positive individuals reduces their ability to clear the virus. HIV-positive women are reported to 
progress to cervical cancer 10 years earlier compared to HIV-negative women (Lomalisa et al., 
2000). These findings suggest that providing HIV-positive women with regular cervical 
screening will help to reduce the prevalence of cervical cancer among them. 
 
We also demonstrated that more men than women acquired HPV but also cleared their 
infection. The clearance of HPV was diminished in HIV positive individuals. Women and men 
acquired similar LR-HPV types while they acquired different HR-HPV types. In women α3 and 
α9 HPV species were most acquired while in men α3 and α7 HPV species were most acquired 
HPV. HPV-11 was found to be the least cleared of all LR-HPV types and HPV-16 was the least 
cleared of all types followed by HPV-11. HIV-positive women and men with high HIV viral 
load have an increased risk of HPV acquisition. 
 
Type-specific HPV concordance amongst partners was related to HIV co-infection and high 
HPV viral load; suggesting that more virus increases the chance of transmission. In men, type-
specific HPV concordance was associated with their own HIV-positive status and that of their 
female partner. While in women type-specific HPV concordance was only associated with their 
own HIV-positive status and not that of their male partner. The risk of acquiring HPV increased 
when a partner was infected with the same type and in men with partners with abnormal 
cervical cytology. This data suggest that men with a female partner with abnormal cervical 
cytology are at great risk of HPV infection and possible HPV associated genital warts and 
cancer. It was interesting to note that HIV-discordant couples’ type-specific HPV concordance 
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decreased with time during follow-up suggesting that they changed their sexual behaviour, by 
started using condoms, after counselling  
 
HPV transmission from female to male was more common than male to female HPV 
transmission. Women were more likely to transmit HR-HPV to their male partners while men 
were more likely to transmit LR-HPV types to their female partners. We cannot conclude that 
women transmit more of HR-HPV and men transmit more of LR-HPV because in this study in 
women only the cervix was sampled. Including a vaginal sample from women might have 
increased the amount of LR-HPV found transmitted to men. HIV-co-infection and low CD4 
counts were found associated with HPV transmission to both women and men from their sexual 
partners. HPV transmission was not associated with increased number of sexual act couples had 
a month before the visit indicating that the observed HPV transmission was the true HPV 
transmission not just HPV DNA deposited by the partner from previous sexual act.  
 
More women were found to mount a serum antibody response compared to men to all nine 
HPV types investigated. HPV seropositivity was not significantly associated with age but HIV 
co-infection was associated with HPV seropositivity. Using ARVs among HIV-positive women 
and men was found to be associated with HPV-11 seropositivity. However, the number of study 
participants that were using ARVs was too small to make conclusive conclusions. The 
association of ARVs with HPV seropositivity still requires further investigation and the reason 
why the use of ARVs was not associated with seropositivity of the other HPV types is not clear. 
In both women and men HPV HPV-11 antibodies were most common. HPV antibodies were 
not associated with HPV clearance.  
 
Data from this study indicate that South African women and men are highly exposed to 
numerous HPV types including HPV-6, -11, -16 or -18 which Gardasil® HPV vaccine 
effectively protect against, indicating that vaccines in our country will be of great benefit in 
reducing HPV associated cancers in women and men. South Africa has high prevalence of 
HIV, cervical cancer and genital warts mostly in HIV-positive individuals. Therefore 
introduction of vaccine in our country to both HIV-positive and HIV-negative individuals will 
reduce the cost used in treating the high rate of cervical cancer and genital warts.  Data from 
this study will add considerably to the very limited data available on HPV infection and the 
impact of HIV co-infection especially in men and sexual active couples. Data from this study 
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will also help to inform the government on HPV vaccine policy as well as cervical screening 
policies. 
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APPENDIX 1 
 
Prof Anna-Lise Williamson HPV laboratory participated in the 2010 WHO HPV LabNet 
Proficiency study. In which samples were provided by WHO and I (Z.Z.A Mbulawa) 
performed the DNA extraction and HPV genotyping. A test was regarded as proficient in 
typing if it can detect 50 International Units (IU) / 5 µl of HPV 16 and HPV 18 DNA, and 500 
genome equivalents (GE) / 5 µl of the other HPV types included in the panel both in samples 
with single and multiple plasmids. In addition, the specificity of the reported types should be 
>97 % (i.e. at most 1 false positive result). 
 
Our laboratory was proficient for detection of HPV 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 58, 
59, 66 and 68 using Roche Linear Array HPV genotyping assay. 
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Table 1. WHO HPV LabNet Proficiency results comparison of WHO results and our results 
 
*cross reactive probe HPV52 cannot be excluded 
HPV 68a cannot be detected using PGMY 09/11 based primer systems or primers targeted to other 
regions than L1. 
Panel ID HPV type(s) in the panel 
 
Content (IU or GE per 
5µl) 
Our results Roche Linear Array HPV 
genotyping, 50µl input volume 
1 59 50 59 
2 31 500 31 
3 6, 16, 18, 51 500 6, 16, 18, 51 
4 45 500 45 
5 16 50 16 
6 35, 59, 66, 68ME 500 35, 59, 66, 68;*  
7 56 500 56 
8 18 50 18 
9 35 500 35 
10 68ME 500 68 
11 11, 16, 31, 33, 58 50 11, 16, 31, 33, 58;*  
12 51 50 51 
13 6 500 6 
14 58 500 58;*  
15 66 50 66 
16 39, 45, 52, 56, 68a 500 39, 45, 52, 56 
17 33 500 33; * 
18 39 50 39 
19 52 500 52 
20 68 50 negative 
21 11 500 11 
22 11, 16, 31, 33, 58 500 11, 16, 31, 33, 58;*  
23 16 5 16 
24 56 50 56 
25 33 50 33; *  
26 6, 16, 18, 51 50 6, 16, 18, 51 
27 Negative 0 negative 
28 35 50 35; * 
29 18 5 18 
30 58 50 58; *  
31 68ME 50 68 
32 39, 45, 52, 68 50 39, 45, 52 
33 6 50 6 
34 45 50 45 
35 68 500 negative 
36 66 500 66 
37 11 50 11 
38 59 500 59 
39 52 50 52, 70 
40 35, 59, 66, 68ME 50 35, 59, 66, 68; *  
41 31 50 31 
42 39 500 39 
43 51 500 51 
A 16 25 negative 
B none 0 no isolate 
C 16 2500 16 
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BASELINE FEMALE QUESTIONNAIRE 
FOR HPV COUPLES  STUDY 
Version 2 (from 02 Oct 2007) 
 
 
Use this questionnaire for 
1. New recruits entering the HPV study from 02/10/07 
2. All ex-PIP study participants recruited into HPV study 
3. All new partners of existing participant in the HPV study 
 
      
Form Number         -   STUDY 
NUMBER _______    -  
 Interviewer Initials                                                                       
   Date of Interview     DDMMYY______  /  /   
 
 
HIV Test Result  from PIP  ___________________1.  Positive  2. Negative       
 
 
IF POSITIVE: Go to next section on Demographic characteristics 
 
IF NEGATIVE: 
HIV pretest counseling________________________________1.  Yes  2. No       
HIV Test Result       ___________________ ______1.  Positive  2. Negative       
HIV Post test counseling_______________________________1.  Yes  2. No       
 
 
DEMOGRAPHIC CHARACTERISTICS 
1. Date of Birth ____________________________DDMMYY   /  /   
2.Age (Years)__________________________________________________________    
 
I would like to ask you a few more details about your education and employment. 
 
3.What is the highest level of education that you have completed?_______                                                           
0.  Did not attend school at all                              7    Std 5    Grade 7                                     
1.  Sub A    Grade 1                                                   8    Std 6    Grade 8                                      
2.  Sub B    Grade 2                                       9    Std 7    Grade 9                                     
3.    Std 1    Grade 3                                       10  Std 8    Grade 10                                      
4.    Std 2    Grade 4                                       11  Std 9    Grade 11                                      
5     Std 3    Grade 5                                     12  Std 10   Grade 12                                      
6     Std 4    Grade 6                                                                       
 
4. Did you have any training of a year or more after school     1. Yes  2. No_____   
 
IF YES: 
Place sticker 
here 
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4a. How many years at                                                        
1.  University_________________________________________________  years      
2.  Technical College/Technikon __________________________________years      
3.  Other, Specify ______________________________________________years                                                  
5. Do you do work that you are paid for      1. Yes    2. No__________ _______________  
 
IF YES: 
5a.What work do you do?    Specify:___________________________________________                    
 
 
6. IF NO: Are you:                  
1. Unemployed-looking for work 
2. Unemployed-not looking for work 
3. Home-maker (by choice)       
4. Full-time student          
5. Disabled (physically or mentally) or a pensioner (government or private civil     
pension/not working due to old age)             
                                              
 
7. What is the approximate total household income per month? 
(This money could be coming from grants and donations from various sources) 
              R      
PARTNERSHIP CHARACTERISTICS 
 
Now I am going to ask you some questions about your relationships. 
1. Are you married to the partner that you came to the clinic with? 1. Yes    2. No_____  
 
 
2. For how long have you been having a sexual relationship with the current partner? 
                                MONTHS        YEARS   
3.  Including the one at the clinic, how many regular sexual partners do you  have?   
4.  In addition to you, does your partner have any other regular partners  1. Yes  2. No  
5.   Do you live together with your current partner?   1. Yes    2. No_________________  
 
SEXUAL PRACTICES 
 
1.  At what age did you have your first sexual encounter? (Age in years)_________   
2.  How many sexual partners have  you had in your life? _____________________   
3.  How many sexual partners have you had in the past 1-year?________________   
4.  How many NEW sexual partners have you had in the past 1-year?___________   
 
5.  How many times have you had sex with your current partner in the past 1-month? 
                                                   
6.  Are you or your partner currently using any kind of contraception?   
Yes=1 No =2  Don’t know =3__________________________________________________  
 
  
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7.  Which of the following methods of contraception are you (or your partner) using 
currently?  
 
(Read all,           1. YES    2. NO) 
 
Oral contraceptive pill 
 
  
 3-month injectable (‘depo’)   
2-month injectable (‘nuristerate’)   
Injectable but don’t know which one   
Female sterilization   
Male condom   
Female condom   
Other methods   
Specify: 
 
8.  Have you ever used condoms with your current partner?  1. Yes    2. No__________  
 
SMOKING HISTORY 
 
1. Do you now or have you ever smoked cigarettes?                           
 
   1. Never 
   2. Ex-smoker                
    
   3. Present smoker        
 
If never go to next section on STI infections 
 
IF  EX-SMOKER:  (STOPPED MORE THAN ONE YEAR PREVIOUSLY)         
2.     How many cigarettes did you smoke a day?_____________________________            
3    For how long did you smoke?______________________months    years        
  
IF PRESENT SMOKER:   (SMOKING SOMETIME DURING THE PAST YEAR)                                       
4.     How many cigarettes do you smoke a day?       __________________________             
5.     For how long have you been smoking?  ________months    years      
 
SEXUALLY TRANSMITTED INFECTIONS (STI) 
 
I would like to talk about diseases or conditions that may affect the genital area. These 
include: a discharge from the vagina or penis - sometimes this discharge causes itching or 
may be foul smelling or may cause you some worry; a sore, warts or blisters on your 
private parts  
 
Have you had any of the following symptoms:   
1.  Vaginal discharge that has caused you some worry. 1. YES  2. NO___  ___      
 
IF YES:  
1a. When was the last time it occurred:   _____  ______________  
  in the last week     =1 
  more than 1 week but less than a month ago =2 
  more than 1 month but less than 6 months =3 
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  more than 6 months ago    =4 
 
2. Ulcers/blisters/warts on the genitals 1. YES  2. NO ___________  
 
IF YES: 
2a. When was the last time it occurred:      _____  
  in the last week     =1 
more than 1 week but less than a month ago =2 
  more than1 month but less than 6 months  =3 
  more than 6 months ago    =4 
 
To be completed if participant is HIV + 
3.  Are you taking anti-retrovirals  (ARVs)     1. YES  2. NO___   _____________  
IF YES: 
  
3a. What are the names of the ARVS that you are taking 
 ______________________________________________________________  
  
PREGNANCY HISTORY  
 
I am now going to ask you about pregnancies.  
1.   Have you ever been pregnant?  1. YES  2. NO_________________ _____  
 
If no → go to next section on Pap smears 
1a. IF YES:  How many live children do you have?__________________    
 2. Have any of your children died      1. YES  2. NO_____________________  
 
IF YES: 
2a.    How many___________________________________________________  
3. Have you had any stillborn infants? 1. YES  2. NO____________________  
 
IF YES:  
3a.     How many___________________________________________________  
4. Were any of these babies born by Caesarian section? 1. YES  2. NO______  
 
IF YES:    
4a.   How many____________________________________________________  
5. Have you had any miscarriages? 1. YES  2. NO_____________________    
                 (abortions/ectopic pregnancies) 
 
 IF YES:   
5a.   How many____________________________________________________   
                                                            
PAP/CERVICAL SMEARS 
 
I am now going to talk about PAP smears 
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Do you know what a Pap smear is? Could you describe this for me?   
 
If the person fully understands don’t give an explanation again. 
Otherwise say, “Let me go over it again” and then give explanation:  
It is a test to detect abnormal cells in the mouth of the womb that could lead to cancer.  
When performing this test the doctor or nurse places an instrument called a speculum (spoon) in 
the woman’s vagina so that he/she can see the mouth of the womb and the test is done.  
 
then interviewer to ask:  
Did you ever have this test done?  1. YES  2. NO    9.UNKNOWN __________________        
 
If  No: go to Locator information sheet 
 
IF YES:  
2. How many times have you ever had a PAP?___________________________    
3. Age at first?________________________________ _______________ _Years    
4. Age at last?________________________________________________  Years    
5. Did you ever get the result of any of your PAP smears/tests?  1. YES  2. NO________   
IF YES:   
5a. What were you told:____________________________________________________   
 
6. Have you ever been told that there was something wrong with the mouth of your 
womb?      1. YES  2. NO__________________________________________________    
IF YES:  
6a. What were you told:________________________________________________  
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Complete  Locator information sheet (back page)  
 
 
            
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
                                                                                                                                          Appendix 2      
 178 
 
  EXAMINATION AND SPECIMEN CHECK LIST 
 
      Form Number____   -   
  DYAD STUDY NUMBER__   -  
 
 
1.  Pelvic Examination 
 
Symptoms Present/ Absent Comment Code 
Warts    
 
 
 
Discharge    
 
 
 
Other 
observations 
   
 
 
 
 
 
2. Specimens for TESTS - tick when completed 
    
WOMEN 
Cytobrush for PAP smear                                               
Cytobrush for HPV                                                         
Buccal swab                                                                    
Orasure test                                                                     
Blood:  1 Red top test tube                                                
            For HIV +: 2 Purple top  test tubes                     
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INFORMATION FOR FOLLOW-UP  
(KEEP SEPARATE FOR REASONS OF CONFIDENTIALITY) 
 
 Form Number ______   -   
   DYAD STUDY NUMBER     -  
 
Participants Name: _________________________________________________________ 
 
Participants Address:     ____________________________          
          ____________________________ 
                    ____________________________ 
                    ____________________________  
                    
Patient’s Tel no  (   )-   -     
Cell phone            (   )-   -     
 
 
 
Information on neighbour, family member or close friend  (For follow up purposes) 
 
Name:        ____________________________________________________________ 
 
Address:      ____________________________           
         ____________________________ 
         ____________________________ 
         ____________________________  
         
Tel no           (   )-   -     
Cell phone           (   )-   -     
 
Date of Follow up visit ___________ DD/MM/YY   /  /   
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BASELINE MALE QUESTIONNAIRE 
FOR HPV COUPLES  STUDY 
Version 2 (from 02 Oct 2007) 
 
 
Use this questionnaire for 
1. New recruits entering the HPV study from 02/10/07 
2. All ex-PIP study participants recruited into HPV study 
3. All new partners of existing participant in the HPV study 
 
      
               Form Number         -   
   STUDY NUMBER_______   -  
 Interviewer Initials                                                                       
   Date of Interview     DDMMYY______  /  /   
 
HIV Test Result  from PIP  ___________________1.  Positive  2. Negative       
 
IF POSITIVE: Go to next section on Demographic characteristics 
 
IF NEGATIVE: 
HIV pretest counseling________________________________1.  Yes  2. No       
HIV Test Result       ___________________ ______1.  Positive  2. Negative       
HIV Post test counseling_______________________________1.  Yes  2. No       
 
DEMOGRAPHIC CHARACTERISTICS 
1. Date of Birth ____________________________DDMMYY   /  /   
2.Age (Years)___________________________________________________________    
 
I would like to ask you a few more details about your education and employment. 
 
3.What is the highest level of education that you have completed?_______                                                           
0.  Did not attend school at all                              7    Std 5    Grade 7                                     
1.  Sub A    Grade 1                                                   8    Std 6    Grade 8                                      
2.  Sub B    Grade 2                                       9    Std 7    Grade 9                                     
3.    Std 1    Grade 3                                       10  Std 8    Grade 10                                      
4.    Std 2    Grade 4                                       11  Std 9    Grade 11                                      
5     Std 3    Grade 5                                     12  Std 10   Grade 12                                      
6     Std 4    Grade 6                                                                       
 
4. Did you have any training of a year or more after school     1. Yes  2. No_____   
 
IF YES: 
4a. How many years at                                                        
1.  University_________________________________________________  years      
2.  Technical College/Technikon __________________________________years      
3.  Other, Specify ______________________________________________years                                                  
5. Do you do work that you are paid for      1. Yes    2. No__________ _______________  
Place sticker 
here 
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IF YES: 
5a.What work do you do?    Specify:___________________________________________                    
 
6. IF NO: Are you:                  
1. Unemployed-looking for work 
2. Unemployed-not looking for work 
3. Home-maker (by choice)       
4. Full-time student          
5. Disabled (physically or mentally) or a pensioner (government or private civil     
pension/not working due to old age)                                                  
      
7. What is the approximate total household income per month? 
(This money could be coming from grants and donations from various sources) 
              R      
PARTNERSHIP CHARACTERISTICS 
Now I am going to ask you some questions about your relationships. 
1. Are you married to the partner that you came to the clinic with? 1. Yes    2. No_____  
 
2. For how long have you been having a sexual relationship with the current partner? 
                                MONTHS        YEARS   
3.  Including the one at the clinic, how many regular sexual partners do you  have?   
4.  In addition to you, does your partner have any other regular partners  1. Yes  2. No  
5.   Do you live together with your current partner?   1. Yes    2. No_________________  
 
SEXUAL PRACTICES 
1.  At what age did you have your first sexual encounter? (Age in years)_________   
2.  How many sexual partners have  you had in your life? _____________________   
3.  How many sexual partners have you had in the past 1-year?________________   
4.  How many NEW sexual partners have you had in the past 1-year?___________   
5.  How many times ha e you had sex with your current partner in the past 1-month? 
                                                   
6.  Are you or your partner currently using any kind of contraception?   
Yes=1 No =2  Don’t know =3__________________________________________________  
 
7.  Which of the following methods of contraception are you (or your partner) using 
currently?  
(Read all,           1. YES    2. NO) 
 
Oral contraceptive pill 
 
  
 3-month injectable (‘depo’)   
2-month injectable (‘nuristerate’)   
Injectable but don’t know which one   
Female sterilization   
Male condom   
Female condom   
Other methods   
Specify: 
  
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8.  Have you ever used condoms with your current partner?  1. Yes    2. No__________  
9. Are you circumsized?  1. Yes   2. No_________________________________________   
 
SMOKING HISTORY 
1. Do you now or have you ever smoked cigarettes?                           
   1. Never 
   2. Ex-smoker                
      3. Present smoker        
 
If never go to next section on STI infections 
 
IF  EX-SMOKER:  (STOPPED MORE THAN ONE YEAR PREVIOUSLY)         
2.     How many cigarettes did you smoke a day?_____________________________            
3    For how long did you smoke?______________________months    years        
  
IF PRESENT SMOKER:   (SMOKING SOMETIME DURING THE PAST YEAR)                                       
4.     How many cigarettes do you smoke a day?       __________________________             
5.     For how long have you been smoking?  ________months    years      
 
SEXUALLY TRANSMITTED INFECTIONS (STI) 
I would like to talk about diseases or conditions that may affect the genital area. These 
include: a discharge from the vagina or penis - sometimes this discharge causes itching or 
may be foul smelling or may cause you some worry; a sore, warts or blisters on your 
private parts  
 
Have you had any of the following symptoms:   
1.  Penile discharge that has caused you some worry. 1. YES  2. NO___        
IF YES:  
1a. When was the last time it occurred:   _____  ______________  
  in the last week     =1 
  more than 1 week but less than a month ago =2 
  more than 1 month but less than 6 months =3 
  more than 6 months ago    =4 
 
2. Ulcers/blisters/warts on the genitals 1. YES  2. NO ___________  
 
IF YES: 
2a. When was the last time it occurred:      _____  
  in the last week     =1 
more than 1 week but less than a month ago =2 
  more than1 month but less than 6 months  =3 
  more than 6 months ago    =4 
 
To be completed if participant is HIV + 
3.  Are you taking anti-retrovirals  (ARVs)     1. YES  2. NO___   _____________  
 
IF YES: 
 3a. What are the names of the ARVS that you are taking 
 ______________________________________________________________  
  
 
    
Complete  Locator information sheet (back page 
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  EXAMINATION AND SPECIMEN CHECK LIST 
 
      Form Number____   -   
  DYAD STUDY NUMBER__   -  
 
 
1.  Pelvic Examination 
 
Symptoms Present/ Absent Comment Code 
Warts    
 
 
 
Discharge    
 
 
 
Other 
observations 
   
 
 
 
 
 
2. Specimens for TESTS - tick when completed 
    
MEN 
 
Penile swab for HPV                                                      
 
Buccal swab                                                                     
Orasure test                                                                    
Blood:  1 Red top test tube                                                
            For HIV +: 2 Purple top  test tubes                     
 
 
 
 
 
 
